NO339422B1 - Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer - Google Patents
Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer Download PDFInfo
- Publication number
- NO339422B1 NO339422B1 NO20074993A NO20074993A NO339422B1 NO 339422 B1 NO339422 B1 NO 339422B1 NO 20074993 A NO20074993 A NO 20074993A NO 20074993 A NO20074993 A NO 20074993A NO 339422 B1 NO339422 B1 NO 339422B1
- Authority
- NO
- Norway
- Prior art keywords
- ylmethyl
- benzyl
- methyl
- aza
- bicyclo
- Prior art date
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 title description 30
- 239000004471 Glycine Substances 0.000 title description 15
- 239000003112 inhibitor Substances 0.000 title description 11
- 125000002619 bicyclic group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 131
- -1 pyrroloimidazoyl Chemical group 0.000 claims description 73
- WZTRQGJMMHMFGH-UHFFFAOYSA-N 1-methyl-imidazole-4-carboxylic acid Chemical compound CN1C=NC(C(O)=O)=C1 WZTRQGJMMHMFGH-UHFFFAOYSA-N 0.000 claims description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 208000028017 Psychotic disease Diseases 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 23
- 201000000980 schizophrenia Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 19
- 208000020925 Bipolar disease Diseases 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 208000019901 Anxiety disease Diseases 0.000 claims description 12
- 208000027691 Conduct disease Diseases 0.000 claims description 12
- 208000016285 Movement disease Diseases 0.000 claims description 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 12
- 230000036506 anxiety Effects 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 6
- 208000020706 Autistic disease Diseases 0.000 claims description 6
- 208000020401 Depressive disease Diseases 0.000 claims description 6
- 208000012661 Dyskinesia Diseases 0.000 claims description 6
- 206010026749 Mania Diseases 0.000 claims description 6
- 208000026139 Memory disease Diseases 0.000 claims description 6
- 208000036626 Mental retardation Diseases 0.000 claims description 6
- 208000019022 Mood disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000027465 Psychotic Affective disease Diseases 0.000 claims description 6
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 208000016620 Tourette disease Diseases 0.000 claims description 6
- 230000003542 behavioural effect Effects 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 208000035548 disruptive behavior disease Diseases 0.000 claims description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000024714 major depressive disease Diseases 0.000 claims description 6
- BBAZVMYRHGNBCQ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide;hydrochloride Chemical compound Cl.CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 BBAZVMYRHGNBCQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000164 antipsychotic agent Substances 0.000 claims description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims description 3
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 claims description 3
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 3
- 229960003036 amisulpride Drugs 0.000 claims description 3
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 3
- 208000015114 central nervous system disease Diseases 0.000 claims description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 3
- 229960004170 clozapine Drugs 0.000 claims description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 229960002419 flupentixol Drugs 0.000 claims description 3
- 229960002690 fluphenazine Drugs 0.000 claims description 3
- 229940003380 geodon Drugs 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 229960000423 loxapine Drugs 0.000 claims description 3
- COHFMAOLODNHPW-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methylimidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(Cl)C(Cl)=C1 COHFMAOLODNHPW-UHFFFAOYSA-N 0.000 claims description 3
- DKYPWVLLGYCVPS-UHFFFAOYSA-N n-[[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 DKYPWVLLGYCVPS-UHFFFAOYSA-N 0.000 claims description 3
- GRBOAFAUUCFZPU-UHFFFAOYSA-N n-[[3-[(1-hydroxycyclohexyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 GRBOAFAUUCFZPU-UHFFFAOYSA-N 0.000 claims description 3
- 229960005017 olanzapine Drugs 0.000 claims description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 3
- 229960003634 pimozide Drugs 0.000 claims description 3
- JOMHSQGEWSNUKU-UHFFFAOYSA-N pipotiazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 JOMHSQGEWSNUKU-UHFFFAOYSA-N 0.000 claims description 3
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims description 3
- 229960003111 prochlorperazine Drugs 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 229960004431 quetiapine Drugs 0.000 claims description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 3
- 229960003448 remoxipride Drugs 0.000 claims description 3
- 229960001534 risperidone Drugs 0.000 claims description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 3
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000652 sertindole Drugs 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 229960002784 thioridazine Drugs 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 229960000607 ziprasidone Drugs 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 229940068151 pipothiazine Drugs 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 claims 3
- 125000006500 3-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC(F)(F)F)=C1[H])C([H])([H])* 0.000 claims 3
- KYLOBHXXQOZRKK-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(F)C(Cl)=C1 KYLOBHXXQOZRKK-UHFFFAOYSA-N 0.000 claims 3
- GPPHRVCAHLYGOE-UHFFFAOYSA-N n-[[3-[2-(3-hydroxypyrrolidin-1-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CC(O)CC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 GPPHRVCAHLYGOE-UHFFFAOYSA-N 0.000 claims 3
- RBJMJCVAKPEWRY-UHFFFAOYSA-N 1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(2,2,2-trifluoroethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(CC(F)(F)F)=C1 RBJMJCVAKPEWRY-UHFFFAOYSA-N 0.000 claims 2
- FZYJJFIJVLMBHU-UHFFFAOYSA-N 1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(C(F)(F)F)=C1 FZYJJFIJVLMBHU-UHFFFAOYSA-N 0.000 claims 2
- BXCHICFAGLMBMD-UHFFFAOYSA-N 1-methyl-n-[[3-(1-methylazetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1N(C)CC1N1CC2C(CN(CC=3C=C(C=CC=3)C(F)(F)F)C(=O)C=3N=CN(C)C=3)C2C1 BXCHICFAGLMBMD-UHFFFAOYSA-N 0.000 claims 2
- DBHLMXRKUILKMR-UHFFFAOYSA-N 1-methyl-n-[[3-(1-methylsulfonylazetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CN(C2)S(C)(=O)=O)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 DBHLMXRKUILKMR-UHFFFAOYSA-N 0.000 claims 2
- NNVPWXCLBSNFDK-UHFFFAOYSA-N 1-methyl-n-[[3-(oxolan-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4OCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 NNVPWXCLBSNFDK-UHFFFAOYSA-N 0.000 claims 2
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 claims 2
- CTLIRQHXAZCWBX-UHFFFAOYSA-N N-[(3-chlorophenyl)methyl]-N-[[3-(cyclopentylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CCCC4)CC32)CC=2C=C(Cl)C=CC=2)=C1 CTLIRQHXAZCWBX-UHFFFAOYSA-N 0.000 claims 2
- 229960001076 chlorpromazine Drugs 0.000 claims 2
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 2
- KVLRHEPMHNECTD-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[[3-(2,2,2-trifluoroethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(CC(F)(F)F)C=CC=2)=C1 KVLRHEPMHNECTD-UHFFFAOYSA-N 0.000 claims 2
- LIISIJJLSVWJKR-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(C=CC=2)C(F)(F)F)=C1 LIISIJJLSVWJKR-UHFFFAOYSA-N 0.000 claims 2
- YPZBAGLZMGDXAV-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide;hydrochloride Chemical compound Cl.CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(C=CC=2)C(F)(F)F)=C1 YPZBAGLZMGDXAV-UHFFFAOYSA-N 0.000 claims 2
- PLBXIELKVXWRST-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3,4-dichlorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(Cl)C(Cl)=CC=2)=C1 PLBXIELKVXWRST-UHFFFAOYSA-N 0.000 claims 2
- CXRFVIDIDPENGH-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3-chloro-4-fluorophenyl)methyl]-1-methylimidazole-4-carboxamide;hydrochloride Chemical compound Cl.CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(Cl)C(F)=CC=2)=C1 CXRFVIDIDPENGH-UHFFFAOYSA-N 0.000 claims 2
- IBMCRYWEPTUOAZ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3-chlorophenyl)methyl]-1-methylimidazole-4-carboxamide;hydrochloride Chemical compound Cl.CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(Cl)C=CC=2)=C1 IBMCRYWEPTUOAZ-UHFFFAOYSA-N 0.000 claims 2
- UQEZTLWMQVJJLH-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3-cyclohexyloxy-4-fluorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(OC3CCCCC3)C(F)=CC=2)=C1 UQEZTLWMQVJJLH-UHFFFAOYSA-N 0.000 claims 2
- PYXQMOCIZRMWJA-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3-cyclopentyloxy-4-fluorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(OC3CCCC3)C(F)=CC=2)=C1 PYXQMOCIZRMWJA-UHFFFAOYSA-N 0.000 claims 2
- QOUHFHYOLQMCBS-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(4-fluoro-3-propan-2-yloxyphenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound C1=C(F)C(OC(C)C)=CC(CN(CC2C3CNCC32)C(=O)C=2N=CN(C)C=2)=C1 QOUHFHYOLQMCBS-UHFFFAOYSA-N 0.000 claims 2
- ALRUNSDWRZERDW-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-(1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(C=CC=2)C(C(F)(F)F)C(F)(F)F)=C1 ALRUNSDWRZERDW-UHFFFAOYSA-N 0.000 claims 2
- WGHBNGJMSVRWDS-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-(2,2-dimethylpropoxy)-4-fluorophenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(OCC(C)(C)C)C(F)=CC=2)=C1 WGHBNGJMSVRWDS-UHFFFAOYSA-N 0.000 claims 2
- XELDHIXEKKDAGK-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CNCC32)C(=O)C=2N=CSC=2)=C1 XELDHIXEKKDAGK-UHFFFAOYSA-N 0.000 claims 2
- DCUOEMDGTJSUAW-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 DCUOEMDGTJSUAW-UHFFFAOYSA-N 0.000 claims 2
- BWGOPDDECGKNNF-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide;hydrochloride Chemical compound Cl.CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 BWGOPDDECGKNNF-UHFFFAOYSA-N 0.000 claims 2
- YKPFTOAVQHYFPA-UHFFFAOYSA-N n-[(2,4-dichlorophenyl)methyl]-1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(Cl)C=C1Cl YKPFTOAVQHYFPA-UHFFFAOYSA-N 0.000 claims 2
- QHCLQWXENVQCPI-UHFFFAOYSA-N n-[(2,4-dichlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methylimidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(Cl)C=C1Cl QHCLQWXENVQCPI-UHFFFAOYSA-N 0.000 claims 2
- AJMJMBXYTPETHG-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(Cl)C(Cl)=C1 AJMJMBXYTPETHG-UHFFFAOYSA-N 0.000 claims 2
- LCAJNYRHQIMAAS-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC(Cl)=CC(Cl)=C1 LCAJNYRHQIMAAS-UHFFFAOYSA-N 0.000 claims 2
- XFDDUIVLPHZQKZ-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methylimidazole-4-carboxamide;hydrochloride Chemical compound Cl.C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC(Cl)=CC(Cl)=C1 XFDDUIVLPHZQKZ-UHFFFAOYSA-N 0.000 claims 2
- YUANMZCFGUVPAE-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-1-methyl-n-[[3-(1-methylazetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C1N(C)CC1N1CC2C(CN(CC=3C=C(Cl)C(F)=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 YUANMZCFGUVPAE-UHFFFAOYSA-N 0.000 claims 2
- MPZQBQRKCONCOL-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methylimidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(F)C(Cl)=C1 MPZQBQRKCONCOL-UHFFFAOYSA-N 0.000 claims 2
- OUKZBFKTXARKQJ-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-methyl-n-[[3-(1-methylazetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C1N(C)CC1N1CC2C(CN(CC=3C=C(Cl)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 OUKZBFKTXARKQJ-UHFFFAOYSA-N 0.000 claims 2
- XMBAEMMSEFOTME-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-methyl-n-[[3-[[4-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(OC(F)(F)F)=CC=4)CC32)CC=2C=C(Cl)C=CC=2)=C1 XMBAEMMSEFOTME-UHFFFAOYSA-N 0.000 claims 2
- LYQKWZQQEMVURT-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CC4)CC32)CC=2C=C(Cl)C=CC=2)=C1 LYQKWZQQEMVURT-UHFFFAOYSA-N 0.000 claims 2
- RWEJRLQFYNHXFS-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1,5-dimethyl-n-[[3-(trifluoromethoxy)phenyl]methyl]pyrazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C1=NN(C)C(C)=C1)CC1=CC=CC(OC(F)(F)F)=C1 RWEJRLQFYNHXFS-UHFFFAOYSA-N 0.000 claims 2
- WYGMSRKXIAPRNN-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide;hydrochloride Chemical compound Cl.C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 WYGMSRKXIAPRNN-UHFFFAOYSA-N 0.000 claims 2
- CBJIPPJDHMCPGJ-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(C(F)(F)F)=C1 CBJIPPJDHMCPGJ-UHFFFAOYSA-N 0.000 claims 2
- NWSJCISMNTZTHG-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-5-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,2-oxazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C1=NOC(C)=C1)CC1=CC=CC(OC(F)(F)F)=C1 NWSJCISMNTZTHG-UHFFFAOYSA-N 0.000 claims 2
- BZLBTXPPBKDDDV-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-5-propyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,2-oxazole-3-carboxamide Chemical compound O1C(CCC)=CC(C(=O)N(CC2C3CN(CC)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=N1 BZLBTXPPBKDDDV-UHFFFAOYSA-N 0.000 claims 2
- ZAIKGNYVYWDZMR-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(F)C(C(F)(F)F)=C1 ZAIKGNYVYWDZMR-UHFFFAOYSA-N 0.000 claims 2
- RZEUGCQMOZWLOG-UHFFFAOYSA-N n-[[3-(1h-imidazol-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4NC=CN=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 RZEUGCQMOZWLOG-UHFFFAOYSA-N 0.000 claims 2
- WDUXZXJIHQBRIQ-UHFFFAOYSA-N n-[[3-(azetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CNC2)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 WDUXZXJIHQBRIQ-UHFFFAOYSA-N 0.000 claims 2
- CDNJZMNSYJROHI-UHFFFAOYSA-N n-[[3-(azetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CNC2)CC=2C=C(C=CC=2)C(F)(F)F)=C1 CDNJZMNSYJROHI-UHFFFAOYSA-N 0.000 claims 2
- GPXLCVDUOCDVDZ-UHFFFAOYSA-N n-[[3-(azetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[(3-chloro-4-fluorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CNC2)CC=2C=C(Cl)C(F)=CC=2)=C1 GPXLCVDUOCDVDZ-UHFFFAOYSA-N 0.000 claims 2
- VJWMXKLVEZLZSO-UHFFFAOYSA-N n-[[3-(azetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CNC2)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 VJWMXKLVEZLZSO-UHFFFAOYSA-N 0.000 claims 2
- DBQBAHSSKFGSRU-UHFFFAOYSA-N n-[[3-(cyclopentylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 DBQBAHSSKFGSRU-UHFFFAOYSA-N 0.000 claims 2
- CPYMDABMMJOVJT-UHFFFAOYSA-N n-[[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CC4)CC32)CC=2C=C(C=CC=2)C(F)(F)F)=C1 CPYMDABMMJOVJT-UHFFFAOYSA-N 0.000 claims 2
- ZCGZHKAQFHPYOT-UHFFFAOYSA-N n-[[3-[(1-ethyl-3-methylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CC1=NN(CC)C=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 ZCGZHKAQFHPYOT-UHFFFAOYSA-N 0.000 claims 2
- WSBTXGMJVVEVJD-UHFFFAOYSA-N n-[[3-[(1-hydroxycyclopentyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 WSBTXGMJVVEVJD-UHFFFAOYSA-N 0.000 claims 2
- KCGLCKUDJAVXOC-UHFFFAOYSA-N n-[[3-[(2-ethyl-1h-imidazol-5-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound N1C(CC)=NC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 KCGLCKUDJAVXOC-UHFFFAOYSA-N 0.000 claims 2
- AWZXUQFVCATAJQ-UHFFFAOYSA-N n-[[3-[(2-ethyl-5-methyl-1h-imidazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound N1C(CC)=NC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CN(C)C=4)C3C2)=C1C AWZXUQFVCATAJQ-UHFFFAOYSA-N 0.000 claims 2
- DJFWFMVBOSTWLP-UHFFFAOYSA-N n-[[3-[2-(2-chlorophenyl)-2-hydroxyethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(O)C=4C(=CC=CC=4)Cl)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 DJFWFMVBOSTWLP-UHFFFAOYSA-N 0.000 claims 2
- YZCQNYVLFSIUMU-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=C(F)C(C(F)(F)F)=C1 YZCQNYVLFSIUMU-UHFFFAOYSA-N 0.000 claims 2
- UXQXYHFMZJEZPQ-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-n-[[3-(1-methylazetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C1N(C)CC1N1CC2C(CN(CC=3C=C(C(F)=CC=3)C(F)(F)F)C(=O)C=3N=CN(C)C=3)C2C1 UXQXYHFMZJEZPQ-UHFFFAOYSA-N 0.000 claims 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 2
- 229960002324 trifluoperazine Drugs 0.000 claims 2
- OZQNMDKJLLBSQE-UHFFFAOYSA-N 1-(3-chlorophenyl)-n-[(3-chlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C=1)C=1C=C(Cl)C=CC=1)CC1=CC=CC(Cl)=C1 OZQNMDKJLLBSQE-UHFFFAOYSA-N 0.000 claims 1
- CMUSMAXKDUSFKB-UHFFFAOYSA-N 1-[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]-N-[[3-(trifluoromethoxy)phenyl]methyl]methanamine Chemical compound FC(F)(F)OC1=CC=CC(CNCC2C3CN(CC4CC4)CC32)=C1 CMUSMAXKDUSFKB-UHFFFAOYSA-N 0.000 claims 1
- FRWYZAMVFPVWRL-UHFFFAOYSA-N 1-[3-[(5-methyl-1H-pyrazol-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]-N-[[3-(trifluoromethoxy)phenyl]methyl]methanamine Chemical compound N1C(C)=CC(CN2CC3C(CNCC=4C=C(OC(F)(F)F)C=CC=4)C3C2)=N1 FRWYZAMVFPVWRL-UHFFFAOYSA-N 0.000 claims 1
- IYJXYVHMRWVLDS-UHFFFAOYSA-N 1-[4-(trifluoromethoxy)phenyl]imidazole-4-carboxylic acid Chemical compound C1=NC(C(=O)O)=CN1C1=CC=C(OC(F)(F)F)C=C1 IYJXYVHMRWVLDS-UHFFFAOYSA-N 0.000 claims 1
- KZGLQLQAYRHURB-UHFFFAOYSA-N 1-butyl-n-[(3-chlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound CCCCN1C=NC(C(=O)N(CC2C3CN(CC)CC32)CC=2C=C(Cl)C=CC=2)=C1 KZGLQLQAYRHURB-UHFFFAOYSA-N 0.000 claims 1
- BTLYVDKQSGFMHW-UHFFFAOYSA-N 1-butyl-n-[(3-chlorophenyl)methyl]-n-[(3-propyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound CCCCN1C=NC(C(=O)N(CC2C3CN(CCC)CC32)CC=2C=C(Cl)C=CC=2)=C1 BTLYVDKQSGFMHW-UHFFFAOYSA-N 0.000 claims 1
- SPZPSSFXWANYQS-UHFFFAOYSA-N 1-methyl-N-[[3-[(1-methylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound Cn1cnc(c1)C(=O)N(CC1C2CN(Cc3cnn(C)c3)CC12)Cc1cccc(OC(F)(F)F)c1 SPZPSSFXWANYQS-UHFFFAOYSA-N 0.000 claims 1
- DQLUYTRFZQCSKU-UHFFFAOYSA-N 1-methyl-N-[[3-[(1-methylpyrrol-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound Cn1cnc(c1)C(=O)N(CC1C2CN(Cc3cccn3C)CC12)Cc1cccc(OC(F)(F)F)c1 DQLUYTRFZQCSKU-UHFFFAOYSA-N 0.000 claims 1
- CZJFBFXRBRPLKU-UHFFFAOYSA-N 1-methyl-N-[[3-[(1-pyridin-2-ylpyrrol-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound Cn1cnc(c1)C(=O)N(CC1C2CN(Cc3cccn3-c3ccccn3)CC12)Cc1cccc(OC(F)(F)F)c1 CZJFBFXRBRPLKU-UHFFFAOYSA-N 0.000 claims 1
- AZVRUZMJEWYKQL-UHFFFAOYSA-N 1-methyl-N-[[3-[(1-pyrimidin-2-ylpyrrol-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound Cn1cnc(c1)C(=O)N(CC1C2CN(Cc3cccn3-c3ncccn3)CC12)Cc1cccc(OC(F)(F)F)c1 AZVRUZMJEWYKQL-UHFFFAOYSA-N 0.000 claims 1
- WSOWXTQQDXTOBK-UHFFFAOYSA-N 1-methyl-n-(2-methylbutyl)-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC(F)(F)F)CC2C1CN(CC(C)CC)C(=O)C1=CN(C)C=N1 WSOWXTQQDXTOBK-UHFFFAOYSA-N 0.000 claims 1
- BSWNQEGQCXTCAO-UHFFFAOYSA-N 1-methyl-n-[(3-propan-2-yl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(C(C)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 BSWNQEGQCXTCAO-UHFFFAOYSA-N 0.000 claims 1
- QPOXEJJRBVSMBC-UHFFFAOYSA-N 1-methyl-n-[(3-pyrazin-2-yl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C=2N=CC=NC=2)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 QPOXEJJRBVSMBC-UHFFFAOYSA-N 0.000 claims 1
- RQUOCJJWTGKEOA-UHFFFAOYSA-N 1-methyl-n-[[3-(1,2-oxazol-3-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4=NOC=C4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 RQUOCJJWTGKEOA-UHFFFAOYSA-N 0.000 claims 1
- JNDRMVCCUPNLOE-UHFFFAOYSA-N 1-methyl-n-[[3-(1-methylazetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1N(C)CC1N1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 JNDRMVCCUPNLOE-UHFFFAOYSA-N 0.000 claims 1
- CCJOIWGEOODMAY-UHFFFAOYSA-N 1-methyl-n-[[3-(2-methylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(C)CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 CCJOIWGEOODMAY-UHFFFAOYSA-N 0.000 claims 1
- NYKNKJWZDWFIDU-UHFFFAOYSA-N 1-methyl-n-[[3-(2-methylpropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(C)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 NYKNKJWZDWFIDU-UHFFFAOYSA-N 0.000 claims 1
- OKSMHSNFROTFAP-UHFFFAOYSA-N 1-methyl-n-[[3-(2-morpholin-4-yl-2-oxoethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CCOCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 OKSMHSNFROTFAP-UHFFFAOYSA-N 0.000 claims 1
- AYZDYTPFDGWMMK-UHFFFAOYSA-N 1-methyl-n-[[3-(2-oxo-2-piperidin-1-ylethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CCCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 AYZDYTPFDGWMMK-UHFFFAOYSA-N 0.000 claims 1
- QEYUVDJMAQEIJH-UHFFFAOYSA-N 1-methyl-n-[[3-(2-oxo-2-pyrrolidin-1-ylethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 QEYUVDJMAQEIJH-UHFFFAOYSA-N 0.000 claims 1
- IEZHTONVRRROHH-UHFFFAOYSA-N 1-methyl-n-[[3-(2-oxo-2-thiomorpholin-4-ylethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CCSCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 IEZHTONVRRROHH-UHFFFAOYSA-N 0.000 claims 1
- KVIKTWPUAPXXAI-UHFFFAOYSA-N 1-methyl-n-[[3-(3-phenylpropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CCCC=4C=CC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 KVIKTWPUAPXXAI-UHFFFAOYSA-N 0.000 claims 1
- YNYLALFSJOQTIU-UHFFFAOYSA-N 1-methyl-n-[[3-(naphthalen-1-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C5=CC=CC=C5C=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 YNYLALFSJOQTIU-UHFFFAOYSA-N 0.000 claims 1
- MFOMOJBXLDYLLL-UHFFFAOYSA-N 1-methyl-n-[[3-(naphthalen-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=C5C=CC=CC5=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 MFOMOJBXLDYLLL-UHFFFAOYSA-N 0.000 claims 1
- INZYGSLMHXJKDJ-UHFFFAOYSA-N 1-methyl-n-[[3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CCOCC2)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 INZYGSLMHXJKDJ-UHFFFAOYSA-N 0.000 claims 1
- ZEHOMNFMGWGWTA-UHFFFAOYSA-N 1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CCC(F)(F)F)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 ZEHOMNFMGWGWTA-UHFFFAOYSA-N 0.000 claims 1
- UTWBGAMHPYPLAT-UHFFFAOYSA-N 1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-(3,5,5-trimethylhexyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC(C)CC(C)(C)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 UTWBGAMHPYPLAT-UHFFFAOYSA-N 0.000 claims 1
- XWNMOHASRIOOSP-UHFFFAOYSA-N 1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[2-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C(=CC=CC=4)OC(F)(F)F)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 XWNMOHASRIOOSP-UHFFFAOYSA-N 0.000 claims 1
- MUAPATUTBCCVDJ-UHFFFAOYSA-N 1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=C(OC(F)(F)F)C=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 MUAPATUTBCCVDJ-UHFFFAOYSA-N 0.000 claims 1
- GSQWLRPPONLSDN-UHFFFAOYSA-N 1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[4-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(OC(F)(F)F)=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 GSQWLRPPONLSDN-UHFFFAOYSA-N 0.000 claims 1
- YNHDZSPPROEOFH-UHFFFAOYSA-N 1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[4-(trifluoromethyl)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(=CC=4)C(F)(F)F)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 YNHDZSPPROEOFH-UHFFFAOYSA-N 0.000 claims 1
- YWLWRGRCSNSAPD-UHFFFAOYSA-N 1-methyl-n-[[3-[(1-methylimidazol-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4N(C=CN=4)C)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 YWLWRGRCSNSAPD-UHFFFAOYSA-N 0.000 claims 1
- GQPWYGPFDKRJAP-UHFFFAOYSA-N 1-methyl-n-[[3-[(2-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CC1=CC=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 GQPWYGPFDKRJAP-UHFFFAOYSA-N 0.000 claims 1
- BLBPIJXGVVEBDF-UHFFFAOYSA-N 1-methyl-n-[[3-[(3-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CC1=CC=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CN(C)C=4)C3C2)=C1 BLBPIJXGVVEBDF-UHFFFAOYSA-N 0.000 claims 1
- LOZBJQLMVXPDTR-UHFFFAOYSA-N 1-methyl-n-[[3-[(4-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 LOZBJQLMVXPDTR-UHFFFAOYSA-N 0.000 claims 1
- METLCENPVBFDKA-UHFFFAOYSA-N 1-methyl-n-[[3-[(4-phenoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(OC=5C=CC=CC=5)=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 METLCENPVBFDKA-UHFFFAOYSA-N 0.000 claims 1
- JQVXIGPNTARNQW-UHFFFAOYSA-N 1-methyl-n-[[3-[(4-phenylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(=CC=4)C=4C=CC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 JQVXIGPNTARNQW-UHFFFAOYSA-N 0.000 claims 1
- RASXVMURGXXRFR-UHFFFAOYSA-N 1-methyl-n-[[3-[(4-propan-2-ylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 RASXVMURGXXRFR-UHFFFAOYSA-N 0.000 claims 1
- ZHCKMLMHMZIOHT-UHFFFAOYSA-N 1-methyl-n-[[3-[(5-methyl-1h-imidazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound N1C=NC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CN(C)C=4)C3C2)=C1C ZHCKMLMHMZIOHT-UHFFFAOYSA-N 0.000 claims 1
- QHDLTQCQOAKWQG-UHFFFAOYSA-N 1-methyl-n-[[3-[(6-oxo-1h-pyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4NC(=O)C=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 QHDLTQCQOAKWQG-UHFFFAOYSA-N 0.000 claims 1
- IYXZYOJUGURVEK-UHFFFAOYSA-N 1-methyl-n-[[3-[(6-phenoxypyridin-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=NC(OC=5C=CC=CC=5)=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 IYXZYOJUGURVEK-UHFFFAOYSA-N 0.000 claims 1
- ODZVMAXMPZUOJS-UHFFFAOYSA-N 1-methyl-n-[[3-[2-(2-methylpyrrolidin-1-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CC1CCCN1C(=O)CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 ODZVMAXMPZUOJS-UHFFFAOYSA-N 0.000 claims 1
- BIKDWMRKUISCPP-UHFFFAOYSA-N 1-methyl-n-[[3-[2-(3-methylpiperidin-1-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C(C)CCCN1C(=O)CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 BIKDWMRKUISCPP-UHFFFAOYSA-N 0.000 claims 1
- UERRCNAYVWONGZ-UHFFFAOYSA-N 1-methyl-n-[[3-[2-(4-methylphenyl)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1CCN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 UERRCNAYVWONGZ-UHFFFAOYSA-N 0.000 claims 1
- UWLQDGMTQGJBAA-UHFFFAOYSA-N 1-methyl-n-[[3-[2-(4-methylpiperidin-1-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1CC(C)CCN1C(=O)CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 UWLQDGMTQGJBAA-UHFFFAOYSA-N 0.000 claims 1
- OKKUCKHRXUCRCQ-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[(1-methylpyrazol-3-yl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC4=NN(C)C=C4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 OKKUCKHRXUCRCQ-UHFFFAOYSA-N 0.000 claims 1
- IBMYOZAJOFHRHS-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[(2-methylpyrazol-3-yl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC=4N(N=CC=4)C)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 IBMYOZAJOFHRHS-UHFFFAOYSA-N 0.000 claims 1
- LASLOQHQTPRRPC-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[methyl(1-pyridin-4-ylethyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C=1C=NC=CC=1C(C)N(C)C(=O)CN(CC12)CC1C2CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 LASLOQHQTPRRPC-UHFFFAOYSA-N 0.000 claims 1
- WYJWDTBYWAVSDY-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[methyl(2,2,2-trifluoroethyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)N(CC(F)(F)F)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 WYJWDTBYWAVSDY-UHFFFAOYSA-N 0.000 claims 1
- OJYGIMDUYHBOJB-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[methyl(2-methylsulfonylethyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)N(CCS(C)(=O)=O)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 OJYGIMDUYHBOJB-UHFFFAOYSA-N 0.000 claims 1
- AOAFOZHAJDWKGC-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2CN1CC(=O)N(C)CCC1=CC=CC=C1 AOAFOZHAJDWKGC-UHFFFAOYSA-N 0.000 claims 1
- HXKCJDNVBNLDPG-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[methyl(thiophen-3-ylmethyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2CN1CC(=O)N(C)CC=1C=CSC=1 HXKCJDNVBNLDPG-UHFFFAOYSA-N 0.000 claims 1
- BBIFBGYKYVPSAB-UHFFFAOYSA-N 1-methyl-n-[[3-[2-[methyl-[(3-methylpyridin-2-yl)methyl]amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2CN1CC(=O)N(C)CC1=NC=CC=C1C BBIFBGYKYVPSAB-UHFFFAOYSA-N 0.000 claims 1
- NWBOXICMBOWKAL-UHFFFAOYSA-N 1-methyl-n-[[3-[2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CSCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 NWBOXICMBOWKAL-UHFFFAOYSA-N 0.000 claims 1
- AJYBVKCINIHDKV-UHFFFAOYSA-N 1-methyl-n-[[3-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NCC(F)(F)F)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 AJYBVKCINIHDKV-UHFFFAOYSA-N 0.000 claims 1
- ZFRQOWTZEGNPTL-UHFFFAOYSA-N 1-methyl-n-[[3-[2-oxo-2-(3-phenylpyrrolidin-1-yl)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CC(CC4)C=4C=CC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 ZFRQOWTZEGNPTL-UHFFFAOYSA-N 0.000 claims 1
- GRUHMSPOMBZBQD-UHFFFAOYSA-N 1-methyl-n-[[3-[2-oxo-2-(propan-2-ylamino)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)NC(C)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 GRUHMSPOMBZBQD-UHFFFAOYSA-N 0.000 claims 1
- HWIKACHLFVDHQD-UHFFFAOYSA-N 1-methyl-n-[[3-[2-oxo-2-(pyridin-2-ylamino)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC=4N=CC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 HWIKACHLFVDHQD-UHFFFAOYSA-N 0.000 claims 1
- LFNHKKNJOLBVBV-UHFFFAOYSA-N 1-methyl-n-[[3-[2-oxo-2-(pyridin-3-ylamino)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC=4C=NC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 LFNHKKNJOLBVBV-UHFFFAOYSA-N 0.000 claims 1
- SOWFRDMHXSQRRO-UHFFFAOYSA-N 1-methyl-n-[[3-[3-(5-methylfuran-2-yl)butyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C=1C=C(C)OC=1C(C)CCN(CC12)CC1C2CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 SOWFRDMHXSQRRO-UHFFFAOYSA-N 0.000 claims 1
- UHDUSWADDVWRHM-UHFFFAOYSA-N 1-methyl-n-pentyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC(F)(F)F)CC2C1CN(CCCCC)C(=O)C1=CN(C)C=N1 UHDUSWADDVWRHM-UHFFFAOYSA-N 0.000 claims 1
- QXTJOIFEHQDGOG-UHFFFAOYSA-N 2-chloro-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[(1-methylimidazol-4-yl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1C(=C(C=CC=1)C(F)(F)F)Cl)CC1=CN(C)C=N1 QXTJOIFEHQDGOG-UHFFFAOYSA-N 0.000 claims 1
- HOXLFMXJBDOIAV-UHFFFAOYSA-N 2-ethyl-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-5-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]pyrazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N(N=C(C)C=1)CC)CC1=CC=CC(OC(F)(F)F)=C1 HOXLFMXJBDOIAV-UHFFFAOYSA-N 0.000 claims 1
- JNHNKCJMTTVWKF-UHFFFAOYSA-N 3-chloro-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[(1-methylimidazol-4-yl)methyl]benzamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1C=C(Cl)C=CC=1)CC1=CN(C)C=N1 JNHNKCJMTTVWKF-UHFFFAOYSA-N 0.000 claims 1
- ANPCOWKCZPKWEH-UHFFFAOYSA-N 5-chloro-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]pyridine-2-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CC(Cl)=CC=1)CC1=CC=CC(OC(F)(F)F)=C1 ANPCOWKCZPKWEH-UHFFFAOYSA-N 0.000 claims 1
- QZJBWWKZAJXDPT-UHFFFAOYSA-N 5-cyclopropyl-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1h-pyrazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C1=NNC(=C1)C1CC1)CC1=CC=CC(OC(F)(F)F)=C1 QZJBWWKZAJXDPT-UHFFFAOYSA-N 0.000 claims 1
- RQOGDDHLYALEKW-UHFFFAOYSA-N 5-ethyl-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-2-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]pyrazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N(N=C(CC)C=1)C)CC1=CC=CC(OC(F)(F)F)=C1 RQOGDDHLYALEKW-UHFFFAOYSA-N 0.000 claims 1
- QKWCLVCEVWYIDT-UHFFFAOYSA-N 5-ethyl-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,2-oxazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C1=NOC(CC)=C1)CC1=CC=CC(OC(F)(F)F)=C1 QKWCLVCEVWYIDT-UHFFFAOYSA-N 0.000 claims 1
- OVQPRZAQTUMHTG-UHFFFAOYSA-N FC(F)(F)OC1=CC=CC(CNCC2C3CN(CCC=4C=CC=CC=4)CC32)=C1 Chemical compound FC(F)(F)OC1=CC=CC(CNCC2C3CN(CCC=4C=CC=CC=4)CC32)=C1 OVQPRZAQTUMHTG-UHFFFAOYSA-N 0.000 claims 1
- IZZUHBRSOQFUIT-UHFFFAOYSA-N FC(F)(F)OC1=CC=CC(CNCC2C3CNCC32)=C1 Chemical compound FC(F)(F)OC1=CC=CC(CNCC2C3CNCC32)=C1 IZZUHBRSOQFUIT-UHFFFAOYSA-N 0.000 claims 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims 1
- SFRZRNCUFHNZNT-UHFFFAOYSA-N N-[[3-(2-bicyclo[2.2.1]hept-5-enylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-N-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound Cn1cnc(c1)C(=O)N(CC1C2CN(CC3CC4CC3C=C4)CC12)Cc1cccc(OC(F)(F)F)c1 SFRZRNCUFHNZNT-UHFFFAOYSA-N 0.000 claims 1
- MTNPGFBTOCRKCW-UHFFFAOYSA-N N-[[3-[(1-methylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound Cn1cc(CN2CC3C(CN(Cc4cccc(OC(F)(F)F)c4)C(=O)c4cscn4)C3C2)cn1 MTNPGFBTOCRKCW-UHFFFAOYSA-N 0.000 claims 1
- MPNYPTVPVKYBOH-UHFFFAOYSA-N N-[[3-[(1-methylpyrrol-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound Cn1cccc1CN1CC2C(CN(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cscn3)C2C1 MPNYPTVPVKYBOH-UHFFFAOYSA-N 0.000 claims 1
- FNQBWWORCSKEHI-UHFFFAOYSA-N N-[[3-[(1-pyrimidin-2-ylpyrrol-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)Oc1cccc(CN(CC2C3CN(Cc4cccn4-c4ncccn4)CC23)C(=O)c2cscn2)c1 FNQBWWORCSKEHI-UHFFFAOYSA-N 0.000 claims 1
- YEOLNOQWPBRAHV-UHFFFAOYSA-N N-[[3-[(4-chloro-1-methylpyrazol-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-N-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound Cn1cnc(c1)C(=O)N(CC1C2CN(Cc3nn(C)cc3Cl)CC12)Cc1cccc(OC(F)(F)F)c1 YEOLNOQWPBRAHV-UHFFFAOYSA-N 0.000 claims 1
- BDDYXQJMFWZQKZ-UHFFFAOYSA-N N-[[3-[(4-chloro-1-methylpyrazol-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound Cn1cc(Cl)c(CN2CC3C(CN(Cc4cccc(OC(F)(F)F)c4)C(=O)c4cscn4)C3C2)n1 BDDYXQJMFWZQKZ-UHFFFAOYSA-N 0.000 claims 1
- HLPWBJMUOTVAQI-UHFFFAOYSA-N N-[[3-[2-(cyclopropylmethylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-N-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1(CC1)CNC(=O)CN1CC2C(C2C1)CN(C(=O)C=1N=CN(C1)C)CC1=CC(=CC=C1)OC(F)(F)F HLPWBJMUOTVAQI-UHFFFAOYSA-N 0.000 claims 1
- CCORHJDBDREEMU-UHFFFAOYSA-N ethyl 2-methyl-3-[6-[[(1-methylimidazole-4-carbonyl)-[[3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-3-azabicyclo[3.1.0]hexan-3-yl]propanoate Chemical compound C12CN(CC(C)C(=O)OCC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 CCORHJDBDREEMU-UHFFFAOYSA-N 0.000 claims 1
- ABCRUMKRORTHAJ-UHFFFAOYSA-N ethyl 2-methyl-3-[6-[[1,3-thiazole-4-carbonyl-[[3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-3-azabicyclo[3.1.0]hexan-3-yl]propanoate;1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC=N1.C12CN(CC(C)C(=O)OCC)CC2C1CN(C(=O)C=1N=CSC=1)CC1=CC=CC(OC(F)(F)F)=C1 ABCRUMKRORTHAJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004938 molindone Drugs 0.000 claims 1
- ULDICCYHCIDWMX-UHFFFAOYSA-N n-(2-ethylbutyl)-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC(F)(F)F)CC2C1CN(CC(CC)CC)C(=O)C1=CN(C)C=N1 ULDICCYHCIDWMX-UHFFFAOYSA-N 0.000 claims 1
- TVKJCEOADLNVSL-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-(3-phenylpropyl)imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CCCC=2C=CC=CC=2)CC2C3CNCC32)=C1 TVKJCEOADLNVSL-UHFFFAOYSA-N 0.000 claims 1
- YALHMDZMZDMRMX-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-(4-phenylbutyl)imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CCCCC=2C=CC=CC=2)CC2C3CNCC32)=C1 YALHMDZMZDMRMX-UHFFFAOYSA-N 0.000 claims 1
- CYFPTLUUAPPFBF-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[(3-phenylphenyl)methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(C=CC=2)C=2C=CC=CC=2)=C1 CYFPTLUUAPPFBF-UHFFFAOYSA-N 0.000 claims 1
- PXJRYGDFNQZDOB-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[(4-phenoxyphenyl)methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1 PXJRYGDFNQZDOB-UHFFFAOYSA-N 0.000 claims 1
- RDCYFRMPEUQPKR-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[(4-phenylphenyl)methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 RDCYFRMPEUQPKR-UHFFFAOYSA-N 0.000 claims 1
- CZHGFMLYHRCXJL-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[2-[3-(trifluoromethyl)phenyl]ethyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CCC=2C=C(C=CC=2)C(F)(F)F)CC2C3CNCC32)=C1 CZHGFMLYHRCXJL-UHFFFAOYSA-N 0.000 claims 1
- IXNFQIVSDQKFAF-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[[2-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C(=CC=CC=2)OC(F)(F)F)=C1 IXNFQIVSDQKFAF-UHFFFAOYSA-N 0.000 claims 1
- YIZIBSUQSOSKMB-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-1-methyl-n-[[2-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C(=CC=CC=2)C(F)(F)F)=C1 YIZIBSUQSOSKMB-UHFFFAOYSA-N 0.000 claims 1
- FGVNFEFLUCUXDN-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(2,3-dichlorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C(=C(Cl)C=CC=2)Cl)=C1 FGVNFEFLUCUXDN-UHFFFAOYSA-N 0.000 claims 1
- VYHQJFYQYBXRCS-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(2,4-dichlorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C(=CC(Cl)=CC=2)Cl)=C1 VYHQJFYQYBXRCS-UHFFFAOYSA-N 0.000 claims 1
- CECLYFRTYUKWGB-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(2,4-difluorophenyl)methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC(F)=CC=C1CN(C(=O)C=1N=CSC=1)CC1C2CNCC21 CECLYFRTYUKWGB-UHFFFAOYSA-N 0.000 claims 1
- SLHHWSKXXVNPOD-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3,5-dichlorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(Cl)C=C(Cl)C=2)=C1 SLHHWSKXXVNPOD-UHFFFAOYSA-N 0.000 claims 1
- CQPLQTJABFDRNJ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3-cyclohexyloxy-4-fluorophenyl)methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(OC2CCCCC2)C(F)=CC=C1CN(CC1C2CNCC21)C(=O)C1=CSC=N1 CQPLQTJABFDRNJ-UHFFFAOYSA-N 0.000 claims 1
- BHNOHLJBCXEJLF-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(3-cyclopentyloxy-4-fluorophenyl)methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(OC2CCCC2)C(F)=CC=C1CN(CC1C2CNCC21)C(=O)C1=CSC=N1 BHNOHLJBCXEJLF-UHFFFAOYSA-N 0.000 claims 1
- KWEJCGKONZOMIQ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[(4-fluoro-3-propan-2-yloxyphenyl)methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(F)C(OC(C)C)=CC(CN(CC2C3CNCC32)C(=O)C=2N=CSC=2)=C1 KWEJCGKONZOMIQ-UHFFFAOYSA-N 0.000 claims 1
- JODRWSPRCFVMER-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[2-(3-chlorophenyl)ethyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CCC=2C=C(Cl)C=CC=2)CC2C3CNCC32)=C1 JODRWSPRCFVMER-UHFFFAOYSA-N 0.000 claims 1
- ZURWFIIZPFWNTR-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[2-(4-chlorophenyl)ethyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CCC=2C=CC(Cl)=CC=2)CC2C3CNCC32)=C1 ZURWFIIZPFWNTR-UHFFFAOYSA-N 0.000 claims 1
- YVDTYTSSONVILZ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[2-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC=C1CN(C(=O)C=1N=CSC=1)CC1C2CNCC21 YVDTYTSSONVILZ-UHFFFAOYSA-N 0.000 claims 1
- OYQASORIFBCGCQ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[2-(trifluoromethyl)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1CN(C(=O)C=1N=CSC=1)CC1C2CNCC21 OYQASORIFBCGCQ-UHFFFAOYSA-N 0.000 claims 1
- ZKZYPXKKQFDGGB-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C(=CC=C(C=2)C(F)(F)F)F)=C1 ZKZYPXKKQFDGGB-UHFFFAOYSA-N 0.000 claims 1
- ZOWXLZZFNSGHPL-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]pyridine-2-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1CN(C(=O)C=1N=CC=CC=1)CC1C2CNCC21 ZOWXLZZFNSGHPL-UHFFFAOYSA-N 0.000 claims 1
- XQTGDDLDWLLUFJ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-(2,2-dimethylpropoxy)-4-fluorophenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(F)C(OCC(C)(C)C)=CC(CN(CC2C3CNCC32)C(=O)C=2N=CSC=2)=C1 XQTGDDLDWLLUFJ-UHFFFAOYSA-N 0.000 claims 1
- DFPBCVFABBJEQN-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-(trifluoromethoxy)phenyl]methyl]pyridine-2-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CNCC32)C(=O)C=2N=CC=CC=2)=C1 DFPBCVFABBJEQN-UHFFFAOYSA-N 0.000 claims 1
- LIBKRRUWKXABAC-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CN(CC2C3CNCC32)C(=O)C=2N=CSC=2)=C1 LIBKRRUWKXABAC-UHFFFAOYSA-N 0.000 claims 1
- FONBDVMQUSSWDL-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CNCC32)CC=2C=C(C=C(F)C=2)C(F)(F)F)=C1 FONBDVMQUSSWDL-UHFFFAOYSA-N 0.000 claims 1
- LWELBZVVRSRCFW-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1=CC(F)=CC(CN(CC2C3CNCC32)C(=O)C=2N=CC=CC=2)=C1 LWELBZVVRSRCFW-UHFFFAOYSA-N 0.000 claims 1
- NMHXYFSOHOAXBZ-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]pyridine-2-carboxamide Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1CN(C(=O)C=1N=CC=CC=1)CC1C2CNCC21 NMHXYFSOHOAXBZ-UHFFFAOYSA-N 0.000 claims 1
- USYPDKJROXJVCF-UHFFFAOYSA-N n-(3-azabicyclo[3.1.0]hexan-6-ylmethyl)-n-[[5-fluoro-2-(trifluoromethyl)phenyl]methyl]pyridine-2-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C(CN(CC2C3CNCC32)C(=O)C=2N=CC=CC=2)=C1 USYPDKJROXJVCF-UHFFFAOYSA-N 0.000 claims 1
- YRJRMTQUWNPWAT-UHFFFAOYSA-N n-(3-cyclopentylpropyl)-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CCCC2CCCC2)CC2C3CN(CCC(F)(F)F)CC32)=C1 YRJRMTQUWNPWAT-UHFFFAOYSA-N 0.000 claims 1
- KBZUBFQFBLCWDC-UHFFFAOYSA-N n-(cyclohexylmethyl)-1-methyl-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1CCCCC1 KBZUBFQFBLCWDC-UHFFFAOYSA-N 0.000 claims 1
- PXKLWGDXSYZOAU-UHFFFAOYSA-N n-(cyclohexylmethyl)-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CCC(F)(F)F)CC32)CC2CCCCC2)=C1 PXKLWGDXSYZOAU-UHFFFAOYSA-N 0.000 claims 1
- DCYNNTRBDCFWJL-UHFFFAOYSA-N n-(cyclohexylmethyl)-n-[[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CC4)CC32)CC2CCCCC2)=C1 DCYNNTRBDCFWJL-UHFFFAOYSA-N 0.000 claims 1
- JLPGREZMHQTPRY-UHFFFAOYSA-N n-(cyclopropylmethyl)-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2CC2)CC2C3CN(CCC(F)(F)F)CC32)=C1 JLPGREZMHQTPRY-UHFFFAOYSA-N 0.000 claims 1
- SCKHRDRMXSQIAQ-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1h-imidazole-5-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=CNC=1)CC1=CC=C(F)C(Cl)=C1 SCKHRDRMXSQIAQ-UHFFFAOYSA-N 0.000 claims 1
- PHOBLFLXKXRRLI-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CCC(F)(F)F)CC32)CC=2C=C(Cl)C=CC=2)=C1 PHOBLFLXKXRRLI-UHFFFAOYSA-N 0.000 claims 1
- ZQRDLLGGEBOUMF-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-methyl-n-[[3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CCOCC2)CC=2C=C(Cl)C=CC=2)=C1 ZQRDLLGGEBOUMF-UHFFFAOYSA-N 0.000 claims 1
- HERBFTKBOYNVPO-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-propan-2-yl-n-[(3-propyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC)CC2C1CN(C(=O)C=1N=CN(C=1)C(C)C)CC1=CC=CC(Cl)=C1 HERBFTKBOYNVPO-UHFFFAOYSA-N 0.000 claims 1
- XBZCSKKCARDGLV-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-propan-2-yl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CC(C)N1C=NC(C(=O)N(CC2C3CN(CCC(F)(F)F)CC32)CC=2C=C(Cl)C=CC=2)=C1 XBZCSKKCARDGLV-UHFFFAOYSA-N 0.000 claims 1
- STIDSGIKWXMFNZ-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-propyl-n-[(3-propyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC)CC2C1CN(C(=O)C=1N=CN(CCC)C=1)CC1=CC=CC(Cl)=C1 STIDSGIKWXMFNZ-UHFFFAOYSA-N 0.000 claims 1
- YFUQYYBNOKGAKA-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-1-propyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CCCN1C=NC(C(=O)N(CC2C3CN(CCC(F)(F)F)CC32)CC=2C=C(Cl)C=CC=2)=C1 YFUQYYBNOKGAKA-UHFFFAOYSA-N 0.000 claims 1
- ZYQIGBDCXCIODK-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-[4-(trifluoromethoxy)phenyl]imidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C=1)C=1C=CC(OC(F)(F)F)=CC=1)CC1=CC=CC(Cl)=C1 ZYQIGBDCXCIODK-UHFFFAOYSA-N 0.000 claims 1
- UQMUBDPKZJHVMB-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-propan-2-ylimidazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CN(C=1)C(C)C)CC1=CC=CC(Cl)=C1 UQMUBDPKZJHVMB-UHFFFAOYSA-N 0.000 claims 1
- JGUZZBVREPHPOQ-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-propylimidazole-4-carboxamide Chemical compound CCCN1C=NC(C(=O)N(CC2C3CN(CC)CC32)CC=2C=C(Cl)C=CC=2)=C1 JGUZZBVREPHPOQ-UHFFFAOYSA-N 0.000 claims 1
- ADJDFYGQMCWYQP-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[(3-propyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-[2-[4-(trifluoromethoxy)phenyl]ethyl]imidazole-4-carboxamide Chemical compound C12CN(CCC)CC2C1CN(C(=O)C=1N=CN(CCC=2C=CC(OC(F)(F)F)=CC=2)C=1)CC1=CC=CC(Cl)=C1 ADJDFYGQMCWYQP-UHFFFAOYSA-N 0.000 claims 1
- ZYSCCPYKNZRXAJ-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[(3-propyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-[4-(trifluoromethoxy)phenyl]imidazole-4-carboxamide Chemical compound C12CN(CCC)CC2C1CN(C(=O)C=1N=CN(C=1)C=1C=CC(OC(F)(F)F)=CC=1)CC1=CC=CC(Cl)=C1 ZYSCCPYKNZRXAJ-UHFFFAOYSA-N 0.000 claims 1
- IFVIBFOMCGYNDM-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[(3-propyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-[4-(trifluoromethyl)phenyl]imidazole-4-carboxamide Chemical compound C12CN(CCC)CC2C1CN(C(=O)C=1N=CN(C=1)C=1C=CC(=CC=1)C(F)(F)F)CC1=CC=CC(Cl)=C1 IFVIBFOMCGYNDM-UHFFFAOYSA-N 0.000 claims 1
- UCISBROBSMBLFQ-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[(3-propyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-[[4-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC)CC2C1CN(C(=O)C=1N=CN(CC=2C=CC(OC(F)(F)F)=CC=2)C=1)CC1=CC=CC(Cl)=C1 UCISBROBSMBLFQ-UHFFFAOYSA-N 0.000 claims 1
- XUJSRHNVRPLDBC-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[[3-[(1-hydroxycyclohexyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCCCC4)CC32)CC=2C=C(Cl)C=CC=2)=C1 XUJSRHNVRPLDBC-UHFFFAOYSA-N 0.000 claims 1
- YNMHUKDPXQMXSI-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[[3-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CC5=CC=CC=C5C4)CC32)CC=2C=C(Cl)C=CC=2)=C1 YNMHUKDPXQMXSI-UHFFFAOYSA-N 0.000 claims 1
- KLKGSILXENMETB-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-[[3-[(4-hydroxyoxan-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCOCC4)CC32)CC=2C=C(Cl)C=CC=2)=C1 KLKGSILXENMETB-UHFFFAOYSA-N 0.000 claims 1
- NEWJKCZCXLPXIC-UHFFFAOYSA-N n-[(3-cyclobutyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CCC2)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 NEWJKCZCXLPXIC-UHFFFAOYSA-N 0.000 claims 1
- LNSHLQXEKJQFAT-UHFFFAOYSA-N n-[(3-cyclopentyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CCCC2)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 LNSHLQXEKJQFAT-UHFFFAOYSA-N 0.000 claims 1
- WYWJDDAAMNNCOA-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]pyrazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C1=NN(C)C=C1)CC1=CC=CC(OC(F)(F)F)=C1 WYWJDDAAMNNCOA-UHFFFAOYSA-N 0.000 claims 1
- TXSNHKQBQBWEJW-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-2-propan-2-yl-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=C(SC=1)C(C)C)CC1=CC=CC(OC(F)(F)F)=C1 TXSNHKQBQBWEJW-UHFFFAOYSA-N 0.000 claims 1
- ZQXAWGDSTXBARC-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-5-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]-1h-imidazole-2-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1NC(C)=CN=1)CC1=CC=CC(OC(F)(F)F)=C1 ZQXAWGDSTXBARC-UHFFFAOYSA-N 0.000 claims 1
- IGHHRSJMNBOSBE-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-5-propan-2-yl-n-[[3-(trifluoromethoxy)phenyl]methyl]-1h-pyrazole-3-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C1=NNC(=C1)C(C)C)CC1=CC=CC(OC(F)(F)F)=C1 IGHHRSJMNBOSBE-UHFFFAOYSA-N 0.000 claims 1
- AXXFJSSZVYWLOB-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CSC=1)CC1=CC=CC(OC(F)(F)F)=C1 AXXFJSSZVYWLOB-UHFFFAOYSA-N 0.000 claims 1
- IBPDNAJICJMLIA-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]pyridine-2-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=CC=CC=1)CC1=CC=CC(OC(F)(F)F)=C1 IBPDNAJICJMLIA-UHFFFAOYSA-N 0.000 claims 1
- VUDRNFWKDHKNCW-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]quinoline-2-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1N=C2C=CC=CC2=CC=1)CC1=CC=CC(OC(F)(F)F)=C1 VUDRNFWKDHKNCW-UHFFFAOYSA-N 0.000 claims 1
- ZCDQAMKXHBBPBB-UHFFFAOYSA-N n-[(3-ethyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]quinoline-4-carboxamide Chemical compound C12CN(CC)CC2C1CN(C(=O)C=1C2=CC=CC=C2N=CC=1)CC1=CC=CC(OC(F)(F)F)=C1 ZCDQAMKXHBBPBB-UHFFFAOYSA-N 0.000 claims 1
- HFJSDUSJWZVBKM-UHFFFAOYSA-N n-[(3-heptyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCCCCCC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 HFJSDUSJWZVBKM-UHFFFAOYSA-N 0.000 claims 1
- RSPJJMKZTCMZKG-UHFFFAOYSA-N n-[(3-methyl-3-azabicyclo[3.1.0]hexan-6-yl)methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-6,7-dihydro-5h-pyrrolo[1,2-a]imidazole-2-carboxamide Chemical compound C12CN(C)CC2C1CN(C(=O)C=1N=C2CCCN2C=1)CC1=CC=CC(OC(F)(F)F)=C1 RSPJJMKZTCMZKG-UHFFFAOYSA-N 0.000 claims 1
- ZGJVDDZYTYUBPC-UHFFFAOYSA-N n-[[3-(1,2-oxazol-3-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC4=NOC=C4)CC32)C(=O)C=2N=CSC=2)=C1 ZGJVDDZYTYUBPC-UHFFFAOYSA-N 0.000 claims 1
- XGAWOCOVUPRSTL-UHFFFAOYSA-N n-[[3-(1,3-benzodioxol-4-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=5OCOC=5C=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 XGAWOCOVUPRSTL-UHFFFAOYSA-N 0.000 claims 1
- ATSXGIRGUZBENJ-UHFFFAOYSA-N n-[[3-(1,3-benzodioxol-4-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=5OCOC=5C=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 ATSXGIRGUZBENJ-UHFFFAOYSA-N 0.000 claims 1
- XZQFGSKIVHXJDB-UHFFFAOYSA-N n-[[3-(1,3-benzodioxol-5-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=C5OCOC5=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 XZQFGSKIVHXJDB-UHFFFAOYSA-N 0.000 claims 1
- UJBPYYZVZIFROU-UHFFFAOYSA-N n-[[3-(1,3-benzodioxol-5-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=C5OCOC5=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 UJBPYYZVZIFROU-UHFFFAOYSA-N 0.000 claims 1
- UKDXUSJSLLLRES-UHFFFAOYSA-N n-[[3-(1,3-benzothiazol-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4SC5=CC=CC=C5N=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 UKDXUSJSLLLRES-UHFFFAOYSA-N 0.000 claims 1
- DKPXRPGFTSOVMR-UHFFFAOYSA-N n-[[3-(1h-benzimidazol-2-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C=2NC3=CC=CC=C3N=2)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 DKPXRPGFTSOVMR-UHFFFAOYSA-N 0.000 claims 1
- JIAFFYZLKILPPK-UHFFFAOYSA-N n-[[3-(1h-benzimidazol-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4NC5=CC=CC=C5N=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 JIAFFYZLKILPPK-UHFFFAOYSA-N 0.000 claims 1
- MRMOPRRMKAUVLG-UHFFFAOYSA-N n-[[3-(1h-imidazol-5-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4NC=NC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 MRMOPRRMKAUVLG-UHFFFAOYSA-N 0.000 claims 1
- YJVIYLIJDFNBSE-UHFFFAOYSA-N n-[[3-(1h-imidazol-5-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4NC=NC=4)CC32)C(=O)C=2N=CSC=2)=C1 YJVIYLIJDFNBSE-UHFFFAOYSA-N 0.000 claims 1
- CRKMGJWLCKSTJG-UHFFFAOYSA-N n-[[3-(1h-indol-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4NC5=CC=CC=C5C=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 CRKMGJWLCKSTJG-UHFFFAOYSA-N 0.000 claims 1
- YMOJQPXKBQHHQD-UHFFFAOYSA-N n-[[3-(1h-indol-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4NC5=CC=CC=C5C=4)CC32)C(=O)C=2N=CSC=2)=C1 YMOJQPXKBQHHQD-UHFFFAOYSA-N 0.000 claims 1
- GDQUSKRRYJMALU-UHFFFAOYSA-N n-[[3-(1h-indol-3-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C5=CC=CC=C5NC=4)CC32)C(=O)C=2N=CSC=2)=C1 GDQUSKRRYJMALU-UHFFFAOYSA-N 0.000 claims 1
- FYRUCKCHHSAZSV-UHFFFAOYSA-N n-[[3-(1h-indol-5-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=C5C=CNC5=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 FYRUCKCHHSAZSV-UHFFFAOYSA-N 0.000 claims 1
- GIRRVEGDDPYGBT-UHFFFAOYSA-N n-[[3-(1h-indol-5-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=C5C=CNC5=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 GIRRVEGDDPYGBT-UHFFFAOYSA-N 0.000 claims 1
- FWNJMXHRFNXVCA-UHFFFAOYSA-N n-[[3-(1h-pyrrol-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4NC=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 FWNJMXHRFNXVCA-UHFFFAOYSA-N 0.000 claims 1
- SFKAHDHDRBVEOB-UHFFFAOYSA-N n-[[3-(2,2-dimethylpropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(C)(C)C)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 SFKAHDHDRBVEOB-UHFFFAOYSA-N 0.000 claims 1
- XXLJXMYMZNUKNH-UHFFFAOYSA-N n-[[3-(2-anilino-2-oxoethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC=4C=CC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 XXLJXMYMZNUKNH-UHFFFAOYSA-N 0.000 claims 1
- SWDZDQQZMJSTQM-UHFFFAOYSA-N n-[[3-(2-ethyl-3-methylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(CC)C(C)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 SWDZDQQZMJSTQM-UHFFFAOYSA-N 0.000 claims 1
- HDSOBSLJAQGEDP-UHFFFAOYSA-N n-[[3-(2-ethylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(CC)CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 HDSOBSLJAQGEDP-UHFFFAOYSA-N 0.000 claims 1
- JYIQQVZDRUKDLF-UHFFFAOYSA-N n-[[3-(2-ethylhexyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(CC)CCCC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 JYIQQVZDRUKDLF-UHFFFAOYSA-N 0.000 claims 1
- IAEMNFLCCURWRX-UHFFFAOYSA-N n-[[3-(2-hydroxy-2-methylpropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(C)(C)O)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 IAEMNFLCCURWRX-UHFFFAOYSA-N 0.000 claims 1
- JLJRXXPLAHLERW-UHFFFAOYSA-N n-[[3-(2-hydroxycyclopentyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2C(CCC2)O)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 JLJRXXPLAHLERW-UHFFFAOYSA-N 0.000 claims 1
- FMECJYGECRHEJE-UHFFFAOYSA-N n-[[3-(2-phenylethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CCC=4C=CC=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 FMECJYGECRHEJE-UHFFFAOYSA-N 0.000 claims 1
- LNELWFMWBPSSBQ-UHFFFAOYSA-N n-[[3-(2-phenylpropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C=1C=CC=CC=1C(C)CN(CC12)CC1C2CN(C(=O)C=1N=CSC=1)CC1=CC=CC(OC(F)(F)F)=C1 LNELWFMWBPSSBQ-UHFFFAOYSA-N 0.000 claims 1
- MMZLPASJKKGDMH-UHFFFAOYSA-N n-[[3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CCC(C)(C)C)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 MMZLPASJKKGDMH-UHFFFAOYSA-N 0.000 claims 1
- ZIDHSCANFIVXCO-UHFFFAOYSA-N n-[[3-(3-phenylpropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CCCC=4C=CC=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 ZIDHSCANFIVXCO-UHFFFAOYSA-N 0.000 claims 1
- LXCFJRDRUBNZAO-UHFFFAOYSA-N n-[[3-(azetidin-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[(3-chlorophenyl)methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CNC2)CC=2C=C(Cl)C=CC=2)=C1 LXCFJRDRUBNZAO-UHFFFAOYSA-N 0.000 claims 1
- GOFOBWIHKFLTDA-UHFFFAOYSA-N n-[[3-(cyclohexylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CCCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 GOFOBWIHKFLTDA-UHFFFAOYSA-N 0.000 claims 1
- CCGOUGRRVTZKAC-UHFFFAOYSA-N n-[[3-(cyclohexylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC4CCCCC4)CC32)C(=O)C=2N=CSC=2)=C1 CCGOUGRRVTZKAC-UHFFFAOYSA-N 0.000 claims 1
- MVQUSGKVXSWWPS-UHFFFAOYSA-N n-[[3-(cyclopentylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CCCC4)CC32)CC=2C=C(C=CC=2)C(F)(F)F)=C1 MVQUSGKVXSWWPS-UHFFFAOYSA-N 0.000 claims 1
- GNFORGDZFISPMW-UHFFFAOYSA-N n-[[3-(cyclopentylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC4CCCC4)CC32)C(=O)C=2N=CSC=2)=C1 GNFORGDZFISPMW-UHFFFAOYSA-N 0.000 claims 1
- ZCQBJHCGRWYSSR-UHFFFAOYSA-N n-[[3-(cyclopentylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CCCC4)CC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 ZCQBJHCGRWYSSR-UHFFFAOYSA-N 0.000 claims 1
- JMWYMPBVEWZOIE-UHFFFAOYSA-N n-[[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC4CC4)CC32)C(=O)C=2N=CSC=2)=C1 JMWYMPBVEWZOIE-UHFFFAOYSA-N 0.000 claims 1
- IYGWDQJDKJQNOI-UHFFFAOYSA-N n-[[3-(cyclopropylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4CC4)CC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 IYGWDQJDKJQNOI-UHFFFAOYSA-N 0.000 claims 1
- IXZFHQXXERWVMA-UHFFFAOYSA-N n-[[3-(furan-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4OC=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 IXZFHQXXERWVMA-UHFFFAOYSA-N 0.000 claims 1
- ZRDWUPMGAWRWPO-UHFFFAOYSA-N n-[[3-(furan-3-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC4=COC=C4)CC32)C(=O)C=2N=CSC=2)=C1 ZRDWUPMGAWRWPO-UHFFFAOYSA-N 0.000 claims 1
- ZPIYFWYBPAMNFU-UHFFFAOYSA-N n-[[3-(naphthalen-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=C5C=CC=CC5=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 ZPIYFWYBPAMNFU-UHFFFAOYSA-N 0.000 claims 1
- QEPSVXVFMVQPHI-UHFFFAOYSA-N n-[[3-(oxolan-2-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC4OCCC4)CC32)C(=O)C=2N=CSC=2)=C1 QEPSVXVFMVQPHI-UHFFFAOYSA-N 0.000 claims 1
- MTQQMYWBVDSWQW-UHFFFAOYSA-N n-[[3-(quinolin-7-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=C5N=CC=CC5=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 MTQQMYWBVDSWQW-UHFFFAOYSA-N 0.000 claims 1
- CRMZZKXZGDQHTI-UHFFFAOYSA-N n-[[3-(quinolin-8-ylmethyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C5=NC=CC=C5C=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 CRMZZKXZGDQHTI-UHFFFAOYSA-N 0.000 claims 1
- ZUDJSIKDORCOIP-UHFFFAOYSA-N n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[2-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C(=CC=CC=4)OC(F)(F)F)CC32)C(=O)C=2N=CSC=2)=C1 ZUDJSIKDORCOIP-UHFFFAOYSA-N 0.000 claims 1
- IJJUMFWODCIEKF-UHFFFAOYSA-N n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[3-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=C(OC(F)(F)F)C=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 IJJUMFWODCIEKF-UHFFFAOYSA-N 0.000 claims 1
- DSUJLIDGMAPDOM-UHFFFAOYSA-N n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[4-(trifluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 DSUJLIDGMAPDOM-UHFFFAOYSA-N 0.000 claims 1
- UHURCDDIQUNKJX-UHFFFAOYSA-N n-[[3-(trifluoromethoxy)phenyl]methyl]-n-[[3-[[4-(trifluoromethyl)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=CC(=CC=4)C(F)(F)F)CC32)C(=O)C=2N=CSC=2)=C1 UHURCDDIQUNKJX-UHFFFAOYSA-N 0.000 claims 1
- KFIIXKZVPVXYSB-UHFFFAOYSA-N n-[[3-[(1,5-dimethylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=NN(C)C(C)=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 KFIIXKZVPVXYSB-UHFFFAOYSA-N 0.000 claims 1
- VTIPOVQEMPWSEE-UHFFFAOYSA-N n-[[3-[(1,5-dimethylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=NN(C)C(C)=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 VTIPOVQEMPWSEE-UHFFFAOYSA-N 0.000 claims 1
- NJXFHWXILDRCHR-UHFFFAOYSA-N n-[[3-[(1-ethyl-3-methylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound CC1=NN(CC)C=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 NJXFHWXILDRCHR-UHFFFAOYSA-N 0.000 claims 1
- RDIASWNCMNWINE-UHFFFAOYSA-N n-[[3-[(1-ethyl-5-methylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CCN1N=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CN(C)C=4)C3C2)=C1C RDIASWNCMNWINE-UHFFFAOYSA-N 0.000 claims 1
- ZAJSSQSZZJBDRF-UHFFFAOYSA-N n-[[3-[(1-ethyl-5-methylpyrazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound CCN1N=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1C ZAJSSQSZZJBDRF-UHFFFAOYSA-N 0.000 claims 1
- BUTRGMSXLSRZFX-UHFFFAOYSA-N n-[[3-[(1-hydroxycyclohexyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCCCC4)CC32)CC=2C=C(C=CC=2)C(F)(F)F)=C1 BUTRGMSXLSRZFX-UHFFFAOYSA-N 0.000 claims 1
- LGEDTSARZMBKLT-UHFFFAOYSA-N n-[[3-[(1-hydroxycyclopentyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethyl)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCCC4)CC32)CC=2C=C(C=CC=2)C(F)(F)F)=C1 LGEDTSARZMBKLT-UHFFFAOYSA-N 0.000 claims 1
- NJZRVOCQNCOZKL-UHFFFAOYSA-N n-[[3-[(1-methylimidazol-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound CN1C=CN=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 NJZRVOCQNCOZKL-UHFFFAOYSA-N 0.000 claims 1
- ZKXVRYMWVXDQOE-UHFFFAOYSA-N n-[[3-[(2,3-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C(=C(F)C=CC=4)F)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 ZKXVRYMWVXDQOE-UHFFFAOYSA-N 0.000 claims 1
- VNAANYZBOJVRKV-UHFFFAOYSA-N n-[[3-[(2,3-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1F VNAANYZBOJVRKV-UHFFFAOYSA-N 0.000 claims 1
- ZQCIKIBBZVOPJJ-UHFFFAOYSA-N n-[[3-[(2,4-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C(=CC(F)=CC=4)F)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 ZQCIKIBBZVOPJJ-UHFFFAOYSA-N 0.000 claims 1
- BWTWNXVMUUAKEE-UHFFFAOYSA-N n-[[3-[(2,4-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC(F)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 BWTWNXVMUUAKEE-UHFFFAOYSA-N 0.000 claims 1
- URGPTFAJGMTJGG-UHFFFAOYSA-N n-[[3-[(2,4-dimethylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CC1=CC(C)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 URGPTFAJGMTJGG-UHFFFAOYSA-N 0.000 claims 1
- UUDKAMPKMRZHDS-UHFFFAOYSA-N n-[[3-[(2,4-dimethylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound CC1=CC(C)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 UUDKAMPKMRZHDS-UHFFFAOYSA-N 0.000 claims 1
- PVIRINLLGQESTR-UHFFFAOYSA-N n-[[3-[(2,5-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C(=CC=C(F)C=4)F)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 PVIRINLLGQESTR-UHFFFAOYSA-N 0.000 claims 1
- BXNZUSRVACBQPT-UHFFFAOYSA-N n-[[3-[(2,5-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC=C(F)C(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1 BXNZUSRVACBQPT-UHFFFAOYSA-N 0.000 claims 1
- VNLPKYZFKQVEQF-UHFFFAOYSA-N n-[[3-[(2,5-dimethylpyrazol-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1N=C(C)C=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 VNLPKYZFKQVEQF-UHFFFAOYSA-N 0.000 claims 1
- IWUBERBPBNMHJV-UHFFFAOYSA-N n-[[3-[(2-butyl-1h-imidazol-5-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound N1C(CCCC)=NC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 IWUBERBPBNMHJV-UHFFFAOYSA-N 0.000 claims 1
- FIMIGAZHEJVVAT-UHFFFAOYSA-N n-[[3-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4SC(Cl)=NC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 FIMIGAZHEJVVAT-UHFFFAOYSA-N 0.000 claims 1
- MKWMVRXZLXETAN-UHFFFAOYSA-N n-[[3-[(2-chloro-1,3-thiazol-5-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4SC(Cl)=NC=4)CC32)C(=O)C=2N=CSC=2)=C1 MKWMVRXZLXETAN-UHFFFAOYSA-N 0.000 claims 1
- IYWSWIYNUXDFAN-UHFFFAOYSA-N n-[[3-[(2-chloropyridin-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C(=NC=CC=4)Cl)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 IYWSWIYNUXDFAN-UHFFFAOYSA-N 0.000 claims 1
- RBSUWNLSTGESPQ-UHFFFAOYSA-N n-[[3-[(2-chloropyridin-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C(=NC=CC=4)Cl)CC32)C(=O)C=2N=CSC=2)=C1 RBSUWNLSTGESPQ-UHFFFAOYSA-N 0.000 claims 1
- IJBFQRCWBIVBSL-UHFFFAOYSA-N n-[[3-[(2-ethyl-5-methyl-1h-imidazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound N1C(CC)=NC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1C IJBFQRCWBIVBSL-UHFFFAOYSA-N 0.000 claims 1
- IQMSYDNSXWSRSU-UHFFFAOYSA-N n-[[3-[(2-fluoro-4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC(OC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 IQMSYDNSXWSRSU-UHFFFAOYSA-N 0.000 claims 1
- LIDHQZCKPUTHMF-UHFFFAOYSA-N n-[[3-[(2-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 LIDHQZCKPUTHMF-UHFFFAOYSA-N 0.000 claims 1
- BOONHJZRILUADK-UHFFFAOYSA-N n-[[3-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CC5=CC=CC=C5C4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 BOONHJZRILUADK-UHFFFAOYSA-N 0.000 claims 1
- ZTNUBVJVHZUHJK-UHFFFAOYSA-N n-[[3-[(2-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound CC1=CC=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 ZTNUBVJVHZUHJK-UHFFFAOYSA-N 0.000 claims 1
- SVCGVGBXEMCJBK-UHFFFAOYSA-N n-[[3-[(3,5-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=C(F)C=C(F)C=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 SVCGVGBXEMCJBK-UHFFFAOYSA-N 0.000 claims 1
- UHOYECVLUKPNJY-UHFFFAOYSA-N n-[[3-[(3,5-difluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC(F)=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1 UHOYECVLUKPNJY-UHFFFAOYSA-N 0.000 claims 1
- VHDXVUBPSUPNIX-UHFFFAOYSA-N n-[[3-[(3,5-dimethylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound CC1=CC(C)=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1 VHDXVUBPSUPNIX-UHFFFAOYSA-N 0.000 claims 1
- OOTGAGOTWBKFPE-UHFFFAOYSA-N n-[[3-[(3-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=C(Cl)C=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 OOTGAGOTWBKFPE-UHFFFAOYSA-N 0.000 claims 1
- YQMJDXJBDAXROI-UHFFFAOYSA-N n-[[3-[(3-cyano-4-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(C#N)C(F)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 YQMJDXJBDAXROI-UHFFFAOYSA-N 0.000 claims 1
- KHBZQFCEHJDNDB-UHFFFAOYSA-N n-[[3-[(3-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=C(C=CC=4)C#N)CC32)C(=O)C=2N=CSC=2)=C1 KHBZQFCEHJDNDB-UHFFFAOYSA-N 0.000 claims 1
- IHARUSKVRZHDCO-UHFFFAOYSA-N n-[[3-[(3-fluoro-4-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 IHARUSKVRZHDCO-UHFFFAOYSA-N 0.000 claims 1
- ZFCQOJDYLIAKMY-UHFFFAOYSA-N n-[[3-[(3-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC1=CC=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1 ZFCQOJDYLIAKMY-UHFFFAOYSA-N 0.000 claims 1
- GAGRLLPUUJVCAZ-UHFFFAOYSA-N n-[[3-[(3-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound CC1=CC=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1 GAGRLLPUUJVCAZ-UHFFFAOYSA-N 0.000 claims 1
- WVNDEKGQIJKVMB-UHFFFAOYSA-N n-[[3-[(4-butoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OCCCC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 WVNDEKGQIJKVMB-UHFFFAOYSA-N 0.000 claims 1
- NXIONYAMFQINAD-UHFFFAOYSA-N n-[[3-[(4-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(Cl)=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 NXIONYAMFQINAD-UHFFFAOYSA-N 0.000 claims 1
- RIBVIBJMFRASEN-UHFFFAOYSA-N n-[[3-[(4-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-pentylimidazole-4-carboxamide Chemical compound C=1N(C)C=NC=1C(=O)N(CCCCC)CC(C1C2)C1CN2CC1=CC=C(Cl)C=C1 RIBVIBJMFRASEN-UHFFFAOYSA-N 0.000 claims 1
- ULCHVWKQOFJTNX-UHFFFAOYSA-N n-[[3-[(4-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-(cyclohexylmethyl)-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(Cl)=CC=4)CC32)CC2CCCCC2)=C1 ULCHVWKQOFJTNX-UHFFFAOYSA-N 0.000 claims 1
- FLDYHUYLNPPWJI-UHFFFAOYSA-N n-[[3-[(4-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-(cyclopropylmethyl)-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2CC2)CC2C3CN(CC=4C=CC(Cl)=CC=4)CC32)=C1 FLDYHUYLNPPWJI-UHFFFAOYSA-N 0.000 claims 1
- OGSFVFLLILUTBT-UHFFFAOYSA-N n-[[3-[(4-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=CC(Cl)=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 OGSFVFLLILUTBT-UHFFFAOYSA-N 0.000 claims 1
- YXVKOKLSRAAMAE-UHFFFAOYSA-N n-[[3-[(4-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(=CC=4)C#N)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 YXVKOKLSRAAMAE-UHFFFAOYSA-N 0.000 claims 1
- OAENXSCPQPQAAG-UHFFFAOYSA-N n-[[3-[(4-cyanophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=CC(=CC=4)C#N)CC32)C(=O)C=2N=CSC=2)=C1 OAENXSCPQPQAAG-UHFFFAOYSA-N 0.000 claims 1
- PVEGLSWCNNTEBB-UHFFFAOYSA-N n-[[3-[(4-ethoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OCC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 PVEGLSWCNNTEBB-UHFFFAOYSA-N 0.000 claims 1
- TUKBKAPAFSAMDY-UHFFFAOYSA-N n-[[3-[(4-ethylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=CC(CC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 TUKBKAPAFSAMDY-UHFFFAOYSA-N 0.000 claims 1
- VUCQNIMRIOEZGG-UHFFFAOYSA-N n-[[3-[(4-ethylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(CC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 VUCQNIMRIOEZGG-UHFFFAOYSA-N 0.000 claims 1
- GWGREEFVTLKBOY-UHFFFAOYSA-N n-[[3-[(4-fluoro-3-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1 GWGREEFVTLKBOY-UHFFFAOYSA-N 0.000 claims 1
- WGLWJARIBASNPL-UHFFFAOYSA-N n-[[3-[(4-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 WGLWJARIBASNPL-UHFFFAOYSA-N 0.000 claims 1
- BZTJRQXYAJBKQB-UHFFFAOYSA-N n-[[3-[(4-hydroxyoxan-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCOCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 BZTJRQXYAJBKQB-UHFFFAOYSA-N 0.000 claims 1
- CXGJHSAFBNZOTR-UHFFFAOYSA-N n-[[3-[(4-methoxy-3-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=C(C)C(OC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 CXGJHSAFBNZOTR-UHFFFAOYSA-N 0.000 claims 1
- UBDPPTSXOATONO-UHFFFAOYSA-N n-[[3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 UBDPPTSXOATONO-UHFFFAOYSA-N 0.000 claims 1
- FFHHKRGNUDMYGO-UHFFFAOYSA-N n-[[3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 FFHHKRGNUDMYGO-UHFFFAOYSA-N 0.000 claims 1
- BSRZKKVUIZDCKE-UHFFFAOYSA-N n-[[3-[(4-methylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 BSRZKKVUIZDCKE-UHFFFAOYSA-N 0.000 claims 1
- ARFCVGZQOASWGK-UHFFFAOYSA-N n-[[3-[(4-phenoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=CC(OC=5C=CC=CC=5)=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 ARFCVGZQOASWGK-UHFFFAOYSA-N 0.000 claims 1
- YLOVSFMBTMLBJM-UHFFFAOYSA-N n-[[3-[(4-phenylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4C=CC(=CC=4)C=4C=CC=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 YLOVSFMBTMLBJM-UHFFFAOYSA-N 0.000 claims 1
- XABSURVDUOOITG-UHFFFAOYSA-N n-[[3-[(4-propan-2-ylphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 XABSURVDUOOITG-UHFFFAOYSA-N 0.000 claims 1
- OOEDRIWMVVFTJC-UHFFFAOYSA-N n-[[3-[(5-methyl-1h-imidazol-4-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound N1C=NC(CN2CC3C(CN(CC=4C=C(OC(F)(F)F)C=CC=4)C(=O)C=4N=CSC=4)C3C2)=C1C OOEDRIWMVVFTJC-UHFFFAOYSA-N 0.000 claims 1
- FIIVGVYBTYKSBV-UHFFFAOYSA-N n-[[3-[(6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C5CC(C5(C)C)CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 FIIVGVYBTYKSBV-UHFFFAOYSA-N 0.000 claims 1
- DTJZXSWFJADIEF-UHFFFAOYSA-N n-[[3-[(6-oxo-1h-pyridin-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CN(CC2C3CN(CC=4NC(=O)C=CC=4)CC32)C(=O)C=2N=CSC=2)=C1 DTJZXSWFJADIEF-UHFFFAOYSA-N 0.000 claims 1
- NIIWGPZVRMGITB-UHFFFAOYSA-N n-[[3-[2-(1,3-dihydroisoindol-2-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CC5=CC=CC=C5C4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 NIIWGPZVRMGITB-UHFFFAOYSA-N 0.000 claims 1
- OMCDIXOAVCBKLV-UHFFFAOYSA-N n-[[3-[2-(1-methoxypropan-2-ylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)NC(C)COC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 OMCDIXOAVCBKLV-UHFFFAOYSA-N 0.000 claims 1
- SPRQDNPYHJBOLY-UHFFFAOYSA-N n-[[3-[2-(1h-imidazol-2-ylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC=4NC=CN=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 SPRQDNPYHJBOLY-UHFFFAOYSA-N 0.000 claims 1
- PQCXFOWZLMKJCH-UHFFFAOYSA-N n-[[3-[2-(2,2-dimethylpropylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NCC(C)(C)C)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 PQCXFOWZLMKJCH-UHFFFAOYSA-N 0.000 claims 1
- XKRWAMQLKZBUQS-UHFFFAOYSA-N n-[[3-[2-(2,6-dimethylmorpholin-4-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C(C)OC(C)CN1C(=O)CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 XKRWAMQLKZBUQS-UHFFFAOYSA-N 0.000 claims 1
- SNUHJQNWKWFNAA-UHFFFAOYSA-N n-[[3-[2-(2-hydroxypropylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)NCC(O)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 SNUHJQNWKWFNAA-UHFFFAOYSA-N 0.000 claims 1
- ILNOKIARAHSBOZ-UHFFFAOYSA-N n-[[3-[2-(2-methoxyethylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)NCCOC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 ILNOKIARAHSBOZ-UHFFFAOYSA-N 0.000 claims 1
- WIIBSPSVSHZEMX-UHFFFAOYSA-N n-[[3-[2-(3,4-difluoropyrrolidin-1-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CC(F)C(F)C4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 WIIBSPSVSHZEMX-UHFFFAOYSA-N 0.000 claims 1
- BHJOSZXVRAELIM-UHFFFAOYSA-N n-[[3-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CC(O)CCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 BHJOSZXVRAELIM-UHFFFAOYSA-N 0.000 claims 1
- QAOYAYKXEZCPSS-UHFFFAOYSA-N n-[[3-[2-(4-methylphenyl)ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1CCN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 QAOYAYKXEZCPSS-UHFFFAOYSA-N 0.000 claims 1
- JZLUXWWPHWTVDQ-UHFFFAOYSA-N n-[[3-[2-(cyclobutylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC4CCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 JZLUXWWPHWTVDQ-UHFFFAOYSA-N 0.000 claims 1
- BRHACIKFUOJNIV-UHFFFAOYSA-N n-[[3-[2-(cyclohexylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC4CCCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 BRHACIKFUOJNIV-UHFFFAOYSA-N 0.000 claims 1
- MXSUGJMZXVAAMK-UHFFFAOYSA-N n-[[3-[2-(cyclopentylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC4CCCC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 MXSUGJMZXVAAMK-UHFFFAOYSA-N 0.000 claims 1
- XQXFWNXKAIBLCT-UHFFFAOYSA-N n-[[3-[2-(cyclopropylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC4CC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 XQXFWNXKAIBLCT-UHFFFAOYSA-N 0.000 claims 1
- MDHROJQWIBIIQI-UHFFFAOYSA-N n-[[3-[2-(dimethylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)N(C)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 MDHROJQWIBIIQI-UHFFFAOYSA-N 0.000 claims 1
- KHLDYSWUVJFREY-UHFFFAOYSA-N n-[[3-[2-(furan-2-ylmethylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NCC=4OC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 KHLDYSWUVJFREY-UHFFFAOYSA-N 0.000 claims 1
- FPCFYLPQHVXHHE-UHFFFAOYSA-N n-[[3-[2-(tert-butylamino)-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC(C)(C)C)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 FPCFYLPQHVXHHE-UHFFFAOYSA-N 0.000 claims 1
- YCKODPODPOMBMS-UHFFFAOYSA-N n-[[3-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)NC(C)(C)CO)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 YCKODPODPOMBMS-UHFFFAOYSA-N 0.000 claims 1
- WTITYZVSVLMXSJ-UHFFFAOYSA-N n-[[3-[2-[(2-amino-2-oxoethyl)-methylamino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)N(CC(N)=O)C)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 WTITYZVSVLMXSJ-UHFFFAOYSA-N 0.000 claims 1
- GTNBOUWOVSOFFN-UHFFFAOYSA-N n-[[3-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4C(CCC4)CO)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 GTNBOUWOVSOFFN-UHFFFAOYSA-N 0.000 claims 1
- IPHPTUDWHGHBIG-UHFFFAOYSA-N n-[[3-[2-[3-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)N4CC(CO)CC4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 IPHPTUDWHGHBIG-UHFFFAOYSA-N 0.000 claims 1
- PLDLILZRFWDWAK-UHFFFAOYSA-N n-[[3-[2-[benzyl(methyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2CN1CC(=O)N(C)CC1=CC=CC=C1 PLDLILZRFWDWAK-UHFFFAOYSA-N 0.000 claims 1
- JKNRSFNQGGHBSB-UHFFFAOYSA-N n-[[3-[2-[butan-2-yl(methyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)N(C)C(C)CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 JKNRSFNQGGHBSB-UHFFFAOYSA-N 0.000 claims 1
- BKWDIDUTZZTJLJ-UHFFFAOYSA-N n-[[3-[2-[cyclopropylmethyl(methyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2CN1CC(=O)N(C)CC1CC1 BKWDIDUTZZTJLJ-UHFFFAOYSA-N 0.000 claims 1
- ARQUZRKBYDRNED-UHFFFAOYSA-N n-[[3-[2-[ethyl(2-hydroxyethyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)N(CCO)CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 ARQUZRKBYDRNED-UHFFFAOYSA-N 0.000 claims 1
- YAGYVGYTUMBAKF-UHFFFAOYSA-N n-[[3-[2-[ethyl(propan-2-yl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CC(=O)N(C(C)C)CC)CC2C1CN(C(=O)C=1N=CN(C)C=1)CC1=CC=CC(OC(F)(F)F)=C1 YAGYVGYTUMBAKF-UHFFFAOYSA-N 0.000 claims 1
- GHLHMHXBSHXDPW-UHFFFAOYSA-N n-[[3-[2-[furan-2-ylmethyl(methyl)amino]-2-oxoethyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound C1C2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2CN1CC(=O)N(C)CC1=CC=CO1 GHLHMHXBSHXDPW-UHFFFAOYSA-N 0.000 claims 1
- XUTVJQCPFGLCIH-UHFFFAOYSA-N n-[[3-[[4-(difluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(OC(F)F)=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 XUTVJQCPFGLCIH-UHFFFAOYSA-N 0.000 claims 1
- MFCHMXVMSAOUBO-UHFFFAOYSA-N n-[[3-[[4-(difluoromethoxy)phenyl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(OC(F)F)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 MFCHMXVMSAOUBO-UHFFFAOYSA-N 0.000 claims 1
- JMMUNGNIFVLOGD-UHFFFAOYSA-N n-[[3-[[5-(methoxymethyl)furan-2-yl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methyl-n-[[3-(trifluoromethoxy)phenyl]methyl]imidazole-4-carboxamide Chemical compound O1C(COC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CN(C)C=3)C2C1 JMMUNGNIFVLOGD-UHFFFAOYSA-N 0.000 claims 1
- NEVJNDINJARJSC-UHFFFAOYSA-N n-[[3-[[5-(methoxymethyl)furan-2-yl]methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-n-[[3-(trifluoromethoxy)phenyl]methyl]-1,3-thiazole-4-carboxamide Chemical compound O1C(COC)=CC=C1CN1CC2C(CN(CC=3C=C(OC(F)(F)F)C=CC=3)C(=O)C=3N=CSC=3)C2C1 NEVJNDINJARJSC-UHFFFAOYSA-N 0.000 claims 1
- MDFPBDQXTNBIBD-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CCC(F)(F)F)CC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 MDFPBDQXTNBIBD-UHFFFAOYSA-N 0.000 claims 1
- UEOQPXQQRXHBFI-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-n-[[3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C2CCOCC2)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 UEOQPXQQRXHBFI-UHFFFAOYSA-N 0.000 claims 1
- RQRRJSBBNCTHMA-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-n-[[3-[(4-phenoxyphenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=CC(OC=5C=CC=CC=5)=CC=4)CC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 RQRRJSBBNCTHMA-UHFFFAOYSA-N 0.000 claims 1
- GVKNHIBWYKXFOI-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-n-[[3-[(6-phenoxypyridin-3-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC=4C=NC(OC=5C=CC=CC=5)=CC=4)CC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 GVKNHIBWYKXFOI-UHFFFAOYSA-N 0.000 claims 1
- CBCSZNIKSZGSDB-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-n-[[3-[(1-hydroxycyclohexyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CCCCC4)CC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 CBCSZNIKSZGSDB-UHFFFAOYSA-N 0.000 claims 1
- YFCJJVCGDMRUGA-UHFFFAOYSA-N n-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-n-[[3-[(2-hydroxy-1,3-dihydroinden-2-yl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC4(O)CC5=CC=CC=C5C4)CC32)CC=2C=C(C(F)=CC=2)C(F)(F)F)=C1 YFCJJVCGDMRUGA-UHFFFAOYSA-N 0.000 claims 1
- VTOFQCKSGOLJNR-UHFFFAOYSA-N n-butyl-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC(F)(F)F)CC2C1CN(CCCC)C(=O)C1=CN(C)C=N1 VTOFQCKSGOLJNR-UHFFFAOYSA-N 0.000 claims 1
- FZCSDOOQOMACLQ-UHFFFAOYSA-N n-butyl-n-[[3-[(4-chlorophenyl)methyl]-3-azabicyclo[3.1.0]hexan-6-yl]methyl]-1-methylimidazole-4-carboxamide Chemical compound C=1N(C)C=NC=1C(=O)N(CCCC)CC(C1C2)C1CN2CC1=CC=C(Cl)C=C1 FZCSDOOQOMACLQ-UHFFFAOYSA-N 0.000 claims 1
- RXFGPYVJCPDLGV-UHFFFAOYSA-N n-heptyl-1-methyl-n-[[3-(3,3,3-trifluoropropyl)-3-azabicyclo[3.1.0]hexan-6-yl]methyl]imidazole-4-carboxamide Chemical compound C12CN(CCC(F)(F)F)CC2C1CN(CCCCCCC)C(=O)C1=CN(C)C=N1 RXFGPYVJCPDLGV-UHFFFAOYSA-N 0.000 claims 1
- 229960003252 pipotiazine Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- 238000000034 method Methods 0.000 description 25
- 239000002904 solvent Substances 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000001299 aldehydes Chemical class 0.000 description 9
- 150000001602 bicycloalkyls Chemical group 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 8
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- SQWZJVZJWXGYEP-UHFFFAOYSA-N 2-[6-[[(1-methylimidazole-4-carbonyl)-[[3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-3-azabicyclo[3.1.0]hexan-3-yl]acetic acid Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(O)=O)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 SQWZJVZJWXGYEP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- VKZCEMULAYAEHL-UHFFFAOYSA-N tert-butyl 6-[[(1-methylimidazole-4-carbonyl)-[[3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC32)C(=O)OC(C)(C)C)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 VKZCEMULAYAEHL-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FDORQEIHOKEJNX-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-3-(4-phenylphenoxy)propyl]-methylamino]acetic acid Chemical compound C=1C=C(F)C=CC=1C(CCN(C)CC(O)=O)OC(C=C1)=CC=C1C1=CC=CC=C1 FDORQEIHOKEJNX-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HULOOLSDRQAARS-UHFFFAOYSA-N benzyl 2-[6-[[(1-methylimidazole-4-carbonyl)-[[3-(trifluoromethoxy)phenyl]methyl]amino]methyl]-3-azabicyclo[3.1.0]hexan-3-yl]acetate Chemical compound CN1C=NC(C(=O)N(CC2C3CN(CC(=O)OCC=4C=CC=CC=4)CC32)CC=2C=C(OC(F)(F)F)C=CC=2)=C1 HULOOLSDRQAARS-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- JVIDPFGQYMFQDZ-UHFFFAOYSA-N tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2C(CO)C21 JVIDPFGQYMFQDZ-UHFFFAOYSA-N 0.000 description 2
- CFHHKURYBRYQTI-UHFFFAOYSA-N tert-butyl 6-[[[3-(trifluoromethoxy)phenyl]methylamino]methyl]-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C12CN(C(=O)OC(C)(C)C)CC2C1CNCC1=CC=CC(OC(F)(F)F)=C1 CFHHKURYBRYQTI-UHFFFAOYSA-N 0.000 description 2
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000005859 (C1-C6)alkanoyloxymethyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000000166 1,3-dioxalanyl group Chemical group 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- HVVHNDCZXDNLMC-UHFFFAOYSA-N 1-methylimidazole-4-carbonyl chloride;hydrochloride Chemical compound Cl.CN1C=NC(C(Cl)=O)=C1 HVVHNDCZXDNLMC-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- TUOBWRCTSVDTSM-UHFFFAOYSA-N 2-methylbenzamide;piperidine Chemical class C1CCNCC1.CC1=CC=CC=C1C(N)=O TUOBWRCTSVDTSM-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KYSZLSYGLCGLOS-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexan-6-ylmethanol;hydrochloride Chemical compound Cl.C1NCC2C(CO)C21 KYSZLSYGLCGLOS-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- HEOQXHNKRXRCTO-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulene Chemical compound C1CCCCC2=CC=CC=C21 HEOQXHNKRXRCTO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 229940124802 CB1 antagonist Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyloxyacetoaldehyde Natural products CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000000575 glycinergic effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940101972 mirapex Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- UWBHMRBRLOJJAA-UHFFFAOYSA-N oxaluric acid Chemical compound NC(=O)NC(=O)C(O)=O UWBHMRBRLOJJAA-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- APVQOOKHDZVJEX-QTPLPEIMSA-N pramipexole hydrochloride Chemical compound O.Cl.Cl.C1[C@@H](NCCC)CCC2=C1SC(N)=N2 APVQOOKHDZVJEX-QTPLPEIMSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002934 propentofylline Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940113775 requip Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940071182 stannate Drugs 0.000 description 1
- 125000005402 stannate group Chemical group 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940000238 tasmar Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 1
- NZZFUILVSGRYMR-UHFFFAOYSA-N tert-butyl 6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2C(C=O)C12 NZZFUILVSGRYMR-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002643 thermotrophic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Bakgrunn.
Den foreliggende oppfinnelse vedrører bisykliske [3.1.0] heteroarylamider og farma-søytiske sammensetninger inneholdende disse som kan anvendes i behandling av sentralnervesystemforstyrrelser, kognitive forstyrrelser, schizofreni, demens og andre forstyrrelser i pattedyr, inkluderende mennesker. Disse forbindelser oppviser aktivitet som inhibitorer av glysin type I transporter.
Schizofreni, en progressiv nevrologisk forstyrrelse manifistreres i dets tidlige faser gjennom forstyrrelser så som hallusinasjoner, paranoide illusjoner, og bisarre tankemønstre, felles benevnt som positive symptomer. Disse tidlige gjenkjennelige symptomer ga sykdommen det historiske navn "sinnsyke". Idet sykdommen utviklet seg ble negative symptomer så som sosial tilbaketrekkelse og anhedonia, og kognitive symptomer så som demens mer fremtredende. Kun ca en tredjedel av schizo-frene pasienter kan behandles med suksess og returneres til samfunnet, mens den resterende del generelt blir plassert på institusjon. Byrden på samfunnet for denne tilintetgjørende sykdom og belastningen på familiemedlemmer til påvirkede pasienter gjør den til den mest kostbare av alle CNS sykdommer.
Farmakologisk behandling for schizofreni har tradisjonelt involvert blokkering av dopaminsystemet, som er tenkt å være ansvarlig for de positive symptomer. Slik behandling ignorerer imidlertid de negative og kognitive aspekter av sykdommen. Et annet nevrotransmittersystem som er antatt å ha en funksjon i schizofreni er glutamatsystemet, det vesentligste eksitatoriske transmittersystem i hjernen. Denne hypotese er basert på observasjonen at blokade av glutamatsystemet med forbindelser så som PCP (englestøv) kan repetere mange av symptomene for schizofreni, inkludert dets positive, negative og kognitive aspekter.
Dersom schizofreni involverer en mangel av glutamatergisk transitasjon, kan en forsterking av glutamatsystemet, og spesielt av NMDA-reseptoren være fordelaktig. Idet glutamat er hovedagonisten ved NMDA-reseptorer, er glysin nødvendig som en koagonist for å innstille "nyansene" av reseptoren for dets respons til glutamat. Å forsterke denne "nyanse" ved å øke effekten av glysin vil forsterke NMDA neurotransmisjon, og tilveiebringe potensiell nytte i behandling av schizofreni.
En spesifikk mekanisme for å forstreke den glysinergiske "nyanse" på NMDA-reseptorer ble beskrevet nylig av Bergeren, et al. ( Proe. Nati. Acad. Sei. USA, 95, 15730, (1998)), som herved inkorporeres med referanse. Denne gruppe viste at en spesifikk og potent inhibitor av glysin type I transporter (GlyT1) ansvarlig for å fjerne glysin fra synapsen ved NMDA-reseptoren, benevnt NFPS (W097/45115), kunne forsterke NMDA-reseptorfunksjon. Foreksempel, NFPS økte den postsynaptiske strøm som drives av NMDA-reseptoren, en effekt som ble blokkert av både spesifikk NMDA-seteantagonist og en glysin-seteantagonist. Selv om glysinnivåene i hjernen er høye relativt til mengden som er nødvendig til å virke som en NMDA-reseptor koagonist, viser dette arbeid at GlyT1 fjerner glysin effektivt ved synapsen, og at inhibering av GlyT1 kan forstreke NMDA-reseptorfunksjon. WO03/089411 beskriver piperedinmetylbenzamidforbindelser som er nyttige som GlyT1-inhibitorer. Den foreliggende oppfinnelse tilveiebringer ytterligere GlyT1-inhibitorer som en behandling for forstyrrelser eller tilstander så som schizofreni gjennom dets forstreking av glutamatergisk neurotransmisjon.
Sammendrag av oppfinnelsen.
Den foreliggende oppfinnelse vedrører forbindelser av formelen I hvor
Formel I
hvor Ri representerer et heteroaryl valgt blant gruppen omfattende: imidazolyl, tiazolyl, pyridyl, oksazolyl, pyrazolyl, triazolyl, oksadiazolyl, quinolinyl, isoksazolyl, pyroloimidazoyl og tiadiazol, hvor nevnte heteroaryl er valgfritt substituert med en eller flere substituenter valgt blant -OH, -NR7R8, halogen, (Ci-C8)alkyl, (C3-Cio)sykloalkyl, (Ci-C8)alkoksy, (Ci-Ci2)alkoksyalkyl, (Ci-C8)hydroksyalkyl, (C6-Ci4)aryl og benzyl;
R2, R3og A uavhengig representerer H eller (Ci-C8)alkyl hvor nevnte alkyl er valgfritt substituert av en eller flere -OH, (Ci-C8)alkoksy, -NR7R8eller halogen;
Q representerer -(ChbV, hvor n = 1, 2, 3 eller 4 eller -(Chhjm-O-, hvor m = 2, 3 eller 4;
Z representerer (C6-Ci4)aryl, (Ci-C8)alkyl eller (C3-C8)sykloalkyl;
R4 og R5representerer hver uavhengig H, halogen, (Ci-C8)alkyl, (C6-Ci4)aryl, (C6-Ci4)aryloksy, (Ci-C8)alkoksy, (3-10 leddet)heterosykloalkyl eller (C3-C8)sykloalkoksy; hvor R4og R5er valgfritt substituert av en eller flere -OH, (Ci-Csjalkoksy, - NR7R8eller halogen;
Y representerer -R6, -(CH2)0-R6, -C(R6)3eller -CH(R6)2, hvor0= 1, 2 eller 3;
R6representerer H, (C6-Ci4)aryl, (Ci-Cio)alkyl, (C3-Cio)sykloalkyl, (C5-Ci8)bisykloalkyl, (C5-Ci8)trisykloalkyl, (3-10 leddet)heterosykloalkyl, (5-10 leddet)heteroaryl, -C(=0)NR7R8, eller -C(=0)OR7, hvor nevnte R6- grupper kan valgfritt være substituert med en eller flere X grupper;
hvor X = -OH, (Ci-C8)alkoksy, -NR11R12, -SO2R10, -C(=O)Ri0, halogen, cyano, (Ci-C8)alkyl, (Ci-Cio)alkoksyalkyl, (5-10 leddet)heteroaryl, (C6-Ci4)aryl, (C6-Ci4)aryloksy, benzyl, eller (Ci-C8)hydroksyalkyl;
hvor R7og R8uavhengig representerer H, (Ci-C8)alkyl, (C3-C8)sykloalkyl, (5-10 leddet)heterosykloalkyl, (Ci-C8)hydroksyalky, (5-10 leddet)heteroaryl eller (C1-Cio)alkoksyalkyl; hvor R7og R8valgfritt kan være substituert av en eller flere X-grupper;
eller R7og R8til sammen med nitrogener hvortil de kan være tilfestet kan danne en (3-10 leddet)heterosykloalkylgruppe valgfritt substituert av en eller flere X-grupper;
hvor R10representerer (Ci-C8)alkyl, (C3-C8)sykloalkyl, (3-10 leddet)heterosykloalkyl, (Ci-C8)hydroksyalkyl, (5-10 leddet)heteroaryl eller (d-Cio)alkoksyalkyl;
hvor Rnog R12uavhengig representerer H, (Ci-C8)alkyl, (C3-C8)sykloalkyl, (5-10 leddet)heterosykloalkyl, (Ci-C8)hydroksyalky, (5-10 leddet)heteroaryl eller (C1-Cio)alkoksyalkyl;
eller farmasøytisk akseptable salter eller solvater derav.
Detaljert beskrivelse av oppfinnelsen.
Med mindre annet er angitt, som anvendt heri, inkluderer termene "halogen" og "halo" F, Cl, Br og I. Med mindre annet er angitt, som anvendt heri, inkluderer termen "alkyl" mettete monovalente hydrokarbonradikaler som har rettkjedete eller for-grenete enheter. Eksempler på alkylgrupper inkluderer, men er ikke begrenset til, metyl, etyl, n-propyl, isopropyl, syklopropylmetylen (CH2-syklopropyl) og f-butyl.
Med mindre annet er angitt, som anvendt heri, inkluderer termen "alkenyl" alkylenheter som har minst en karbon-karbon dobbeltbinding hvor alkyl er som definert over. Eksempler på alkenyl inkluderer men er ikke begrenset til etenyl og propenyl.
Med mindre annet er angitt, som anvendt heri, inkluderer termen "alkynyl" alkylenheter som har minst en karbon-karbon trippelbinding hvor alkyl er som definert over. Eksempler på alkynylgrupper inkluderer, men er ikke begrenset til, etynyl og 2-propynyl.
Med mindre annet er angitt, som anvendt heri, betyr termen "alkoksy" "alkyl-0-", hvor "alkyl" er som definert over. Eksempler på "alkoksy"-grupper inkluderer, men er ikke begrenset til metoksy, etoksy, propoksy, butoksy, pentoksy og allyloksy.
Med mindre annet er angitt, som anvendt heri, betyr termen "alkoksyalkyl" alkyl-O-alkyl, hvor alkyl er som definert over.
Med mindre annet er angitt, som anvendt heri, angir termen "hydroksyalkyl" alkyl-OH, hvor alkyl er som definert over.
Med mindre annet er angitt, som anvendt heri, betyr termen "alkenoksy" "alkenyl-O-" hvor "alkenyl" er som definert over.
Med mindre annet er angitt, som anvendt heri termen "sykloalkyl" inkluderer ikkearomatiske mettete sykliske alkylenheter hvor alkyl er som definert over. Eksempler på sykloalkyl inkluderer, men er ikke begrenset til, syklopropyl, syklobutyl, syklopentyl, sykloheksyl og sykloheptyl. "Bisykloalkyl"- og "trisykloalkyl"-grupper inkluderer ikke-aromatiske mettete sykliske alkylenheter som består av to eller tre ringer, respektivt, hvor nevnte ringer deler minst et karbonatom. "Bisykloalkyl"- og "trisykloalkyl-grupper-" inkluderer også sykliske enheter bestående av to eller tre ringer, respektivt, hvor en ring er aryl eller heteroaryl og hvor nevnte ringer deler to karbonatomer. For formålene ifølge foreliggende oppfinnelse, og med mindre annet er angitt, inkluderer bisykloalkylgrupper spirogrupper og fusjonerte ringgrupper. Eksempler på bisykloalkylgrupper inkluderer, men er ikke begrenset til, bisyklo-[3.1.0]-heksyl, bisyklo-[2.2.1]-hept-1-yl, norbornyl, spiro[4.5]desyl, spiro[4.4]nonyl, spiro[4.3]oktyl, spiro[4.2]heptyl, indan, teralen (1,2,3,4-tetrahydronaflen) og 6, 7, 8, 9-tetrahydro-5H-benzosyklohepten. Eksempel på en trisykloalkylgruppe er adamant-anyl. Andre sykloalkyl, bisykloalkyl og trisykloalkylgrupper er kjent innen fagfeltet, og slike grupper er også omfattet av definisjonene "sykloalkyl", "bisykloalkyl" og "trisykloalkyl" heri. "Sykloalkynyl", "bisykloalkynyl" og "trisykloalkynyl" refererer til ikke-aromatiske hver sykloalkyl, bisykloalkyl og trisykloalkylenheter som definert over, med unntak av at de kan hver inkludere en eller flere karbon- karbon- dobbeltbindinger som forbinder karbonring medlemmene (en "endosyklisk" dobbeltbinding) og/eller en eller flere karbon- karbon dobbeltbindinger som forbinder et karbonring medlem og et tilgrensende ikke- ringkarbon (en "eksosyklisk" dobbeltbinding). Eksempler på sykloalkylgrupper inkluderer, men er ikke begrenset til, syklopentenyl, syklobutenyl, og sykloheksenyl. Et ikke begrensende eksempel for en bisyklo-alkenylgruppe er norbornenyl. Sykloalkyl, sykloalkenyl, bisykloalkyl og bisyklo-alkenylgrupper inkluderer også grupper som er substituert med en eller flere okso-enheter. Eksempler på slike grupper med okso- enheter er oksosyklopentyl, oksosyklobutyl, oksosyklopentenyl og norkamforyl. Andre sykloalkenyl, bisykloalkenyl og trisykloalkenylgrupper er kjent inne fagfeltet, og slike grupper er inkludert innen definisjonene "sykloalkenyl", "bisykloalkenyl" og "trisykloalkenyl" heri.
Med mindre annet er angitt, som anvendt heri, termen "aryl" inkluderer et organisk radikal avledet fra et aromatisk hydrokarbon ved fjerning av et hydrogen, så som fenyl (pH), naftyl, indenyl, indanyl og fluorenyl. "Aryl" omfatter fusjonerte ringgrupper hvor minst en ring er aromatisk.
Med mindre annet er angitt, som anvendt heri, termene "heterosyklisk" og "heterosykloalkyl" refererer til ikkearomatiske sykliske grupper inneholdende en eller flere heteroatomer, fortrinnsvis fra en til fire heteroatomer, hver valgt blant 0, S og N. "Heterobisykloalkyl" grupper inkluderer ikke- aromatiske to-ringete sykliske grupper, hvor nevnte ringer deler en eller to atomer, og hvor minst en av ringene inneholder et heteroatom (0, S eller N). "Heterobisykloalkyl" grupper inkluderer også to-ringete sykliske grupper, hvor nevnte ene ring er aryl eller heteroarylring og hvor nevnte ringer deler en eller to atomer, og hvor minst en av ringene inneholder et heteroatom (0, S eller N). Med mindre annet er angitt, for formål med foreliggende oppfinnelse, inkluderer heterobisykloalkylgrupper spirogrupper og fusjonerte ringgrupper. I en utførelse inneholder hver ring i heterobisykloalkylet opp til fire heteroatomer (det vil si fra null til fire heteroatomer, gitt at minst en ring inneholder minst et heteroatom). De heterosykliske grupper ifølge oppfinnelsen kan også inkludere ringsystemer substituert med en eller flere okso-enheter. Eksempler på ikke-aromatiske heterosykliske grupper er aziridinyl, azetidinyl, pyrolidinyl, piperidinyl, azepinyl, piperazinyl, 1,2,3,6-tetrahydropyridinyl, oksiranyl, oksetanyl, tetrahydrofuranyl, tetrahydrotienyl, tetra-hydropropyranyl, tetrahydrotiopyranyl, morfolino, tiomorfolino, tiaoksanyl, pyrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioksanyl, 1,3-dioksalanyl, pyrazolinyl, dihydro-pyranyl, dihydrotienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabisyklo[3.1.0]heksanyl, 3-azabisyklo[4.1.0]heptanyl, quinolizinyl, quinuklidinyl, 1,4-dioksaspiro[4.5]decyl, 1,4-dioksaspiro[4.4]nonyl, 1,4-dioksaspiro[4.3]oktyl, og 1,4-dioksaspiro[4.2]heptyl.
Med mindre annet er angitt, som anvendt heri, "heteroaryl" refererer til aromatiske grupper inneholdende en eller flere heteroatomer, fortrinnsvis fra en til fire heteroatomer, valgt blant O, S og N. En multisyklisk gruppe inneholdende en eller flere heteroatomer hvor minst en ring av denne gruppe er aromatisk er en "heteroaryl" gruppe. Heteroarylgruppene ifølge oppfinnelsen kan også inkludere ringsystemer substituert med en eller flere okso- enheter. Eksempler på heteroarylgrupper er pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroguinolyl, tetrazolyl, furyl, tienyl, isoksazolyl, tiazolyl, oksazolyl, isotiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, sinnolinyl, indazolyl, indolizinyl, ftalazinyl, triazinyl, 1,2,4-trizainyl, 1,3,5-triazinyl, isoindolyl, 1-oksoisoindolyl, purinyl, oksadiazolyl, tiadiazolyl, furazanyl, benzofurazanyl, benzo-tiofenyl, benzotriazolyl, benzotiazolyl, benzoksazolyl, quinazolinyl, quinoeksalinyl, naftyridinyl, dihydroquinolyl, tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroiso-quinolyl, benzofuryl, furopyridinyl, pyrolopyrimidinyl og azaindolyl.
Med mindre annet er angitt, som anvendt heri, termen "sykloalkoksy" betyr "sykloalkyl-O" hvor "sykloalkyl" er som definert over.
Med mindre annet er angitt, som anvendt heri, termen "aryloksy" betyr "aryl-O" hvor "aryl" er som definert over.
Med mindre annet er angitt, som anvendt heri, termen "heterosykloalkoksy" betyr "heterosykloalkyl-O" hvor "heterosykloalkyl" er som definert over.
Med mindre annet er angitt, som anvendt heri, termen "heteroaryloksy" betyr "heteroaryl-O" hvor "heteroaryl" er som definert over.
Med mindre annet er angitt, kan alle de foregående grupper avledet fra hydrokarboner valgfritt være substituert med en eller flere halogenatomer (for eksempel -CH2F, - CHF2-CF3, -PhCI, etc).
Med mindre annet er angitt, termen "en eller flere" substituenter, eller "i det minste en" substituent som anvendt heri refererer til fra en til det maksimale antall substituenter som er mulig basert på antallet tilgjengelige bindingsseter, (eksempler på en eller flere eller i det minste en substituent inkluderer, men er ikke begrenset til, 1 til 10 substituenter, eller 1 til 6 substituenter eller 1 til 3 substituenter).
Med mindre annet er angitt, kan alle de foregående grupper avledet fra hydrokarboner ha opp til ca 1 til ca 20 karbonatomer (for eksempel C1-C20alkyl),
C2-C20alkenyl, C3-C20sykloalkyl, (3-20 leddet)heterosykloalkyl, C6-C2oaryl, (5-20 leddet)heteroaryl, etc.) eller 1 til ca 15 karbonatomer (for eksempel, C1-C15alkyl, C2-C15alkenyl, C3-C15sykloalkyl, (3-15 leddet)heterosykloalkyl, C6-C15aryl, (5-15 leddet)heteroaryl, etc), eller 1 til ca 12 karbonatomer, eller 1 til ca 8 karbonatomer, eller 1 til ca 6 karbonatomer.
De foregående grupper, som avledet fra forbindelsene angitt over, kan være C-bundet eller N-bundet hvor slike er mulige. For eksempel, en gruppe avledet fra pyrol kan være avledet fra pyrol-1-yl (N- bundet) eller pyrol-3-yl (C-bundet). Termene som refererer til gruppene omfatter også alle mulige tautomerer.
I et aspekt av foreliggende oppfinnelse er stereokjemien definert som i formel II eller formel III.
I et aspekt av foreliggende oppfinnelse er Ri imidazolyl valgfritt substituert med metyl.
I et annet aspekt er Z (C6-Ci4)aryl, og R4eller R5er hver uavhengig H, halogen,
-CF3, -OCF3, (C6-Ci4)aryl eller (C6-Ci4)aryloksy.
I et annet aspekt av oppfinnelsen er R2, R3og A hydrogen.
I et ytterligere aspekt er Y lik (Ci-C6)alkyl, en (C3-C6)Sykloalkyl, en (3-6 leddet)-heterosykloalkyl eller -CH2-(C3-C6)sykloalkyl; hvor Y er valgfritt substituert av halogen, OH, -SO2R10, -C(=O)Ri0, eller CH2CH2CF3.
I et ytterligere aspekt av foreliggende oppfinnelse har forbindelsen av formel I følgende struktur:
hvor R<2->R<5>, Q, Z, Y og A som definert over.
Spesifikke utførelser av foreliggende oppfinnelse er vist i eksemplene nedenfor.
Forbindelsene av formel I kan ha optiske sentre og kan derfor forekomme i forskjellige enantiomeriske og diastereomeriske konfigurasjoner. Foreliggende oppfinnelse inkluderer alle enantiomerer, diastereomerer og andre stereoisomerer av slike forbindelser av formel I, og likeledes rasemiske forbindelser og rasemiske blandinger og deres blandinger av stereoisomerer derav.
Farmasøytisk akseptable salter av forbindelsen av formel I inkluderer syreaddisjon-og basesalter derav.
Egnete syreaddisjonssalter kan dannes fra syrer som danner ikke-toksiske salter. Eksempler inkluderer, men er ikke begrenset til, acetat, adipat, aspartat, benzoat, besylat, bikarbonat/karbonat, bisulfat/sulfat, borat, kamsylat, sitrat, syklamat, edisylat, esylat, format, fumarat, gluseptat, glukonat, glukuronat, heksafluorofosfat, hibenzat, hydroklorid/klorid, hydrobromid/bromid, hydroiodid/iodid, isetionat, laktat, malat, maleat, malonat, mandelater, mesylat, metylsulfat, naftylat, 2-napsylat, nikotinat, nitrat, orotat, oksalat, palmitat, pamoat, fosfat/hydrogen fosfat/dihydrogen fosfat, pyroglutamat, salisylat, sakkarat, stearat, sukkinat, sulfonat, stannat, tartrat, tosylat, trifluoroasetat og xsinofoat salter.
Egnete basesalter dannes fra baser som danner ikke-toksiske salter. Eksempler inkluderer, men er ikke begrenset til, aluminium, arginin, benzatin, kalsium, kolin, dietylamin, diolamin, glysin, lysin, magnesium, meglumin, olamin, kalium, natrium, trometamin og sink salter.
Hemisalter av syrer og baser kan også dannes, for eksempel hemisulfat og hemikalsiumsalter.
For en oversikt over egnete salter, se Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002).
Farmasøytisk akseptable salter av forbindelse formel I kan fremstilles av en eller flere av tre metoder;
(I) med omdanning av forbindelsen av formel I med den ønskete syre eller base; (II) ved å fjerne en syre- eller base- labil beskyttende gruppe fra en egnet forløper av forbindelsen av formel I eller ved ringåpning av en egnet syklisk forløper, for eksempel et lakton eller laktam, ved anvendelse av ønsket syre eller base; eller (III) ved å omdanne et salt av forbindelsen av formel I til et annet med reaksjon med egnet syre eller base eller ved hjelp av en egnet ionebyttekolonne.
Alle tre reaksjoner utføres typisk i løsning. Det resulterende salt kan presipitere ut og kan samles med filtrering, eller kan gjenvinnes ved evaporering av oppløsnings-middel. Grad av ionisering i det resulterende salt kan variere fra fullstendig ionisert til omtent ikke-ionisert. Forbindelsene ifølge foreliggende oppfinnelse kan eksistere i et kontinuum av faststofftilstander i områder fra fullstendig amorf til fullstendig krystallinsk. Termen "amorf refererer til en tilstand hvor materialet mangler langtrekkende orden på det molekylære nivå og, avhengig av temperatur, kan oppvise de fysikalske egenskaper av et faststoff eller av en væske. Typisk vil slike materialer ikke gi distinktive røntgendiffraksjonsmønstere, og idet de oppviser egenskaper av et faststoff være mer formelt beskrevet som en væske. Ved oppvarming, vil en forandring fra faststoff til væskeegenskaper forekomme som erkarakterisertmed en forandring av faser, typisk andreorden (glasstransisjon). Termen "krystallinsk" refererer til en faststoffase hvor materialet har en regulert ordnet indre struktur på molekylnivå og gir distinktiv røntgendiffraksjonsmønster med definerte topper. Slike materialer, idet de oppvarmes tilstrekkelig vil også oppvise egenskapene av en væske, men forandringen fra faststoff til væske erkarakterisertmed en fase-forandring, typisk førsteorden (smeltepunkt).
Forbindelsene ifølge foreliggende oppfinnelse kan også eksistere i usolvatiserte og solvatiserte former.
Termen "solvat" anvendes her for å beskrive et molekylkompleks omfattende forbindelsen ifølge oppfinnelsen og et eller flere farmasøytisk akseptable solvent-molekyler, fog eksempel etanol. Termen "hydrat" benyttes dersom nevnte solvent er vann.
Et for tiden akseptert klassifiseringssystem for organiske hydrater er et som definerer isolert sete, kanal eller metallion koordinerte hydrater, se Polymorphism in Pharmaceutical Solids by K. R. Morris (Ed. H. G. Brittain, Marcel Dekker, 1995). Isolert setehydrater er et hvor vannmolekylene er isolert fra direkte kontakt med hverandre med intervenerende organiske molekyler. I kanalhydrater er vannmolekylene i gitterkanalene hvor de er ved siden av andre vannmolekyler. I metallion koordinerte hydrater er vannmolekylene bundet til metallionet. Idet solvent eller vann er tett bundet vil komplekser ha en godt definert støkiometri uavhengig av fuktighet. Imidlertid, idet solvent eller vann er svakt bundet, som i kanalsolvater og hygro-skopiske forbindelser vil vann/solvent innhold variere avhengig av fuktighet og tørke-betingelser. I slike tilfeller vil ikke- støkiometri være normen.
Forbindelsene ifølge foreliggende oppfinnelse kan også eksistere I en mesomorfisk tilstand (mesofase eller væskekrystall). Idet det underlegges egnete betingelser. Den mesomorfe tilstand er et mellomtrinn mellom den sanne krystallform og den sanne væskeform (enten smelte eller løsning). Mesomorfisme oppstår som et resultat av forandring I temperatur og er beskrevet som "termotrofisk" og at den er resultatet av tilsetning av en andre komponent, så som vann eller et annet solvent, er beskrevet som "lyotropisk".
Forbindelser som har potensial til å danne lyotrofe mesofaser er beskrevet som "amfifile" og består av molekyler som oppviser en ionisk (så som -COO"Na<+>, -COO~K<+>, eller -SCVNa*) eller ikke- ionisk (så som -N"N<+>(CH3)3) polare hodegrupper. For mer informasjon, se Crystals and the Polarizing Microscope by N. H. Hartshorne and A. Stuart, 4th Edition (Edward Arnold, 1970). ;Heretter vil alle referanser til forbindelse av formel I inkludere referanser til salter, solvater, multikomponentkomplekser og væskekrystaller derav, og til solvater, multikomponentkomplekser og væskekrystaller av salter derav. ;Forbindelsene ifølge oppfinnelsen inkluderer forbindelse av formel I som ovenfor definert, inkluderende alle polymorfe og krustallhabitater derav, og isomerer derav (inkluderende optiske, geometriske og tautomeriske isomerer) som heretter definert og isotopisk merkete forbindelser av formel I. ;Visse derivater av forbindelsene av formel I som kan ha liten eller ingen farmakologisk aktivitet i seg selv, kan idet de administreres inn i eller på en kropp omdannes til forbindelse av formel I som har den ønskete aktivitet, for eksempel med hydrolytisk spalting. Slike derivater benevnes som "prodrug". Ytterligere informasjon for anvendelse av prodrug kan finnes i Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) og Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association). ;Prodrug kan for eksempel produseres ved å erstatte egnete funksjonaliteter tilstede i forbindelsene av formel I med visse enheter kjent for fagkyndige innen feltet som "pro-enheter" som beskrevet, foreksempel i Design of Prodrugs by H. Bundgaard (Elsevier, 1985). ;Noen eksempler på prodrug inkluderer, men er ikke begrenset til, ;(I) hvor forbindelsen av formel I inneholderen karboksylisk syrefunksjonalitet (-COOH), en ester derav, for eksempel en forbindelse hvor hydrogenet av den karboksyliske syrefunksjonalitet av forbindelsen av formel I er erstattet med (Ci-Cs); (II) hvor forbindelsen av formel I innholder en alkoholfunksjonalitet (-OH), en eter derav, for eksempel en forbindelse hvor hydrogenet av alkoholfunksjonaliteten av forbindelsen av formel I er erstattet av (C1-C6) alkanoyloksymetyl; og (III) hvor forbindelsene i formel I inneholderen primær eller sekundær aminofunksjonalitet (-NH2eller -NHR hvor R * H), et amid derav, for eksempel en forbindelse hvor, slik tilfellet kan være, en eller begge hydrogener av aminofunksjonaliteten av forbindelsen av formel I er erstattet av (C1-C10) alkanoyl.
Ytterligere eksempler på erstatningsgrupper i samsvar med foregående eksempler og eksempler på andre prodrug typer kan finnes i ovenfor nevnte referanser.
Visse forbindelser av formel I kan i seg selv fungere som prodrug for andre forbindelser av formel I.
Også inkludert innen rammen av foreliggende oppfinnelse er metabolitter av forbindelsene av formel I, det vil si forbindelser dannet in vivo ved administrering av medikamenter. Noen eksempler på metabolitter i samsvar med oppfinnelsen inkluderer, men er ikke begrenset til,
(I) hvor forbindelsen av formel I inneholderen metylgruppe, et hydroksymetylderivat derav (-CH3-> -CH2OH): (II) hvor forbindelsen av formel I inneholderen alkoksygruppe, en hydroksyderivat derav (-OR -> -OH); (III) hvor forbindelsen av formel I inneholderen tertiær aminogruppe, en sekundær aminoderivat derav (-NR<1>R<2>-> -NHR<1>or -NHR<2>); (IV) hvor forbindelsen av formel I inneholderen sekundær aminogruppe, et primært derivat derav (-NHR<1>-> -NH2); (V) hvor forbindelsen av formel I inneholder en fenyl enhet, en fenolderivat derav (-Ph -> -PhOH); og (VI) hvor forbindelsen av formel I inneholderen amidgruppe, en karboksylisk syrederivat derav (-CONH2-> COOH).
Forbindelser av formel I inneholdende en eller flere asymmetriske karbonatomer kan eksistere som to eller flere stereoisomerer. Hvor en forbindelse av formel I inneholder en alkenyl eller alkenylengruppe, er geometriske cis/ trans (eller Z/E) isomerer mulig. Hvor strukturelle isomerer er ombyttbare via en lavenergibarriere, kan tauto-merisk isomerisme (("tautomerisme") forekomme. Dette kan ha form av proton-tautomerisme i forbindelse av formel I inneholdende for eksempel en imino, teto eller oksimgruppe, eller såkalt valensteutomerisme i forbindelser som inneholder en aromatisk enhet. Det følger at en enkelt forbindelse kan oppvise mer enn en type isomerisme.
Inkludert innen rammen av foreliggende oppfinnelse er alle stereoisomerer, geometriske isomerer og tautomeriske former av forbindelsen av formel I, inkluderende forbindelser som oppviser mer enn en type isomerisme, og blandinger av en eller flere derav. Også inkludert er syreaddisjon, eller basesalter hvor motionene er optisk aktiv, for eksempel d-laktat eller l-lysin, eller rasemisk, for eksempel c//-tartrat eller dl-arginin.
Cis/ trans-\ somerer kan separeres med konvensjonelle teknikker godt kjent for fagkyndige innen fagfeltet, for eksempel kromatografi og fraksjonert krystallisering.
Konvensjonelle teknikker for framstilling/isolering av individuelle enantiomerer inkluderer kiral syntese fra en egnet optisk ren forløper eller resolusjon av rasematet (eller rasematet av et salt eller derivat) ved anvendelse for eksempel av kiral høytrykk væskekromatografi (HPLC).
Alternativt kan rasematet eller den rasemiske blanding (eller en rasemisk forløper) omdannes med en egnet optisk aktiv forbindelse, for eksempel en alkohol, eller, i tilfeller hvor forbindelsen av formel I inneholder en sur eller basisk enhet, en base eller syre så som en fenylatylamin eller smørsyre. Den resulterende diastereomeriske blanding kan separeres med kromatografi og/eller fraksjonert krystallisering og en eller begge av diastereoisomerene omdannes til den korresponderende rene enantiomer(er) med metoder godt kjent for den fagkyndige. Kirale forbindelser ifølge oppfinnelsen (og kirale forløpere derav) kan oppnås i en enantiomerisk anriket form ved anvendelse av kromatografi, typisk HPLC, for en asymmetrisk resin med en mobilfase bestående av et hydrokarbon, typisk heptan eller heksan, inneholdende fra 0 til 50 % basert på volum av isopropanol, typisk fra 2 % til 20 %, og fra 0 til 5 %, basert på volum, av et alkylamin, typisk 0,1 % dietylamin. Konsentrering av eluatet gir den anrikete blanding.
Idet et hvert rasemat krystalliserer er krystaller av to forskjellige typer mulige. Den første type er den rasemiske forbindelse (sant rasemat) referert til over hvor en homogen form av krystall produseres inneholdende begge enantiomerer i ekvi-molære mengder. Den andre type er den rasemiske blanding eller konglomerat hvor to former av krystallet produseres i ekvimolare mengder hver omfatende en enkel enantiomer.
Idet begge krystallformene foreligger i en rasemisk blanding har identiske fysikalske egenskaper kan de ha forskjellige fysikalske egenskaper sammenlignet med det samme rasemat. Rasemiske blandinger kan separeres med konvensjonelle teknikker kjent for fagkyndige innen fagfeltet, se for eksem pel, Stereochemistry of Organic Compounds by E. L. Eliel and S. H. Wilen (Wiley, 1994).
Den foreliggende oppfinnelse inkluderer alle farmasøytisk akseptable isotopisk merkete forbindelser av formel I hvor en eller flere atomer er erstattet av atomer som har det samme atomtall, men en atomisk masse eller massenummer som er forskjellig fra den atomiske masse eller massenummer som dominerer i naturen.
Eksempler på isotoper egnet for inkludering i forbindelsen ifølge oppfinnelsen inkluderer, men er ikke begrenset til, isotoper av hydrogen så som<2>H og<3>H, karbon, så som1<1>C,<13>C og<14>C, klorin, så som<36>CI, fluor, så som<18>F, jod, så som<123>l og<125>l, nitrogen, så som13N og<15>N, oksygen, så som<15>0,170og<18>0, fosfor, så som 32P, and svovel, så som35S.
Visse isotopisk merkete forbindelser av formel I, for eksempel de som inkorporer en radioaktiv isotop, er nyttige i medikament og/eller substratvevsfordelingsstudier. De radioaktive isotoper tritium,<3>H, og karbon-14, det vil si<14>C, er spesielt nyttige for formålene i lys av deres enkle inkorporering og enkle midler for deteksjon.
Substituering med tyngre isotoper så som deuterium, det vil si<2>H kan gi visse terapeutiske fordeler resulterende av større metabolsk stabilitet, for eksempel økning i in vivo halveringstid eller reduserte dosekrav, og således være foretrukket i noen sitasjoner.
Substituering med positronemitterende isotoper, så som 11C,<18>F,<15>0 og<13>N kan være nyttig i Positron Emisjon Topografi (PET) for å undersøke substratreseptor okkupasjon.
Isotopisk merkete forbindelser av formel I kan generelt fremstilles med konvensjonelle teknikker kjent for fagkyndige innen fagfeltet eller med prosesser som er analoge til de som er beskrevet i de ledsagende eksempler og fremstillinger ved anvendelse av egnete isotopisk merkete reagenser i stedet for den ikke merkete reagens som tidligere er benyttet.
Farmasøytisk akseptable solvater i samsvar med foreliggende oppfinnelse inkluderer de hvor krystalliseringssolvent kan være isotopisk substituert, for eksempel D20, d6-aseton, d6-DMSO.
Ved fremstilling av forbindelser av formel I i samsvar med oppfinnelsen er det åpen-bart for en fagkyndig å rutinemessig velge den form av forbindelsen av formel II som tilveiebringer den beste kommunikasjon av egenskaper for dette formål. Slike egenskaper inkluderer, men er ikke begrenset til, smeltepunkt, løselighet, prosseser- barnet og utbytte av mellomproduktformen og hvor lett produktet kan renses ved isolering.
Foreliggende oppfinnelse vedrører også forbindelsene av formel I for anvendelse for å behandle en forstyrrelse eller tilstand valgt blant psykoser, schizofreni, oppførselsforstyrrelse, forstyrrende atferdsforstyrrelse, bipolar forstyrrelse, psykotiske episoder av angst, angst assosiert med psykoser, psykotiske sinnsstemnings forstyrrelser, så som alvorlig hoved depressiv forstyrrelse; sinnsstemningsforstyrrelse assosiert med psykotiske forstyrrelser så som akutt mani eller depresjon assosiert med bipolar forstyrrelse og sinnsstemningsforstyrrelser assosiert med schizofreni, atferds manifestasjoner av mental utviklingshemming, oppførselsforstyrrelser og autistiske forstyrrelser, bevegelsesforstyrrelser så som Tourettes syndrom, akinetisk rigid syndrom, bevegelsesforstyrrelser assosiert med Parkinsons sykdom, tardiv dyskinesi og andre medikamentinduserte og nevrodegenerering baserte dyskinesier; konsentrasjonssvikt
hyperaktivitetsforstyrrelse; kognitive forstyrrelser som demens, (inkluderende aldersrelatert demens, og senil demens av type Alzheimer) og
hukommelsesforstyrrelser.
Foreliggende oppfinnelse vedrører også en forbindelse av formel I for anvendelse for å behandle en forstyrrelse eller tilstand valgt blant psykoser, schizofreni, oppførsels-forstyrrelse, forstyrrende atferdsforstyrrelse, bipolar forstyrrelse, psykotiske episoder av angst, angst assosiert med psykoser, psykotiske sinnsstemnings forstyrrelser, så som alvorlig hoved depressiv forstyrrelse; sinnsstemningsforstyrrelse assosiert med psykotiske forstyrrelser så som akutt mani eller depresjon assosiert med bipolar forstyrrelse og sinnsstemningsforstyrrelser assosiert med schizofreni, atferds manifestasjoner av mental utviklingshemming, oppførselsforstyrrelser og autistiske forstyrrelser, bevegelsesforstyrrelser så som Tourette's syndrom, akinetisk rigid syndrom, bevegelsesforstyrrelser assosiert med Parkinsons sykdom, tardiv dyskinesi og andre medikamentinduserte og nevrodegenerering baserte dyskinesier; konsentrasjonssvikt hyperaktivitetsforstyrrelse; kognitive forstyrrelser som demens, (inkluderende aldersrelatert demens, og senil demens av type Alzheimer) og hukommelsesforstyrrelser.
Foreliggende oppfinnelse vedrører også en fremgangsmåte for å behandle en forstyrrelse eller tilstand valgt blant psykoser, schizofreni, oppførselsforstyrrelse, forstyrrende atferdsforstyrrelse, bipolar forstyrrelse, psykotiske episoder av angst, angst assosiert med psykoser, psykotiske sinnsstemnings forstyrrelser, så som alvorlig hoved depressiv forstyrrelse; sinnsstemningsforstyrrelse assosiert med psykotiske forstyrrelser så som akutt mani eller depresjon assosiert med bipolar forstyrrelse og sinnsstemningsforstyrrelser assosiert med schizofreni, atferds manifestasjoner av mental utviklingshemming, oppførselsforstyrrelser og autistiske forstyrrelser, bevegelsesforstyrrelser så som Tourette's syndrom, akinetisk rigid syndrom, bevegelsesforstyrrelser assosiert med Parkinsons sykdom, tardiv dyskinesi og andre medikamentinduserte og nevrodegenerering baserte dyskinesier; konsentrasjonssvikt hyperaktivitetsforstyrrelse; kognitive forstyrrelser som demens, (inkluderende aldersrelatert demens, og senil demens av type Alzheimer) og hukommelsesforstyrrelser i pattedyr, inkluderende et menneske, omfattende å administrere til et pattedyr i behov for slik behandling en glysin transportinhiberende mengde av en forbindelse av formel I, eller et farmasøytisk akseptabelt salt derav,
Foreliggende oppfinnelse vedrører også til et farmasøytisk sammensetning for å behandle en forstyrrelse eller tilstand valgt blant psykoser, schizofreni, oppførsels-forstyrrelse, forstyrrende atferdsforstyrrelse, bipolar forstyrrelse, psykotiske episoder av angst, angst assosiert med psykoser, psykotiske sinnsstemnings forstyrrelser, så som alvorlig hoved depressiv forstyrrelse; sinnsstemningsforstyrrelse assosiert med psykotiske forstyrrelser så som akutt mani eller depresjon assosiert med bipolar forstyrrelse og sinnsstemningsforstyrrelser assosiert med schizofreni, atferds manifestasjoner av mental utviklingshemming, oppførselsforstyrrelser og autistiske forstyrrelser, bevegelsesforstyrrelser så som Tourette's syndrom, akinetisk rigid syndrom, bevegelsesforstyrrelser assosiert med Parkinsons sykdom, tardiv dyskinesi og andre medikamentinduserte og nevrodegenerering baserte dyskinesier; konsentrasjonssvikt hyperaktivitetsforstyrrelse; kognitive forstyrrelser som demens, (inkluderende aldersrelatert demens, og senil demens av type Alzheimer) og hukommelsesforstyrrelser i pattedyr, inkluderende et menneske, omfattende en forbindelse av formel I eller et farmasøytisk akseptabelt salt derav, i en glysin transportinhiberende mengde.
Som anvendt heri, termen "behandling" refererer til å reversere, lindre eller inhibere utviklingen av en sykdom, forstyrrelse eller tilstand, eller en eller flere symptomer av slike sykdommer, forstyrrelser eller tilstander, hvortil slike termer anvendes. Som anvendt heri "behandling" kan også referere til reduksjon i sannsynlighet eller hyppighet av forekomst av en sykdom, forstyrrelse eller tilstand i et pattedyr sammenlignet med en ubehandlet kontrollpopulasjon, eller sammenlignet med det samme pattedyr før behandling. For eksempel, som anvendt heri "behandling" kan referere til å hindre en sykdom, forstyrrelse eller tilstand, og kan inkludere og forsinke eller hindre start av en sykdom, forstyrrelse eller tilstand, eller forsinke eller hindre symptomer assosiert med den samme sykdom, forstyrrelse eller tilstand. Som anvendt heri kan "termen" også referere til å redusere alvorligheten av en sykdom, forstyrrelse eller tilstand eller symptomer assosiert med en slik sykdom, forstyrrelse eller tilstand før pattedyrets lidelse av sykdommen, forstyrrelsen eller tilstanden. Slik hindring eller reduksjon av alvorligheten av en sykdom, forstyrrelse eller tilstand før lidelse vedrører administrering av sammensetningene ifølge foreliggende oppfinnelse, som beskrevet heri, til et individ som ved tid for administrering ikke er plaget av sykdommen, forstyrrelsen eller tilstanden. Som anvendt heri "behandling" kan også referere til å hindre tilbakevending av en sykdom, forstyrrelse eller tilstand eller av en eller flere symptomer assosiert med en slik sykdom, forstyrrelse eller tilstand. Termene "behandling" og "terapeutisk" som anvendt heri refererer til virkningen av behandling, som "behandling" er definert over.
Forbindelsene ifølge foreliggende oppfinnelse oppviser glysintransportinhiberende aktivitet og er derfor av verdi i behandling av et bredt spekter av kliniske tilstander som erkarakterisertmed en mangel på glutamatergisk neurotransmisjon i pattedyr, spesielt mennesker. Slike tilstander inkluderer positive og negative symptomer av schizofreni og andre psykoser, og kognitive mangler.
Forbindelsen ifølge foreliggende oppfinnelse kan administreres via enten oral, parenteral (så som subkutanøs, intravenøs, intramuskulær, intrasternal og infusjons-teknikker), rektal, intranasal eller topikalt til pattedyr. Generelt, disse forbindelser administreres hensiktsmessig til mennesker i doseringer i området fra ca 1 mg til ca 200 mg per dag, selv om variasjoner nødvendigvis vil forekomme avhengig av vekten og tilstanden til individet som behandles, og den bestemte administrasjons-rute som velges.
Imidlertid, et doseringsnivå som er i området fra ca 0,1 mg til ca 20 mg per kg kroppsvekt per dag benyttes mest hensiktsmessig. Imidlertid, variasjoner kan fremdeles forekomme avhengig av arten av dyr som behandles og det individuelle respons på nevnte medikament, og likeledes av type farmasøytisk formulering som velges og tidsperioden og intervaller hvorved slik administrering utføres. I noen tilfeller kan doseringsnivået under nevnte grense i ovenfor angitte område være mer adekvat, mens i andre tilfeller kan slike doseringer benyttes uten å forårsake noen skadelige bieffekter gitt at slike høyere doseringsnivåer først deles i flere mindre doseringer for administrering i løpet av dagen.
I en utførelse administreres forbindelsen ifølge oppfinnelsen som adjunktiv terapi med kjente antipsykotiske midler så som Ziprasidon (Geodon), Clozapin, Molindon, Loxapin, Pimozid, Risperidon, Olanzapin, Remoxiprid, Sertindol, Amisulprid, Quetiapin, Prochlorperazin, Fluphenazin, Trifluoroperazin, Thioridazin, Haloperidol, Chloropromazin, Flupentixol og Pipotiazin.
I en annen utførelse kan forbindelsene ifølge foreliggende oppfinnelse også anvendes i kombinasjon med CNS-midler så som antidepressive midler (så som sertralin), antiparkinson midler (så som deprenyl), L-dopa, Requip, Mirapex, MAOB inhibitorer så som selegin og rasalgin, comP- inhibitorer så som Tasmar, A-2 inhibitorer, dopamin reopptaksinhibitorer, NMDA antagonister, nikotinagonister, Dopamin agonister og inhibitorer av neuronal nitrogenoksidsyntase, anti-Alzheimers midler så som denepezil, tacrin, a26 inhibitorer, COX-2 inhibitorer, gaba pentenoider, propentofyllin og metrifonat, og antipsykotiske midler så som PDE10 inhibitorer, 5HT2C-agonister, alfa 7 nikotinisk reseptoragonister, CB1 antagonister og forbindelser som har aktivitet som antagoniserer dopamin D2 reseptorer.
Forbindelsene ifølge foreliggende oppfinnelse kan administreres alene eller i kombinasjon med farmasøytisk akseptable bærere eller fortynningsmidler med enhver av de ovenfor nevnte ruter, og slik administrering kan utføres i en enkelt eller multiple doseringer. Mer fortrinnsvis, de nye terapeutiske midler ifølge oppfinnelsen kan administreres i et bredt spekter av forskjellige doseringsformer, det vil si de kan kombineres med forskjellige farmasøytisk akseptable inerte bærere i form av tabletter, kapsler, lozenger, trocheer, hard krystaller, pulvere, sprayer, kremer, salver, stikkpiller, geleer, geler, pastaer, lotioner, salver, vandige suspensjoner, injiserbare løsninger, eliksirer, siruper og lignende.
Slike bærere inkluderer faststoff fortynningsmidler eller fyllmidler, sterilt vandig medie og forskjellige ikketoksiske organiske oppløsningsmidler, etc. Videre, orale farma-søytiske sammensetninger kan hensiktsmessig søtes og/eller smakstilsettes. Generelt, de terapeutiske effektive forbindelser ifølge foreliggende oppfinnelse foreligger i slike doseringsformer i konsentrasjonsnivåer i området fra ca 5,0 % til ca 70 % basert på vekt.
For oral administrering kan tabletter inneholdende forskjellige eksipienter så som mikrokrystallinsk sellulose, natriumsitrat, kalsiumkarbonat, dikalsiumfosfat, og glysin benyttes sammen med forskjellige disintegrerende midler som stivelse og fortrinnsvis mais, potet eller tapioka stivelse, alginisk syre og visse kompleks silikater, sammen med granuleringsbindere så som polyvinylpyrrolidon, sukkrose, gelatin og akasia. Videre, smøremidler så som magnesiumstearat, natriumlaurylsulfat og talg er ofte svært nyttig for tabletteringsformål. Faststoffsammensetninger og lignende typer kan også benyttes som fyllmaterialer i gelatinkapsler; hvor foretrukne materialer i denne forbindelse også inkluderer laktose eller melkesukker og likeledes høymolekylvekt polyetylenglukoler. I mer vandige suspensjoner og/eller eliksirer er hensiktsmessig for oral administrering kan den aktive ingrediens kombineres med forskjellige søtningsmidler eller smakstilsetningsmidler, fargematerialer eller fargestoff, og, dersom hensiktsmessig, emulsifiserende eller suspenderende midler, sammen med slike fortynningsmidler som vann, etanol, propylenglukol, glyserin og forskjellige kombinasjoner derav.
For parenteral administrering kan løsninger av en forbindelse ifølge foreliggende oppfinnelse i enten sesam eller peanøttolje eller i vandig propylenglukol nyttes. De vandige løsninger bør hensiktsmessig bufres (fortrinnsvis pH > 8) dersom nød-vendig, og væskefortynningsmidler bør først gjøres isotonisk. Disse vandige løsninger er egnet for intravenøse injeksjonsformål. Oljeløsningene er egnet for intraartikulær, intramuskulær og subkutanøse injeksjonsformål. Fremstilling av alle disse løsninger under sterile betingelser kan enkelt utføres av standard farma-søytiske teknikker godt kjent for fagkyndige innen feltet. Videre, det er også mulig å administrere forbindelsene ifølge foreliggende oppfinnelse topikalt ved behandling av inflammatoriske tilstander på huden og dette kan fortrinnsvis utføres ved hjelp av kremer, geleer, geler, pasta, salver og lignende, i samsvar med standard farma-søytisk praksis.
Forbindelsene ifølge foreliggende oppfinnelse ble undersøkt ved anvendelse av GlyT1 radioligand bindingsanalyse beskrevet under.
Fremstilling av testforbindelse: Forbindelser oppløses i DMSO, soniseres dersom nødvendig fortynnes til en konsentrasjon av 0,2 mM i DMSO, og fortynnes deretter med deionisert vann til en konsentrasjon på 10 uM.
Vevspreparering: GlyTIc transporter uttykkes i HEK-293 celler og den frosne cellepellet veies og polytroneres, med 1 g cellepellet i 30 ml analysebuffer (50 mM Tris base, 120 mM NaCI, og 5 mM KCI, pH-justeres til 7,4 med 6N HCI). Blandingen sentrifugeres ved 40000 G i 10 min, supernantanten dekanteres, og pellet resuspenderes ved 1 mg våtvekt per 25 ul analysebuffer.
Analyse: Inkubering av analysen utføres i 60 min, og ved romtemperatur i 96 brønns plater (Beckman 2 ml polypropylen), som vortekses ved tilsetning av vevspreparater. Til hver brønn tilsettes 25 uL testmedikamentløsning eller kontroll, 200 ul 0,7 nM [3H] NPTS (Lowe, John A.; Drozda, Susan E.; Fisher, Katherine; Strick, Christine; Lebel, Lorraine; Schmidt, Christopher; Hiller, Donna; Zandi, Kathleen S. [3H]-(R)-NPTS, en radioligand for type 1 glysintransporter.. Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1291-1292.), og 25 ul vev. Platene filtreres med anvendelse av Brandel cellehøster med GF/B filtre, og filtrene vaskes med 3X1,5 ml analysebuffer, lufttørkes natten over, og telles på en LKB beta plateteller den neste dag.
Forbindelsene ifølge foreliggende oppfinnelse analysert ved denne analyse har blitt funnet å ha signifikant aktivitet i inhibering av glysin reopptak i synaptosomer, og har større enn 20 % inhibering ved 1 uM.
Forbindelsene ifølge formel I kan fremstilles med fremgangsmåtene beskrevet nedenfor, sammen med syntesemetoder kjent innen fagfeltet organisk kjemi, eller modifiseringer og derivatiseringer som er kjente for fagkyndige innen feltet. Foretrukne fremgangsmåter inkluderer, men er ikke begrenset til, de som beskrives nedenfor.
Under enhver av de påfølgende syntetiske sekvenser kan det være nødvendig og/eller hensiktsmessig og beskytte sensitive eller reaktive grupper av enhver av molekylene som er vurdert. Dette kan oppnås ved hjelp av konvensjonelle beskyttelsesgrupper, så som de som er beskrevet i T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991, som inkorporeres heri med referanse.
Forbindelse av formel I eller deres farmasøytisk akseptable salter kan fremstilles i samsvar med følgende reaksjonsskjema I til V som diskutert nedenfor. Med mindre annet er angitt er A, Q, Y, Z og Ri til Rssom definert over. Isolering og rensing av produktene utføres med standard prosedyrer, som er kjent for en kjemiker med ordinære ferdigheter.
De påfølgende skjema er eksempler på fremgangsmåter for å fremstille forbindelsene av formel I.
Skjema I illustrerer en fremgangsmåte for fremstilling av forbindelser som har basisstrukturen av formel I, hvor A er hydrogen, Y er hydrogen og Q, Z og Ri til Re er som definert over.
Med henvisning til skjema I, kan en forbindelse av formel (I) [ SynLett, 1996, 1097] behandles med (BOC)20 i nærvær av en egnet base så som trietylamin, i oppløs-ningsmidler så som CH2CI2, for å produsere den ønskete karbamat av formel (III).
Oksidering av den primære alkohol under Swern-betingelser med DMSO og oksayl-klorid, i nærvær av en egnet base så som trietylamin (TEA) eller diisopropyletylamin (DIEA), i oppløsningsmidlerså som CH2CI2eller 1,2-dikloretan (DCE), i temperaturer i området fra - 78 °C til romtemperatur, fortrinnsvis ved ca romtemperatur, for å produsere det korresponderende aldehyd (ikke avbildet). Andre egnete oksiderende reagenser for denne omdanning inkluderer TRAP/NMO eller PCC.
Behandling av aldehydet med en egnet substituert aminreagens av formel (III) og et egnet reduserende middel så som NaBhU, i et oppløsningsmiddel så som MeOH, ved temperaturer i området fra - 5 °C til romtemperatur, fortrinnsvis ved ca romtemperatur, produserer et ønsket amin av formel (IV). Andre egnete reduserende midler for denne reaksjon inkluderer NaCNBH3eller NaHB(OAc)3, i oppløsnings-midler så som MeOH, CH2CI2eller DCE. Andre egnete betingelser for denne transformasjon inkluderer behandling av det korresponderende aldehyd med aminreagenset (III) i CH2CI2eller DCE i nærvær av 4 A molekylsikter og en base så som TEA ved romtemperatur, etterfulgt av behandling med NaBH4eller NaBH(OAc)3.
Forbindelser av formel (VII) kan fremstilles til behandling av et amin av formel (IV) med en egnet substituert syrekloridreagens av formel (V) i nærvær av en egnet base som DIEA, pyridin eller TEA, i oppløsningsmidler så som DCE eller CH2CI2, ved temperaturer i området fra romtemperatur til omtrent reflukstemperatur, fortrinnsvis ved ca romtemperatur, for å produsere de korresponderende amidforbindelser av formel (VII). Alternativt, forbindelsen av formel (VII) kan fremstilles med å behandle aminer av formel (IV) med karboksyliske syrer av formel (VI) og et egnet koblingsmiddel så som HOBT, HBTU, DCC, EDCI, etc, for å produsere de korresponderende amider av formel (VII). Til slutt kan forbindelsene av formel (VIII) fremstilles med behandling av et karbamat av formel (VII) med TFA eller HCI, i oppløsningsmidler så som EtOAc, Dioksan, CH2CI2eller DCE, ved temperaturer i området fra 0 °C til ca romtemperatur, fortrinnsvis ved ca romtemperatur, for å produsere det korresponderende amin av formel (VIII).
Skjema (II) illustrerer en fremgangsmåte for behandling av forbindelser som har basisstrukturen av formel I, hvor A er hydrogen og Y, U, Z og Ri-R6ersom beskrevet over.
Med henvisning til skjema II nedenfor kan forbindelser av formel (IX) fremstilles med behandling av et amin av formel (VII) med en egnet substituert aldehyd eller keton og et reduserende middel så som NaHB(OAc)3, i oppløsningsmidler så som CH2CI2eller DCE, ved temperaturer i områder fra 0 °C til ca romtemperatur, fortrinnsvis ved ca romtemperatur, for å produsere det korresponderende amin av formel (IX). Andre egnete betingelser for denne prosess inkluderer behandling av aminet av formel (VIII) med et aldehyd i toluen, ved ca reflukstemperatur; etterfulgt av behandling med NaBH4, i oppløsningsmidler så som MeOH, for å produsere det korresponderende amin av formel (IX). Videre, behandling av et amin av formel (VIII) med et aldehyd og NaCNBHai et oppløsningsmiddel så som MeOH produserer det korresponderende amin av formel (IX).
Skjema III illustrerer en alternativ fremgangsmåte for fremstilling av forbindelsene som har basisstrukturen i formel I, hvor A er hydrogen og Y, Q, Z og R1-R5 er som beskrevet over. R9er en sykloalkyl, -(CH2)0-R6, -CH(R6) eller -C(R6)2-
Ved henvisning til skjema III nedenfor kan en forbindelse av formel (VIII) behandles med et epoksidreagens av formel (IX) i nærvær av en egnet base så som trietylamin, i oppløsningsmidler så som metanol eller etanol, i temperaturer i områder fra romtemperatur til ca reflukstemperatur, fortrinnsvis ved ca reflukstemperatur, for å produsere en forbindelse av formel (IX).
Skjema IV nedenfor illustrerer en alternativ fremgangsmåte for fremstilling av forbindelser som har basisstrukturen av formel I, hvor A er hydrogen og Y, Q, Z og Ri-R5er beskrevet som over.
Med henvisning til skjema IV nedenfor, kan forbindelse av formel (XIII) behandles med en egnet base så som NaH eller KH, og en egnet substituert alkylerende middel av formel (XI), hvor L er en egnet avgangsgruppe så som Cl, Br, I, OMer, Oter, i oppløsningsmidler så som THF eller eter, ved temperaturer i området fra 0 °C til ca romtemperatur, fortrinnsvis ved ca romtemperatur, for å produsere forbindelsene av formel (IX).
Skjema V nedenfor illustrerer en alternativ fremgangsmåte for fremstilling av forbindelser som har basisstrukturen av formel I, hvor A er hydrogen og Y, Q, Z og Ri-Rser beskrevet som over.
Med henvisning til skjema V nedenfor, kan forbindelse av formel (VIII) behandles med en egnet beskyttet alfa brom ester derivat av formel (X), så som alfa brom benzylasetat, i nærvær av en base så som kaliumkarbonat, et egnet ammoniumsalt så som tetraetylammoniumklorid og et egnet oppløsningsmiddel så som dimetyl-formamid, ved romtemperatur for å gi den ønskete forbindelse av formel (XI). Forbindelsen av formel (XI) kan behandles med en egnet palladium katalysator, så som palladium hydroksid, i oppløsningsmidler så som metanol eller etanol, for å produsere forbindelser av formel (XII). Til slutt kan forbindelsene av formel (XIV) fremstilles ved å behandle syren av formel (XII) med primære og sekundære aminer av generell formel (XIII) i nærvær av et egnet koblingsmiddel så som O-Benzotriazol-1-yl-N,N,N',N'- tetrametyluronium heksafluorfosfat (HBTU) og trietylamin for å produsere de ønskete forbindelser av formel (XIV).
De påfølgende eksempler og illustreringer demonstrerer foreliggende oppfinnelse. Det skal forstås imidlertid at oppfinnelsen, som beskrevet heri og som angitt i kravene, ikke er tiltenkt å være begrenset av detaljene i de påfølgende eksempler.
Eksempler
Fremstilling 1
6- Hvdroksvmethvl- 3- aza- bisvklor3. 1 . Olheksan- 3- karboksylisk syre tert- butyl ester
Til en løsning av (3-Aza-bisyklo[3.1.0]heks-6-yl)-metanol-HCI (11,8 g, 78,7 mmol) i 350 ml vannfri CH2CI2ved romtemperatur ble det tilsatt et Et3N (32,9 ml, 236 mmol), etterfulgt av (BOC)20 (18,9 g, 86,6 mmol) i porsjoner. Reaksjonen ble omrørt ved
romtemperatur i 18 timer. Blandingen ble vasket med NaHCC>3, vann, saltløsning og tørket over vannfri MgSC>4. Blandingen ble filtrert og konsentrert under redusert trykk for å gi råmateriale som ble renset med flash kromatografi med 10 % MeOH/CH2CI2. Fraksjoner som inneholder produkt ble samlet og konsentrert for å gi 6-hydroksy-metyl-3-aza-bisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester (15.6 g). 400 MHz 1H NMR (CDCI3) 5 3,4-3,6 (m, 4H), 3,2-3,7 (m, 2H), 1,72 (brs, 1H), 1,4-1,4 (m, 10 H), 0,9-0,9 (m, 1H); MS (M+1) 213,2.
Fremstilling 2
6- Formvl- 3- aza- bisvklor3. 1. 01heksane- 3- karboksylisk syre tert- butyl ester Til en omrørende løsning av oksalylklorid (7,8 ml, 89,5 mmol) i 370 ml vannfri CH2CI2ved -78 °C, under Nitrogen ble det tilsatt DMSO (13,8 ml, 193,9 mmol) dråpevis. Etter 10 minutter ble, 6-Hydroksymetyl-3-aza-bisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester (15,9 g, 74,5mmol) i 72 ml vannfri CH2CI2tilsatt. Etter at blandingen var omrørt i 30 minutter ble trietylamin (52,0 ml, 372,9 mmol) tilsatt og blandingen ble tillatt og langsomt oppvarmes til 0 °C I løpet av 1 time. Blandingen ble konsentrert, det resulterende faststoff ble tatt opp I mettet NaHC03og EtOAc, sjiktene ble separert og det vandige skikt ble ekstrahert med EtOAc. De kombinerte organiske skikt ble vasket med saltløsning, tørket, filtrert og konsentrert for å gi et kvantitativt ubehandlet utbytte av6-Formyl-3-aza-bisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester (15,8 g), som ble anvendt i det neste trinn uten rensing. 400 MHz 1H NMR (CDCI3) 5 9,4 (d, J= 4,1 Hz, 1H), 3,6 (dd, J= 11,2 Hz, 37,8 Hz, 2H), 3,4 (d, J = 9,95, 2H), 2,1 (m, 2H), 1, 8 -1,7 (q, J = 3,32 Hz, 1H), 1,4 (s, 9H); GCMS (M+0) 211,0.
Fremstilling 3
6- r( 3- Trifluorometoksv- benzvlamino)- metvn- 3- aza- bisyklor3. 1. 01heksan- 3-karboksvlisk syre tert- butyl ester
Til en omrørende løsning av aldehyd fremstilt over(1,0 g, 4,7 mmol) i 9,5 ml av MeOH ble det tilsatt 3-trifluorometoksy-benzlyamin (0,7 ml, 4,7 mmol). Reaksjonsblandingen ble omrørt ved romtemperatur i 24 timer. Natrium borhydrid (0,4 g, 9,5 mmol) ble deretter tilsatt, oOg reaksjonsblandingen ble omrørt I ytterligere 24 timer. Reaksjonen ble konsentrert under redusert trykk, og det resulterende materialet ble opptatt i 1 N NaOH og ekstrahert med CH2CI2. De kombinerte organiske sjikt ble tørket over vannfri MgS04, filtrert og konsentrert under redusert trykk for å gi 1,8 g av det ønskete amin, som ble tatt med uten rensing. 6-[(3-Trifluorometoksy-benzyl-amino)-metyl]-3-azabisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester 400 MHz 1H NMR (CDCb) 6 7,3 (t, J= 7,8 Hz, 1H), 7,2 (m, 1H), 7,2 (s, 1H), 7,1-7,0 (m, 1H), 3,8 (s, 2H), 3,5 (dd, J= 39,4 Hz, 10,8 Hz, 2H), 3,8 (t, J= 10,8 Hz, 2H), 2,5 (dt, J = 6,0 Hz, 25,7 Hz, 2H), 1,4 (s, 9H), 1,3 (m, 2H) 0,8-0,7 (m, 1H); MS (M+1) 387,3.
De påfølgende forbindelser ble fremstilt ved anvendelse av prosedyren beskrevet i fremstilling 3.
6- r( 3- Trifluormetvl- benzvlamino)- metvn- 3- aza- bisvklor3. 1. 01heksan- 3-karboksylisk syre tert- butyl ester
400 MHz 1H NMR (CDCI3) 6 7,5 (s, 1H), 7,5-7,2 (m, 3H), 3,8 (s, 2H), 3,5 (dd, J = 37,7 Hz, 10,8 Hz, 2H), 3,2 (m, 2H), 2,5 (dt, J= 17,0 Hz, 5,4 Hz, 2H), 1,4 (s, 9H), 1,3-1,2 (m, 2H) 0,8-0,7 (m, 1H); MS (M+1) 371,3.
6- rf3- Klor- benzvlamino)- metvn- 3- aza- bisvklor3. 1. 01heksan- 3- karboksylisk syre tert- butyl ester
400 MHz<1>H NMR (CDCI3) 5 7,3 (s, 1H), 7,2-7,1 (m, 3H), 3,8 (s, 2H), 3,5 (dd, J = 37,3 Hz, 10,8 Hz, 2H), 3,3-3,3 (m, 2H), 2,6-2,5 (m, 2H), 1,4 (m, 9H), 1,3 (m, 2H) 0,8-0,7 (m, 1H); MS (M+1) 337,2.
6- rf4- Fluor- 3- trifluormetvl- benzvlamino)- metvn- 3- aza- bisyklor3. 1. 01heksan- 3
karboksylisk syre tert- butyl ester
400 MHz 1H NMR (CDCI3) 5 7,6-7,5 (m, 1H), 7,5-7,4 (m, 1H), 7,2 (s, 1H), 3,8 (s, 1H) 3,6-3,5 (m, 4H), 2,5-2,5 (m, 2H), 1,4 (s, 9H), 1,3-1,2 (m, 2H) 0,8-0,7 (m, 1H); MS (M+1) 389,3.
6- r( 3- Klor- 4- fluor- benzvlamino)- metvn- 3- aza- bisyklor3. 1. 01heksan- 3-karboksvlisk syre tert- butyl ester
400 MHz 1H NMR (CDCI3) 6 7,3-7,4 (m, 1H); 7,0-7,2 (m, 2H); 3,7 (3, 2H); 3,4-3,6 (m, 2H); 3,3-3,4 (m, 2H); 2,4-2,6 (m, 2H); 1,4(m, 9H); 1,3 (m, 2H); 0,8 (m, 1H).
Fremstilling 4
6- fr( 1- Metvl- 1H- imidazol- 4- karbonvl)-( 3- trifluormetoksv- benzvl)- amino1- metyl>-3- aza- bisvklor3. 1. 01heksan- 3- karboksvlisk syre tert- butyl ester
Til en omrørende løsning av 6-[(3-Trifluormetoksy-benzylamino)-metyl]-3-aza-bisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester fremstilt over (5,9 g, 15,4 mmol) i 192 ml CH3CN ved romtemperatur under N2ble tilsatt DIEA (8,0 ml, 46,1 mmol) og 1-Metyl-1H-imidazol-4-karbonyl klorid HCL (5,6 g, 30,7 mmol). Etter 24 timer ble reaksjonen stoppet med H20, og ekstrahert med EtOAc. Det organiske sjikt ble deretter vasket med en 10 % sitronsyreløsning, H20, NaHC03, og saltløsning. De kombinerte ekstrakter ble tørket over vannfri MgS04, filtrert og konsentrert under redusert trykk for å gi 6,7 g av 6-{[(1-Metyl-1 H-imidazol-4-karbonyl)-(3-trifluor-metoksy-benzyl)-amino]-metyl}-3-aza-bisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester 400 MHz 1H NMR (CDCI3) 6 7,8 (d, J= 1,2 Hz, 1H), 7,3-7,1 (m, 5H), 5,4 (s, 1H), 4,8-4,7 (m, 1H), 4,2 (m, 1H), 3,7 (s, 1H), 3,7 (s, 3H), 3,4-3,2 (m, 3H), 1,4 (s, 9H), 1,3 (m, 2H), 0,8 (m, 1H); MS (M+1) 495,3.
De påfølgende forbindelser ble fremstilt ved anvendelse av prosedyren beskrevet i fremstilling 4.
6- IT( 1- Metvl- 1H- imidazol- 4- karbonvl)-( 3- trifluormetvl- benzvl)- amino1- metvl>- 3-aza- bisvklor3. 1. 0lheksan- 3- karboksvlisk syre tert- butyl ester
400 MHz 1H NMR (CDCI3) 6 7,6-7,2 (m, 6H), 5,4 (s, 1H), 4,9-4,8 (m, 1H), 4,2 (m, 1H), 3,7 (s, 3H), 3,4-3,2 (m, 7H), 1,4 (m, 9H), 0,8 (m, 1H); LCMS (M+0) 479,1.
6- IT( 3- Klor- benzvl)-( 1- metvl- 1H- imidazol- 4- karbonvl)- amino1- metvl>- 3- aza-bisvklor3. 1. 01heksan- 3- karboksvlisk syre tert- butyl ester
400 MHz<1>H NMR (CDCI3) 6 7,6 (s, 1H), 7,4 (s, 1H), 7,2-7,1 (m, 4H), 5,4 (d, 1H), 4,8-4,7 (m, 1H), 4,2 (m, 1H), 3,8 (s, 1H), 3,7 (s, 3H), 3,5-3,4 (m, 2H), 3,3-3,2 (m, 2H), 1,4 (s, 9H), 1,4-1,3 (m, 2H), 0,8 (m, 1H); MS (M+1) 445,3.
6- fr( 4- Fluor- 3- trifluormetvl- benzvl)-( 1- metvl- 1H- imidazol- 4- karbonyl)- amino1-metvl}- 3- aza- bisvklor3. 1. 01heksan- 3- karboksvlisk syre tert- butyl ester 400 MHz 1H NMR (CDCI3) 5 7,6 (s, 1H), 7,5 (m, 2H), 7,3 (m, 1H), 7,1 (t, J=9,5Hz, 1H), 5,4 (s, 1H), 4,8-4,7 (m, 1H), 4,2 (m, 1H), 3,9-3,8 (m, 1H), 3,7 (s, 3H), 3,5 (m, 1H), 3,4-3,2 (m, 4H), 1,4 (m, 2H), 1,4 (s, 9H), 0,8 (m, 1H); MS (M+1) 497,3.
6- fr( 3- Klor- 4- f1uor- benzvl)-( 1- metvl- 1H- imidazol- 4- karbonvl)- amino1- metyl>- 3-aza- bisyklor3. 1. 01heksan- 3- karboksylisk syre tert- butyl ester
400 MHz 1H NMR (CDCI3) 5 7,6 (s, 1H); 7,3-7,4 (m, 2H); 7,1-7,2 (m, 1H); 7,0-7,1 (t, J=8,7 Hz, 1H); 5,3-5,4 (m, 1H); 4,6-4,8 (m, 1H); 4,1-4,2 (m, 1H); 3,7 (m, 3H); 3,2-3,5 (m, 5H); 1,3-1,4 (m, 11H); 0,8 (m, 1H); MS (M+1) 463,0.
Eksempel 1
1- Metyl- 1H- imidazol- 4- karboksylisk syre ( 3- aza- bisyklo[ 3. 1. 0] heks- 6- vlmetyl)-( 3- trifluormetoksv- benzyl)- amid Hvdroklorid
Til 6-{[(1 -Metyl-1 H-imidazol-4-karbonyl)-(3-trifluormetoksy-benzyl)-amino]-metyl}-3-aza-bisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester fremstilt over (7,74g, 15,65 mmol) ble det tilsatt 5 ml mettet HCI i EtOAc ved romtemperatur. Reaksjonen ble omrørt ved romtemperatur i 4 timer. Blandingen ble konsentrert under redusert trykk for å gi 6,63 g av 1-Metyl-1 H-imidazol-4 karboksylisk syre (3-aza-bisyklo-[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid Hydroklorid.
400 MHz 1H NMR (CD3OD) 8 9,0 (s, 1H), 8,2 (brs, 1H), 7,5-7,2 (m, 4H), 5,0, brs, 2H), 4,0-3,9 (m, 4H), 3,6-3,4 (m, 2H), 3,3 (m, 3H), 1,8 (brs, 2H), 1,32 (brs, 1H); MS (M+1) 395,3.
De påfølgende forbindelser ble fremstilt ved anvendelse av prosedyren beskrevet i eksempel 1.
Eksempel 2
1 - Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- aza- bisvklor3. 1. 0lheks- 6- vlmetvl)-( 3- trifluormetvl- benzyl)- amid Hvdroklorid
400 MHz<1>H NMR (CD3OD) 8 9,0 (s, 1H), 8,2 (brs, 1H), 7,6 (m, 4H), 5,0 (brs, 2H), 4,0-3,9 (m, 4H), 3,6 (m, 2H), 3,3-3,2(m, 3H), 1,8 (brs, 2H), 1,2 (brs, 1H).
Eksempel 3
1- Metvl- 1H- imidazol- 4- karboksvlisk syre ( 3- aza- bisvklor3. 1. 0lheks- 6- vlmetvl)-( 3- klor- benzvl)- amid Hvdroklorid
400 MHz 1H NMR (CD3OD) 8 9,0 (s, 1H), 8,2 (brs, 1H), 7,3-7,2 (m, 4H), 5,0, brs, 2H), 4,-3,9 (m, 4H), 3,56 (m, 2H), 3,3 (m, 3H), 1,8 (brs, 2H), 1,2 (brs, 1H); MS (M+1) 345,1.
Eksempel 4
1 - Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- aza- bisvklor3. 1. 0lheks- 6- vlmetvl)-( 4- fluor- 3- trifluormetvl- benzyl)- amid Hvdroklorid
400 MHz 1H NMR (CD3OD) 8 9,0 (s, 1H), 8,2 (brs, 1H), 7,6 (m, 2H), 7,4 (s, 1H), 4,9 (brs, 2H), 4,0 (m, 4H), 3,6-3,4 (m, 2H), 3,3 (s, 3H), 1,8 (brs, 2H), 1,4 (brs, 1H).
Eksempel 5
1 - Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- aza- bisvklor3. 1. 0lheks- 6- vlmetvl)-( 3- klor- 4- fluor- benzvl)- amid Hvdroklorid
400 MHz 1HNMR (CD3OD) 8 9,1 (s, 1H); 8,3 (brs, 1H); 7,5 (m, 1H); 7,2-7,4 (m, 2H); 4.8- 5,2 (m, 4H); 3,9-4,1 (m, 3H); 3,5-3,6 (m, 2H); 3,2-3,3 (m, 2H); 1,8 (m, 3H); 1,4 (m, 1H); MS (M+1) 363,0
Eksempel 6
1- Metvl- 1H- imidazol- 4- karboksvlisk syre ( 3- aza- bisvklor3. 1. 0lheks- 6- vlmetvl)-( 4- fluor- 3- isopropoksv- benzvl)- amid
100 MHz<13>C NMR (CD3OD) 8 19,44, 21,26, 21,78, 35,94, 49,72, 60,37, 72,27, 116,33, 120,59, 124,55, 126,54, 137,30, 146,35, 151,91, 154,35, 158,89, 171,74.
Eksempel 7
1- Metyl- 1 H- imidazol- 4- karboksvlisk acid ( 3- aza- bisvklor3. 1. 01heks- 6- vlmetvl)-( 3-syklopentyloksy- 4- fluor- benzyl)- amid
100 MHz<13>C NMR (CD3OD) 8 19,45, 21,75, 23,71, 32,55, 33,25, 35,80, 49,64, 51,77, 60,36, 79,18, 81,06, 112,50, 116,16, 118,73, 120,05, 124,59, 126,51, 132,29, 133,54, 137,25, 146,44, 152,76 (d, J=248), 158,77, 171,74.
Eksempel 8
1- Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- aza- bisvklor3. 1. 0lheks- 6- vlmetvl)-r3-( 2. 2- dimetvl- propoksv)- 4- fluor- benzvn- amid
100 MHz<13>C NMR (CD3OD) 8 19,41, 21,74, 25,73, 31,79, 35,80, 49,68, 51,74, 79,03, 112,49, 114,60, 115,85, 120,02, 124,53, 126,51, 137,21, 148,05, 152,20 (d, J=245), 158,85.
Eksempel 9
1 - Metyl- 1 H- imidazol- 4- karboksylic syre ( 3- aza- bisyklor3. 1. 0lheks- 6- vlmetvl)-( 3-sykloheksvloksv- 4- fluor- benzyl)- amid
100 MHz<13>C NMR (CD3OD) 8 19,46, 21,73, 23,31, 25,49, 31,62, 35,79, 41,04, 49,56, 51,63, 52,51, 77,23, 116,52, 120,63, 124,59, 126,51, 129,48, 137,21, 151,02, 153,21 (d, J=245), 158,68.
Eksempel 10
1 - Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- aza- bisyklor3. 1. 01heks- 6- vlmetyl)-r3-( 2. 2. 2- trifluor- 1- trifluormetvl- ethvh- benzvn- amid
400 MHz 1HNMR (CDCI3) 8 7,5 (s, 1H); 7,2-7,4 (m, 5H); 5,4 (brs, 1H); 4,8 (brs, 1H); 3.9- 4,1 (m, 2H); 3,6 (s, 3H); 3,3 (m, 1H); 2,6-3,0 (m, 4H); 1,2-1,3 (m, 2H); 0,8-0,9 (m, 1H); 100 MHz<13>C NMR (CD3OD) 8 17,70, 19,01, 21,63, 23,35, 28,55, 33,72,
47,53, 48,24, 49,23, 50,19, 51,74, 54,19 (h, J=29), 118,92, 121,71, 124,54, 126,54, 126,78, 127,34, 128,55, 129,40, 136,85, 138,26, 139,96, 164,28; MS (M+1) 461.
Eksempel 11
1 - Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- aza- bisvklor3. 1. 0lheks- 6- vlmetvl)-r3-( 2, 2, 2- trifluor- etvl)- benzvn- amid
400 MHz 1HNMR (CDCI3) 6 7,5 (s, 1H); 7,1-7,3 (m, 5H); 5,4 (brs, 1H); 4,8 (brs, 1H); 3,9 (brs, 1H); 3,6 (m, 3H); 3,2-3,3 (m, 3H); 2,7-2,8 (m, 3H); 2,1-2,2 (m, 1H); 1,4 (m, 2H); 0,7-0,8 (m, 1H); 100 MHz<13>C NMR (CD3OD) 8 3,13, 17,34, 18,69, 23,82, 33,75, 40,26 (q, J=30), 47,64, 48,89, 49,54, 51,82, 53,66, 121,81, 124,57, 126,43, 127,33, 128,97, 129,42, 130,08, 130,46, 136,85, 138,46, 139,31, 164,29; MS (M+1) 393,0.
Eksempel 12
1- Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- syklopropylmetvl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)-( 3- trifluormetoksv- benzvl)- amid
Til en omrørende løsning av 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo-[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid Hydroklorid fremstilt over (0,8 g, 1,9 mmol) i 18,5 ml DCE ved romtemperatur ble det tilsatt syklopropankarb-aldehyd (0,1 ml, 1m6 mmol) og NaHB(OAc)3(0,8 g, 3,7 mmol). Reaksjonen ble omrørt ved romtemperatur i 16 timer, stoppet med tilsetning av mettet NaHC03, og ekstrahert med CH2CI2. De kombinerte organiske sjikt ble tørket over vannfri MgS04, filtrert og konsentrert under redusert trykk for å gi det ubehandlede materiale, som ble renset med flash kromatografi med 5-30 % MeOH/CH2Cl2. Produktet inneholdende fraksjoner ble samlet og konsentrert for å gi 1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid 0,5 g.
400 MHz<1>H NMR (CDCI3) 5 7,5 (s, 1H), 7,3 (m, 2H) 7,2-7,0 (m, 3H), 5,5 (brs, 1H) 4,8 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,3 (brs, 1H), 3,0 (m, 2H), 2,2 (m, 4H), 1,5 (brs, 1H), 1,3 (m, 2H), 0,8 (m, 1H), 0,4 (m, 2H), 0,0 (m, 2H); MS (M+1) 449,3.
Generell prosedyre for den reduktive alkvlerings fremgangsmåte for forbindelse av formel IX.
Til en omrørende løsning av 1,0 ekviv av en forbindelse av formel (VIII) i 1,2-dikloretan (0,1 M) ved romtemperatur ble det tilsatt det hensiktsmessige substituerte aldehyd eller ketonreagens (1,0-1,5 ekviv) og natrium triasetoksyborhydrid (2,0 ekviv). Reaksjonsblandingene ble omrørt ved romtemperatur i opptil 24 timer. Blandingene ble deretter stoppet ved tilsetning av mettet natriumbikarbonatløsning, og ekstrahert med metylenklorid. Det kombinerte organiske sjikt ble tørket over vannfri MgS04og konsentrert under redusert trykk. Dersom nødvendig ble resulterende ubehandlete materialer renset med flash kromatografi med 4 % MeOH/CH2Cl2. Fraksjonene som inneholder produkt ble samlet, og konsentrert for å gi de ønskete tertielle aminer i 70- 95 % utbytte.
De følgende forbindelser ble fremstilt ved anvendelse av prosedyren over fra eksempel 12, der man starter med de egnete utgangsamin av formel (VIII) og det egnete aldehyd eller ketonreagens.
Videre, farmasøytisk akseptable salter av forbindelsene angitt nedenfor kan fremstilles som følger. Til en omrørende løsning av forbindelsen av den generelle formel (IX) fremstilt som beskrevet ovenfor i eksempel 1 og eksempel 2, 1,0 ekviv til slutt i en egnet oppløsningsmiddel så som etylasetat, dioksan, dietyleter, metyletylketon, metylenklorid / metanol (1:0) eller metanol (0,1 M) ved romtemperatur ble tilsatt til den egnete syre, så som hydroklorisk syre, sitronsyre, trifluoreddiksyre, p-toluensulfonisk syre, metansulfonisk syre eller benzensulfonisk syre (2-3 ekviv) i en porsjon. Den resulterende blanding ble omrørt ved romtemperatur i oppfinnelse til 18 timer, og deretter konsentrert under redusert trykk for å gi de ønskete salter.
Eksempel 13
1 - Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- svklopentvlmetvl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)-( 3- trifluormetoksv- benzvl)- amid
400 MHz 1H NMR (CDCI3) 5 7,5 (m, 1H), 7,3-7,0 (m, 5H), 5,5 (brs, 1H) 4,8 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,3 (brs, 1H), 2,9-2,8 (m, 2H), 2,19 (m, 4H), 1,8 (brs, 1H), 1,6-1,1 (m, 10H); MS (M+1) 477,3.
Eksempel 14
1 - Metyl- 1 H- imidazol- 4- karboksylisk syre f3- trifluormetoksv- benzyl)- r3-( 4-trifluormetoksv- benzvl)- 3- aza- bisyklor3. 1. 01heks- 6- vlmetvn- amid
400 MHz<1>H NMR (CDCI3) 6 7,5 (s, 1H), 7,5-7,0 (m, 9H), 5,5 (brs, 1H) 4,8 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,5-3,4 (m, 2H), 3,3 (m, 1H), 2,8-2,7 (m, 2H), 2,2 (brs, 2H), 1,4 (brs, 1H), 1,2 (brs, 2H); MS (M+1) 569,5.
Eksempel 15
1 - Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- klor- benzvl)-( 3- svklopropvlmetvl- 3-aza- bisvklor3. 1. 0lheks- 6- vlmetvl)- amid
400 MHz 1H NMR (CDCI3) 6 7,5 (m, 1H), 7,3-7,2 (m, 5H), 5,4 (brs, 1H) 4,8 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,3 (brs, 1H), 3,0 (brs, 1H), 2,2 (brs, 4H), 1,7 (brs, 2H), 1,4 (brs, 1H), 1,3 (brs, 2H), 0,4 (m, 2H), 0,0 (m, 2H); MS (M+1) 399,3.
Eksempel 16
Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- klor- benzvl)-( 3- svklopentvlmetvl- 3-aza- bisvklor3. 1. 01heks- 6- vlmetvl)- amid
400 MHz 1H NMR (CDCI3) 6 7,6 (m, 1H), 7,3-7,2 (m, 5H), 5,4 (brs, 1H) 4,8 (brs, 1H), 3,9 (brs, 1H), 3,7 (brs, 3H), 3,3 (m, 1H), 2,9 (m, 2H), 2,2 (m, 3H), 1,9-1,1 (m, 13H); MS (M+1) 427,4.
Eksempel 17
1 - Metyl- 1 H- imidazol- 4- karboksylisk syre ( 3- klor- benzyl)-[ 3-( 4- trifluormetoksy-benzvl)- 3- aza- bisvklor3. 1. 01heks- 6- vlmetvn- amid
400 MHz<1>H NMR (CDCI3) 5 7, 6 (d, 1H), 7,5-7,1 (m, 9H), 5,4 (brs, 1H), 4, 8 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,5 (brs, 2H), 3,3 (d, 1H), 2,8 (m, 2H), 2,2 (m, 2H), 1,40 (brs, 1H), 1,2 (brs, 2H); MS (M+1) 519,4.
Eksempel 18
1- Metyl- 1 H- imidazol- 4- karboksvlisk syre ( 3- syklopropylmetvl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)-( 3- trifluormetvl- benzvl)- amid
400 MHz 1H NMR (CDCI3) 6 7,6-7,4 (m, 6H), 5,4 (brs, 1H) 4,8 (brs, 1H), 3,9-3,7 (m, 5H), 3,0 (m, 2H), 2,9 (m, 2H), 2,4 (brs, 2H), 1,8 (m, 2H), 1,4 (m, 2H), 0,7 (m, 2H), 0,4-0,3 (m, 2H); MS (M+1) 433,3.
Eksempel 19
1 - Metyl- 1 H- imidazol- 4- arboksvlisk syre ( 3- etyl- 3- aza- bisyklor3. 1. 0lheks- 6-vlmetvl)-( 4- fluor- 3- trifluormetvl- benzvl)- amid
400 MHz 1HNMR (CDCI3) 5 7,5-7,6 (m, 3H), 7,3 (s, 1H); 7,1 (t, J = 9,3, 1H), 5,4 (brs, 1H), 4,8 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,3 (brs, 1H), 2,2-3,0 (m, 4H), 1,0-1,7 (m, 8H).
Eksempel 20
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 4- fluor- 3- trifluormetvl- benzvl)-( 3-metvl- 3- aza- bisvklor3. 1. 01heks- 6- vlmetvl)- amid
400 MHz 1 HNMR (CDCI3) 6 7,5-7,6 (m, 3H); 7,3 (s, 1 H); 7,1 (t, J= 9,3, 1H); 5,4 (brs, 1H); 4,8 (brs, 1H); 4,0 (brs, 1H); 3,6-3,7 (m, 3H); 3,3 (brs, 1H); 2,8-3,1 (brs, 2H); 2,3 (brs, 5H); 1,2-1,4 (m, 3H).
Eksempel 21
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3- klor- benzyl)-( 3- etyl- 3- aza-bisvklor3. 1. 0lheks- 6- vlmetvl)- amid
400 MHz 1HNMR (CDCI3) 5 7,5 (m, 1H); 7,1-7,3 (m, 5H); 5,4 (brs, 1H); 4,8 (brs, 1H); 4,0 (brs, 1H); 3,7 (m, 3H); 3,3 (brs, 1H); 3,0 (brs, 2H); 2,1-2,4 (m, 4H); 1,2-1,4 (m, 3H); 0,9-1,0 (m, 3H).
Eksempel 22
1 - Metvl- 1 H- imidazol- 4- karboksylisk syre ( 3- etvl- 3- aza- bisyklor3. 1 . Olheks- 6-vlmetvl)-( 3- trifluormetoksv- benzvl)- amid Hvdroklorid
400 MHz 1HNMR (CD3OD) 8 7,6 (m, 2H); 7,1-7,4 (m, 4H); 5,3 (brs, 1H); 4,8 (brs, 1H); 3,8 (brs, 1H); 3,7 (brs, 3H); 3,3 (brs, 1H); 2,8 (brs, 2H); 2,3-2,5 (m, 4H); 1,3 (brs, 3H); 1,0 (m, 3H).
Eksempel 23
1- Metyl- 1 H- imidazol- 4- karboksylisk syre ( 3- metyl- 3- aza- bisvklo[ 3. 1. 0] heks- 6-vlmetvl)-( 3- trifluormetoksv- benzvl)- amid 400MHz1HNMR(CDCI3)6 7,5(m, 1H); 7,1-7,3 (m, 5 H); 5,5 (brs, 1H); 4,8 (brs, 1H); 4,0 (brs, 1H); 3,7 (brs, 3H); 3,3 (brs, 1H); 2,9 (brs, 2H); 2,2 (brs, 5H); 1,3-1,4 (m, 3H).
Eksempel 24
1- Metvl- 1 H- imidazol- 4- karboksvlisk svre( 3- etvl- 3- aza- bisvklor3. 1. 01heks- 6-vlmetvl)-( 3- trifluormetvl- benzvl)- amid
400 MHz 1 HNMR (CDCI3) 6 7,6 (m, 1H); 7,3-7,5 (m, 5 H); 5,5 (brs, 1H); 4,9 (brs, 1H); 4,0 (brs, 1H); 3,6-3,7 (m, 3H); 3,3 (brs, 1H); 3,0 (brs, 2H); 2,0-2,4 (m, 4H); 1,2-1,5 (m, 3H); 1,0 (brs, 3H).
Eksempel 25
1- Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3- metyl- 3- aza- bisvklor3. 1. 0lheks- 6-vlmetvl)-( 3- trifluormetvl- benzvl)- amid
400 MHz<1>HNMR (CDCI3) 6 7,3-7,6 (m, 6H); 5,5 (brs, 1H); 4,8 (brs, 1H); 4,0 (brs, 1H); 3,6-3,7 (m, 3H); 3,3 (brs, 1H); 3,0 (m, 2H); 2,3 (m, 5H); 1,3-1,7 (m, 3H).
Eksempel 26
1 - Metvl- 1 H- imidazol- 4- karboksvlisk svre( 3, 5- diklor- benzvl)-( 3- metvl- 3- aza-bisvklor3. 1. 0lheks- 6- vlmetvl)- amid
400 MHz 1HNMR (CDCI3) 8 7,6 (m, 1H); 7,3 (brs, 1H); 7,1-7,2 (m, 3H); 5,4 (brs, 1H); 4,7 (brs, 1H); 4,0 (brs, 1H); 3,7 (brs, 3H); 3,3 (brs, 1H); 2,9 (brs, 2H); 2,3 (brs, 5H); 1,2-1,4 (m, 3H).
Eksempel 27
1 - Metyl- 1 H- imidazol- 4- karboksylisk syre ( 3, 5- diklor- benzyl)-( 3- etyl- 3- aza-bisyklor3. 1. 01heks- 6- vlmetyl)- amid Hvdroklorid
400 MHz<1>HNMR (CD3OD) 6 9,0 (s, 1H); 8,3 (brs, 1H) 7,3-7,4 (m, 3H); 4,8 (brs, 2H); 4,0-4,1 (m, 4H); 3,5-3,6 (m, 5H); 3,1-3,2 (m, 2H); 1,8 (m, 3H); 1,2-1,3 (m, 3H).
Eksempel 28
1 - Metvl- 1 H- imidazol- 4- karboksylisk syre ( 3- klor- 4- fluor- benzvl)-( 3- metvl- 3-aza- bisvklor3. 1. 01heks- 6- vlmetvl)- amid
400 MHz 1 HNMR (CDCI3) 6 7,52 (s, 1H), 7,28 (m, 2H), 7,11 (m, 1H), 7,00 (t, J=8, 1H), 4,67 and 5,355 (m, 2H), 3,65 (s, 3H), 3,24 and 3,925 (m, 2H), 2,86 (m, 2H), 2,19 (s, 5H), 1,36 (m, 1H), 1,26 (m, 2H); MS (M+1) 377,1, 100 MHz<13>C-NMR (CDCI3, 5): 18,375, 19,616, 22,763, 33,791, 41,499, 47,025, 48,355, 49,522, 50,112, 57,133, 116,5785 (d, J=21), 120,929, 126,724, 127,576, 129,789, 135,7, 136,742, 138,432, 157,325 (d, J=248), 164,039.
Eksempel 29
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3- klor- 4- fluor- benzvl)-( 3- etyl- 3- aza-bisvklor3. 1. 0lheks- 6- vlmetvl)- amid
400 MHz<1>HNMR (CD3OD) 6 9,0 (s, 1H); 8,2-8,3 (m, 1H) 7,5 (s, 1H); 7,3 (m, 2H); 4,8 (brs, 2H); 3,8-4,0 (m, 4H); 3,4-3,6 (m, 4H); 3,1-3,3 (m, 2H); 1,6-1,8 (m, 3H); 1,3 (m, 3H).
Eksempel30
1 - Metvl- 1 H- imidazol- 4- karboksylisk syre ( 3- klor- benzvl)-( 3- metvl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)- amid
400 MHz 1 HNMR (CDCI3) 5 7,6 (s, 1H); 7,2-7,3 (m, 5H); 5,4 (brs, 1H); 4,8 (brs, 1H); 4,0 (brs, 1H); 3,7 (s, 3H); 3,3 (brs, 1H); 3,0 (brs, 2H); 2,2-2,3 (m, 5H); 1,3-1,5 (m, 3H).
Eksempel 31
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3- azetidin- 3- yl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)-( 3- trifluormetoksv- benzvl)- amid
100 MHz<13>C-NMR (CDCI3) 5 15,45, 19,4, 21,79, 33,88, 42,10, 47,56, 50,31, 50,75, 53,10, 119,33, 119,67, 120,23, 121,89, 126,22, 128,62, 129,09, 130,10, 137,13, 137,75, 141,29, 149,63, 164,38.
Eksempel 32
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 2, 4- diklor- benzvl)-( 3- metvl- 3- aza-bisvklor3. 1. 0lheks- 6- vlmetvl)- amid
400 MHz 1HNMR(CDCI3) 6 7,6 (brs, 1H); 7,2 (m, 3 H); 7,1 (m, 1H); 5,5 (brs, 1H); 4,8 (brs, 1H); 4,1 (brs, 1H); 3,7 (brs, 3H); 3,3 (brs, 1H); 2,9 (brs, 2H); 2,2 (brs, 5H); 1,3-1,4 (m, 3H); MS (M+1) 393,0.
Eksempel 33 1 - Metvl- 1 H- imidazol- 4- karboksylisk syre ( 2, 4- diklor- benzvl)-( 3- etvl- 3- aza-bisvklor3. 1. 0lheks- 6- vlmetvl)- amid 400MHz<1>HNMR(CDCI3)5 7,6(brs, 1H); 7,2-7,4 (m, 3 H); 7,1 (m, 1H); 5,5 (brs, 1H); 4,8 (brs, 1H); 4,1 (brs, 1H); 3,6-3,7 (m, 3H); 3,3 (brs, 1H); 2,9-3,0 (m, 2H); 2,4 (m, 2H); 2,2 (m, 2H); 1,3-1,4 (m, 3H); 0,9-1,0 (m, 3H); MS (M+1) 407,0.
Eksempel 34
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3, 4- diklor- benzvl)-( 3- metvl- 3- aza-bisvklor3. 1. 0lheks- 6- vlmetvl)- amid
400 MHz 1HNMR (CDCI3) 6 7,6 (m, 1H); 7,3-7,4 (m, 3H); 7,1 (brs, 1H); 5,4 (brs, 1H); 4,7 (brs, 1H); 4,0 (brs, 1H); 3,6 (brs, 3H); 3,3 (brs, 1H); 3,0 (brs, 2H); 2,2-2,3 (m, 5H); 1,2-1,4 (m, 3H).
Eksempel 35
1- Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3, 4- diklor- benzvl)-( 3- etvl- 3- aza-bisyklo[ 3. 1. 0] heks- 6- ylmetyl)- amid
400 MHz1 HNMR (CDCI3) 6 7,6 (s, 1H); 7,3-7,4 (m, 3H); 7,1 (brs, 1H); 5,4 (brs, 1H); 4,7 (brs, 1H); 4,0 (brs, 1H); 3,7 (s, 3H); 3,3 (brs, 1H); 3,0 (brs, 2H); 2,2-2,4 (m, 4H); 1,2-1,4 (m, 3H); 1,0 (brs, 3H).
Eksempel 36
1- Metvl- 1 H- imidazol- 4- karboksvlisk syre r3-( 1- metansulfonvl- azetidin- 3- vl)- 3-aza- bisvklo[ 3. 1. 0] heks- 6- vlmetvl]-( 3- trifluormetoksv- benzyl)- amid
100 MHz<13>C-NMR (CDCI3) 6 18,42, 19,70, 21,98, 33,84, 35,62, 47,70, 49,72, 50,69, 51,21, 54,75, 112,50, 119,55, 120,30, 125,98, 126,72, 129,95, 136,82, 138,39, 149,61, 164,17.
Eksempel 37
1- Metyl- 1 H- imidazol- 4- karboksylisk syre ( 3- azetidin- 3- yl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)-( 4- fluor- 3- trifluormetvl- benzyl)- amid
100 MHz<13>C-NMR (CDCI3) 6 18,30, 19,62, 22,02, 22,09, 33,78, 47,55, 48,73, 49,93, 50,67, 51,28, 51,57, 53,06, 53,45, 56,49, 57,66, 117,01 (d, J=21), 121,40, 124,11, 126,28, 126,32, 126,74, 133,23, 135,19, 136,85, 138,12, 158,93 (d, J=255), 164,02; MS(M+1) 452,2.
Eksempel 38
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3- azetidin- 3- yl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)-( 3- klor- 4- fluor- benzyl)- amid
100 MHz<13>C-NMR (CDCI3) 6 18,29, 19,56, 21,99, 33,83, 47,44, 48,52, 49,69, 50,31, 50,58, 51,29, 51,52, 56,37, 116,59 (d, J=21), 126,62, 127,44, 129,75, 135,85, 136,90, 138,08, 157,29 (d, J=245), 164,10; MS (M+1) 418,2.
Eksempel 39
1- Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 4- fluor- 3- trifluormetvl- benzyl)- r3-( 1-metvl- azetidin- 3- vl)- 3- aza- bisyklor3. 1. 01heks- 6- vlmetvn- amid
100 MHz<13>C-NMR (CDCI3) 6 18,40, 19,65, 22,15, 33,84, 46,09, 47,66, 48,95, 50,70, 51,82, 52,97, 61,05, 116,92, 117,12, 126,33, 126,90, 133,29, 136,79; MS (M+1) 466,2.
Eksempel 40
1 - Metyl- 1 H- imidazol- 4- karboksylisk syre ( 3- klor- 4- fluor- benzyl)-[ 3-( 1 - metyl-azetidin- 3- yl)- 3- aza- bisvklor3. 1. 01heks- 6- ylmetvn- amid
100 MHz<13>C-NMR (CDCI3) 5 18,43, 22,11, 33,85, 45,95, 47,55, 49,71, 50,61, 51,84, 52,89, 61,00, 74,97, 116,50, 116,71, 126,82, 127,71, 129,93, 136,85; MS (M+1) 464,2.
Eksempel 41
1- Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3- azetidin- 3- vl- 3- aza-bisvklor3. 1. 01heks- 6- vlmetvl)-( 3- trifluormetvl- benzyl)- amid
100 MHz<13>C-NMR (CDCI3) 6 21,84, 22,02, 25,90, 33,88, 47,17, 50,31, 50,79, 51,53, 52,50, 53,19, 57,37, 124,36, 126,69, 129,14, 131,04, 136,84, 161,09, 164,25; MS (M+1) 434,1.
Eksempel 42
1 - Metvl- 1 H- imidazol- 4- karboksvlisk syre T3-( 1 - metyl- azetidin- 3- vl)- 3- aza-bisvklo[ 3. 1. 0] heks- 6- ylmetyl]-( 3- trifluormetyl- benzyl)- amid
100 MHz<13>C-NMR (CDCI3) 818,41, 19,72, 22,14, 33,83, 45,86, 47,75, 49,23, 49,90, 51,33, 51,79, 52,82, 60,96, 124,05, 124,40, 126,74, 129,07, 131,01, 136,82, 164,17; MS (M+1) 448,4.
Eksempel 43
1 - Metvl- 1 H- imidazol- 4- karboksylisk syre ( 3- klor- benzyl)- r3-( 1 - metyl- azetidin- 3-vl)- 3- aza- bisvklor3. 1. 01heks- 6- vlmetvn- amid
100 MHz<13>C-NMR (CDCI3) 618,43, 19,66, 22,12, 33,82, 46,02, 47,59, 48,97, 51,12, 51,82, 52,89, 61,06, 126,03, 126,67, 127,35, 127,67, 129,86, 134,50, 136,81, 138,55, 164,08; MS MS (M+1) 414,2.
Eksempel 44
1- Metvl- 1 H- imidazol- 4- karboksvlisk syre ( 3- metvl- 3- aza- bisvklor3. 1. 0lheks- 6-vlmetvl)- r3-( 2. 2. 2- trifluor- etvl)- benzvll- amid 400MHz<1>HNMR(CDCI3)5 7,5(s, 1H); 7,1-7,3 (m, 5H); 5,4 (brs, 1H); 4,8 (brs, 1H); 3,9 (brs, 1H); 3,6 (s, 3H); 3,2-3,3 (m, 3H); 2,9 (brs, 2H); 2,2 (m, 5H); 1,4 (m, 1H); 1,2-1,3 (m, 2H); 100 MHz<13>C-NMR (CDCI3) 518,47, 19,64, 22,73, 33,74, 40,31 (q, J=29), 41,50, 46,87, 48,76, 49,22, 50,87, 57,17, 121,87, 124,59, 126,38, 127,34, 128,96, 129,40, 130,45, 136,73, 138,60, 139,32, 164,20; MS (M+1) 407,1.
Eksempel 45
1- Metvl- 1 H- imidazol- 4 karboksvlisk syre ( 3- metyl- 3- aza- bisyklor3. 1. 01heks- 6-vlmetvl)- r3-( 2. 2. 2- trifluor- 1- trifluormetvl- etvl)- benzvn- amid
400 MHz 1 HNMR (CDCI3) 5 7,5 (s, 1H); 7,2-7,4 (m, 5H); 5,4 (brs, 1H); 4,8 (brs, 1H); 3,9-4,0 (m, 2H); 3,6 (s, 3H); 3,3 (brs, 1H); 2,8 (m, 2H); 2,2 (m, 5H); 1,4 (m, 1H); 1,2 (m, 2H); 100 MHz<13>C-NMR (CDCI3) 518,44, 19,62, 22,76, 33,72, 41,43, 47,09, 48,85, 49,50, 50,88, 54,37 (h, J=29), 57,09, 118,94, 121,71, 124,51, 126,48, 126,70, 127,33, 128,26, 129,39, 136,73, 138,51, 139,70, 164,22; MS (M+1) 475,1.
Eksempel 46
1- Metvl- 1 H- imidazol- 4- karboksvlisk syre r3-( 1- hvdroksv- svkloheksvlmetvl)- 3-aza- bisvklor3. 1. 01heks- 6- vlmetvn-( 3- trifluormetoksv- benzvl)- amid Metylensykloheksan epoksid ble tilsatt til en 15 ml rundbunnet flaske under nitrogen, etterfulgt av etanol (3,3 ml), trietylamin (0,097 ml, 0,696 mmol), og 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid hydroklorid (0,100 g, 0,232 mmol). Reaksjonen ble varmet til 60 °C, deretter refluksert i 4,5 timer, og deretter avkjølt til romtemperatur. Reaksjonen ble deretter stumpet med mettet natrium bikarbonatløsning og ekstrahert to ganger med metylenklorid. De kombinerte organiske sjikt ble tørket (MgSC^), filtrert, og konsentrert in vakuum for å gi 0,087 g av 1 -Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-hydroksy-sykloheksylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid.
400 MHz 1H NMR (CDCI3) 6 7,6 (s, 1H), 7,0-7,3 (m, 5H), 5,4 (brs, 1H), 4,8 (brs, 1H), 4,0 (brs, 1H), 3,7(s,3H), 3,3 (brs, 1H), 2,9-3,0 (m, 2H), 2,4-2,5 (m, 2H), 2,3 (m, 2H), 1,2-1,8 (m, 13H); MW (M+1) 507,1
Andre eksempler fremstilt i samsvar med prosedyren for eksempel 46 beskrevet over inkluderer:
Eksempel 47
1 - Metvl- 1 H- imidazol- 4- karboksylisk syre f3- r2-( 2- klor- fenvl)- 2- hydroksv- etvn- 3-aza- bisvklor3. 1. 01heks- 6- vlmetvl>-( 3- trifluormetoksv- benzyl)- amid
400 MHz<1>H NMR (CDCI3) 6 7,6 (d, J = 1,24 Hz, 1H), 7,1-7,4 (m, 9H), 5,5 (brs, 1H), 4,8 (brs, 1H), 4,5 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,3 (brs, 1H), 2,8-3,2 (m, 2H), 2,1-2,6 (m, 4H), 1,2-1,6 (m, 3H); MW (M+1) 549,3.
Eksempel 48
1- Metvl- 1 H- imidazol- 4- karboksylisk syre r3-( 1- hydroksv- svklopentvlmetyl)- 3-aza- bisvklor3. 1. 01heks- 6- vlmetvn-( 3- trifluormetoksv- benzyl)- amid
400 MHz 1H NMR (CDCI3) 6 7,6 (d, J = 1,7 Hz, 1H), 7,3 (t, J = 7,9 Hz, 2H), 7,1-7,2 (m, 2H), 7,1 (d, J = S, 3 Hz, 1H), 5,5 (brs, 1H), 4,8 (brs, 1H), 4,0 (brs, 1H), 3,7 (s, 3H), 3,3 (brs, 2H), 3,0 (m, 2H), 2,4-2,5 (m, 4H), 1,7-1,8 (m, 2H), 1,4-1,6 (m, 6H), 1,3-1,4 (m, 3H); MW (M+1) 493,3.
Fremstilling 5
Benzyl 2-( 6-(( N-( 3-( trifluormetoksv) benzvl)- 1 - metvl- 1 H- imidazol- 4-karboksamido) metvl)- 3- aza- bisvklor3. 1. 01heksan- 3- vl) asetat
Til en omrørende løsning av 6-{[(1-Metyl-1 H-imidazol-4-karbonyl)-(3-trifluormetoksy-benzyl)-amino]-metyl}-3-aza-bisyklo[3.1.0]heksan-3-karboksylisk syre tert-butyl ester fremstilt over (2,63 g, 5,63 mmol) i 30 ml DMF ble det tilsatt kaliumkarbonat (3,89 g, 28,2 mmol), tetraetylammoniumklorid (150 mg), etterfulgt av benzyl 2-bromoasetat (0,88 ml, 5,63 mmol). Reaksjonen ble omrørt ved romtemperatur I 20 timer og stoppet med vann. Blandingen ble fortynnet med etylasetat, sjiktene separert og det vandige sjikt ekstrahert tre ganger med etylasetat. De kombinerte organiske sjikt ble tørket over vannfri natriumsulfat, filtrert og konsentrert for å gi 2,8 g av ubehandlet materiale. Det ubehandlede materiale ble renset med flash kromatografi for å gi 2,7 g benzyl 2-(6-((N-(3-(trifluormetoksy)benzyl)-1 -metyl-1 H-imidazol-4-karboksamido)metyl)-3-aza-bisyklo[3.1.0]heksan-3-yl)asetat; MS (M+1) 543.3.
Fremstilling 6
2-( 6-(( N-( 3-( trifluormetoksv) benzvl)- 1 - metvl- 1 H- imidazol- 4-karboksamido) metvl)- 3- aza- bisvklor3. 1. 01heksan- 3- vl) eddiksyre
Til en par flaske fylt med benzyl 2-(6-((N-(3-(trifluormetoksy)benzyl)-1 -metyl-1 H-imidazol-4-karboksamido)metyl)-3-aza-bisyklo[3.1.0]heksan-3-yl)asetat (2,7 g, 5,07 mmol) i 80 ml CH3OH, ble det tilsatt 300 mg palladium hydroksid på karbon (20%). Blandingen ble hydrogener! under 40 psi H2ved romtemperatur i 1 time. Blandingen ble filtrert over en celite, og celiteputen ble vasket med CH3OH og den resulterende løsning ble konsentrert for å gi 2,3 g av 2-(6-((N-(3-(trifluormetoksy)-benzyl)-1 -metyl-1 H-imidazol-4-karboksamido)metyl)-3-aza-bisyklo[3.1.0]heksan-3-yl)eddiksyre som et gult faststoff;
400 MHz 1H NMR (CDCI3) 5 7,54 (s, 1H), 7,23-7,33 (m, 3H), 7,15 (s, 1H), 7,05 (d, J = 7,9 Hz, 1H), 5,4 (brs, 2H), 4,81 (brs, 1H), 3,96 (brs, 1H), 3,68 (s, 3H), 3,49 (s, 2H), 3,28 (brs, 1H), 3,12 (brs, 2H), 1,76 (brs, 1H), 1,66 (brs, 2H); MS (M+1) 452,1.
Generell prosedyre for Amid Koblinger
En løsning av 2-(6-((N-(3-(trifluormetoksy)benzyl)-1 -metyl-1 H-imidazol-4-karboks-amido)metyl)-3-aza-bisyklo[3.1.0]heksan-3-yl)eddiksyre fremstilt over (1,0 ekviv.) i 1,2-dikloretan/trietylamin/dimetylformamidløsning ble tilsatt til aminene (1,9 ekviv.), etterfulgt av HBTU (2,1 ekviv). Reaksjonene ble omrørt ved romtemperatur natten over, stoppet med 1N NaOH og ekstrahert med diklormetan. De kombinerte organiske sjikt ble tørket og konsentrert for å gi de ubehandlete amider som ble ytterligere renset med flash kromatografi eller HPLC.
Alternativt kan amidene fremstilles ved å benytte en parallell biblioteksyntese prosedyre som beskrevet nedenfor.
To dram ampuller ble fylt med aminer (0,075 mmol, 1,875 ek.). 2-(6-((N-(3-(trifluormetoksy)benzyl)-1-methyl-1H-imidazol-4-karboksamido)metyl)-3-aza-bisyklo[3.1.0]heksan-3-yl)eddiksyre ble opptatt i DC E/TEA/D MF (500/14/100) og ble tilsatt til en uklar suspensjon (0,04 mmol, 18,1 mg, 1,0 ek. per 0,614 ml DCE/TEA/DMF, 1,0 ek. DIEA). Tilsatt HBTU (31,3 mg, 0,0825 mmol, 2,06 ek) oppløst i 0,2 ml DMF. Rist ved romtemperatur natten over. Alikvoter prøver for LC MS analyser. Tilsett 1,5 ml 1 N NaOH og 2,5 ml DCM. Vorteks og fjern det organiske sjikt og appliser på en SCX SPE (6ml, 1g, Silisykle merke). Repeter ekstrahering to ganger. Eluer SCX SPE med 5 ml DCM, deretter 5 ml MeOH. Bytt om til tjærete innsamlingsrør og eluer med 1 N TEA i MeOH (7,5 ml). Tørk ned. Vei, og fremstill TFA- salt (15/485 TFA/DCM). Tørk ned. Rensing med HPLC/MS.
Andre representative eksempler fremstilt i samsvar med prosedyrene og eksemplene beskrevet over inkluderer:
Smeltepunkt ble tatt med en Buchi mikro smeltepunktapparatur, og er ukorrigerte. Infrarødt Ray absorpsjonsspektra (IR) ble målt med en Shimazu infrarødt spektrometer (IR-470). 1H and<13>C kjernemagnetisk resonansspektra (NMR) ble målt i CDCI3med en Varian NMR spektrometer (Unity, 400MHzfor<1>H, 100MHz for 13C) med mindre annet er angitt og topposisjoner er uttrykt i deler per million (ppm) nedstrøms for tetrametylsilan (8). Toppformene er angitt som: s, singlet; d, dublett: t, triplett; m, multiplett; br, bred.
Claims (17)
1. Forbindelse,karakterisert vedat den er av formel I,
hvor: Ri representerer en heteroaryl valgt blant gruppen omfattende: imidazolyl, tiazolyl, pyridyl, oksazolyl, pyrazolyl, triazolyl, oksadiazolyl, quinolinyl, isoksazolyl, pyrroloimidazoyl, og tiadiazol, hvor nevnte heteroaryl er valgfritt substituert med en eller flere substituenter valgt blant -OH, -NR7R8, halogen, (Ci-C8)alkyl, (C3-Cio)sykloalkyl, (Ci-C8)alkoksy, (Ci-Ci2)alkoksyalkyl, (Ci-C8)hydroksyalkyl, (C6-Ci4)aryl og benzyl; R2, R3og A representerer uavhengig H or (Ci-C8)alkyl, hvor nevnte alkyl er valgfritt substituert av en eller flere -OH, (Ci-C8)alkoksy, -NR7R8eller halogen; Q representerer-(CH2)n-, hvor n = 1, 2, 3 eller 4 eller -(CH2)m-0-, hvor m = 2, 3 eller 4; Z representerer (C6-Ci4)aryl, (Ci-C8)alkyl eller (C3-C8)sykloalkyl; R4 og R5representerer hver uavhengig H, halogen, (Ci-C8)alkyl, (C6-Ci4)aryl, (C6-Ci4)aryloksy, (Ci-C8)alkoksy, (3-10 leddet)heterosykloalkyl eller (C3-C8)sykloalkoksy;hvor R4og R5er valgfritt substituert med en eller flere -OH, (d-C8)alkoksy, - NR7R8eller halogen; Y representerer -R6, -(CH2)0-R6, -C(R6)3eller -CH(R6)2, hvor0= 1, 2 eller 3; R6representerer H, (C6-Ci4)aryl, (Ci-Cio)alkyl, (C3-Cio)sykloalkyl, (Cs-Cis)-bisykloalkyl, (C5-Ci8)trisykloalkyl, (3-10 leddet)heterosykloalkyl, (5-10 leddet)- heteroaryl, -C(=0)NR7R8, eller -C(=0)OR7, hvor nevnte R6-grupper valgfritt kan være substituert med en eller flere X- grupper; hvor X = -OH, (Ci-C8)alkoksy, -NRnR12, -S02Rio, -C(=O)Ri0, halogen, cyano, (Ci-C8)alkyl, (Ci-Cio)alkoksyalkyl, (5-10 leddet)heteroaryl, (C6-Ci4)aryl, (C6-Ci4)-aryloksy, benzyl, eller (Ci-Csjhydroksyalkyl; hvor R7og R8uavhengig representerer H, (Ci-Csjalkyl, (C3-C8)sykloalkyl, (5-10 leddet)heterosykloalkyl, (Ci-C8)hydroksyalkyl, (5-10 leddet)heteroaryl eller (Ci-Cio)alkoksyalkyl; hvor R7og Rs valgfritt kan være substituert med en eller flere X- grupper; eller R7og R8sammen med nitrogenet hvortil de kan være tilfestet kan danne en (3-10 leddet)heterosykloalkyl gruppe valgfritt substituert med en eller flere X-grupper; hvor R10representerer (Ci-Csjalkyl, (C3-C8)sykloalkyl, (3-10 leddet)-heterosykloalkyl, (Ci-Csjhydroksyalkyl, (5-10 leddet)heteroaryl eller (C1-Cio)alkoksyalkyl; hvor Rnog Ri2uavhengig representerer H, (Ci-Csjalkyl, (C3-C8)sykloalkyl, (5-10 leddet)heterosykloalkyl, (Ci-Csjhydroksyalkyl, (5-10 leddet)heteroaryl eller (Ci-Cio)alkoksyalkyl; eller farmasøytisk akseptable salter eller solvater derav.
2. Forbindelse i samsvar med krav 1,karakterisert vedat stereokjemien er definert som i Formel II eller Formel III:
3. Forbindelse i samsvar med krav 1,karakterisert vedat Zer (C6-Ci4)aryl, og R4og R5er hver uavhengig H, halogen, -CF3, -OCF3, (C6-Ci4)aryl eller (C6-Ci4)aryloksy.
4. Forbindelse i samsvar med krav 1,karakterisert vedat R2, R3og A er hydrogen.
5. Forbindelse i samsvar med krav 1,karakterisert vedat Yeren (Ci-C6)alkyl, en (C3-C6)sykloalkyl, en (3-6-leddet)heterosykloalkyl eller-CH2-(C3-C6)sykloalkyl; hvor Y er valgfritt substituert med halogen, OH, -S02Rio, -C(=0)Rioeller-CH2CH2CF3.
6. Forbindelse i samsvar med krav 3karakterisert vedat R<1>er imidazolyl.
7. Forbindelse i samsvar med krav 1,karakterisert vedat den har følgende formel:
hvor: R2, R3og A uavhengig representerer H eller (Ci-Csjalkyl, hvor nevnte alkyl er valgfritt substituert av en eller flere -OH, (Ci-Csjalkoksy, -NR7R8eller halogen; Q representerer -(CH2)n-, hvor n = 1, 2, 3 eller 4 eller -(CH2)m-0-, hvor m = 2, 3 eller 4; Z representerer (C6-Ci4)aryl, (Ci-C8)alkyl eller (C3-C8)sykloalkyl; R4 og R5representerer hver uavhengig H, halogen, (Ci-C8)alkyl, (C6-Ci4)aryl, (C6-Ci4)aryloksy, (Ci-C8)alkoksy, (3-10 leddet)heterosykloalkyl eller (C3-C8)sykloalkoksy;hvor R4 og R5 er valgfritt substituert av en eller flere -OH, (d-C8)alkoksy, - NR7R8eller halogen; Y representerer -R6, -(CH2)0-R6, -C(R6)3 eller -CH(R6)2, hvor0= 1, 2 eller 3; R6representerer H, (C6-Ci4)aryl, (Ci-Cio)alkyl, (C3-Cio)sykloalkyl, (C5-C18)-bisykloalkyl, (C5-Ci8)trisykloalkyl, (3-10 leddet)heterosykloalkyl, (5-10 leddet)-heteroaryl, -C(=0)NR7R8, eller -C(=0)OR7, hvor nevnte R6 valgfritt kan være substituert med en eller flere X- grupper; hvor X = -OH, (Ci-C8)alkoksy, -NRnR12, -SO2R10, -C(=O)Ri0, halogen, cyano, (Ci-C8)alkyl, (Ci-Ci0)alkoksyalkyl, (5-10 leddet)heteroaryl, (C6-Ci4)aryl, (C6-Ci4)-aryloksy, benzyl, eller (Ci-C8)hydroksyalkyl; hvor R7 og R8uavhengig representerer H, (Ci-C8)alkyl (C3-C8)sykloalkyl, (5-10 leddet)heterosykloalkyl, (Ci-C8)hydroksyalkyl, (5-10 leddet)heteroaryl eller (C1-C10)-alkoksyalkyl; hvor R7 og R8kan være valgfritt substituert med en eller flere X-grupper; eller R7 og R8sammen med nitrogener hvortil de kan være tilfestet kan danne en (3-10 leddet)heterosykloalkyl gruppe valgfritt substituert med en eller flere X-grupper; hvor R10representerer (Ci-C8)alkyl, (C3-C8)sykloalkyl, (3-10 leddet)-heterosykloalkyl, (Ci-C8)hydroksyalkyl, (5-10 leddet)heteroaryl eller (C1-C10)-alkoksyalkyl; hvor Rnog Ri2 uavhengig representerer H, (Ci-Cs)alkyl, (C3-C8)sykloalkyl, (5-10 leddet)heterosykloalkyl, (Ci-C8)hydroksyalkyl, (5-10 leddet)heteroaryl eller (Ci-Cio)alkoksyalkyl; eller farmasøytisk akseptable salter eller solvater derav.
8. Forbindelse i samsvar med krav 7,karakterisert vedat Zer (C6-Ci4)aryl og R4 eller R5 er hver uavhengig H, halogen, -CF3, -OCF3, (C6-Ci4)aryl eller (C6-Ci4)aryloksy.
9. Forbindelse i samsvar med krav 7,karakterisert vedat R2, R3og A er hydrogen.
10. Forbindelse i samsvar med krav 7karakterisert vedat Yeren (Ci-C6)alkyl, a (C3-C6)sykloalkyl, en (3-20 leddet)heterosykloalkyl eller-CH2-(C3-Ce)sykloalkyl; hvor Y er valgfritt substituert av halogen, OH, -SO2R10, -C(=0)Rio, eller CH2CH2CF3.
11. Forbindelse i samsvar med krav 1,karakterisert vedat nevnte forbindelse er valgt blant gruppen omfattende: 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-klor-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-klor-4-fluor-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-isopropoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-syklopentyloksy-4-fluor-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2-dimetyl-propoksy)-4-fluor-benzyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-sykloheksyloksy-4-fluor-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-1-trifluormetyl-etyl)-benzyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-etyl)-benzyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopentylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(4-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-syklopentylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(4-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3,5-diklor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3,5-diklor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-4-fluor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-4-fluor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (2,4-diklor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (2,4-diklor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3,4-diklor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3,4-diklor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metansulfonyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-klor-4-fluor-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-4-fluor-benzyl)-[3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetyl-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-etyl)-benzyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-1-trifluorTTietyl-etyl)-benzyl]-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-hydroksy-sykloheksylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(2-klor-fenyl)-2-hydroksy-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-hydroksy-syklopentylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3,4-diklor-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3,4-diklor-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-fluor-5-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2,3-diklor-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2,4-diklor-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre(3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2-fluor-5-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-fenyl-propyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fenoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-bipfenyl-4-ylmetyl-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fenyl-butyl)-amid;
Pyridin-2-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-bifenyl-3-ylmetyl-amid;
Pyridin-2-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid;
Pyridin-2-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(5-fluor-2-trifluormetyl-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
Pyridin-2-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2-fluor-5-trifluormetyl-benzyl)-amid;
Pyridin-2-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-fluor-5-trifluormetyl-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2-trifluormetyl-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[2-(4-klor-fenyl)-etyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[2-(3-trifluormetyl-fenyl)-etyl]-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(2,4-difluor-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[2-(3-klor-fenyl)-etyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-isobutyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2,2-dimetyl-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(tetrahydro-furan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(tetrahydro-furan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1 H-imidazol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1 H-imidazol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-metyl-butyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3-metyl-butyl)-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-etyl-butyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-isoksazol-3-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-metyl-pentyl)-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-etyl-3-metyl-butyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-sykloheksylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metyl-1 H-pyrrol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3,3-dimetyl-butyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-heptyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metyl-1 H-imidazol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-bisyklo[2.2.1]hept-5-en-2-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(5-metyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2,4-dimetyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1,5-dimetyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1- Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-cyano-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
2- Metyl-3-(6-{[(1-metyl-1 H-imidazol-4-karbonyl)-(3-trifluormetoksy-benzyl)-amino]-metyl}-3-aza-bisyklo[3.1.0]heks-3-yl)-propionisk syre etyl ester 1 -Metyl-1 H-imidazol-4-karbolsylisk syre (3-fenetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-etyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-etyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-etyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(6-okso-1,6-dihydro-pyridin-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2,5-dimetyl-2H-pyrazol-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-p-tolyl-etyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-etyl-5-metyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-etyl-5-metyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-metoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-etyl-heksyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-etyl-3-metyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-etyl-3-metyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(5-metoksymetyl-furan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3-fenyl-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3-fluor-4-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-klor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-etyl-5-metyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2,5-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-klor-1-metyl-1 H-pyrazol-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-klor-pyridin-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1 H-benzoimidazol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3,5-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre [3-(1 H-indol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-klor-tiazol-5-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2,3-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre [3-(1 H-indol-5-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(3,5,5-trimetyl-heksyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2,4-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-isopropyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-benzo[1,3]dioksol-5-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-pyridin-2-yl-1 H-pyrrol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-naftalen-2-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-benzo[1,3]dioksol-4-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-pyrimidin-2-yl-1 H-pyrrol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-naftalen-1-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[3-(5-metyl-furan-2-yl)-butyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre [3-(6,6-dimetyl-bisyklo[3.1.1 ]hept-2-en-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-benzotiazol-2-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-difluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(4-trifluormetyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-bifenyl-4-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(3-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(3-fenyl-butyl)-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(6-fenoksy-pyridin-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-fenoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(2-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-fluor-benzyl)-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopentylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(4-trifluorTTietoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(1-hydroksy-sykloheksylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(4-fenoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
Tiazol-4-karboksylisk syre (3-fenetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-syklopentylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-klor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-fluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-{[etyl-(2-hydroksy-etyl)-karbamoyl]-metyl}-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(sec-butyl-metyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(1-metyl-1 H-pyrazol-3-ylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopropylkarbamoylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1 H-lmidazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1 H-lmidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(syklopropylmetyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(tert-butylkarbamoyl-metyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklobutylkarbamoylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(2-metoksy-etylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(2-metoksy-1-metyl-etylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopentylkarbamoylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(2-hydroksy-propylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-fenylkarbamoylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre {3-[(1 H-imidazol-2-ylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(isopropylkarbamoyl-metyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(2,2-dimetyl-propylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(pyridin-3-ylkarbamoylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-{[metyl-(3-metyl-pyridin-2-ylmetyl)-karbamoyl]-metyl}-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(2-hydroksy-1,1-dimetyl-etylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(pyridin-2-ylkarbamoylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(2-metyl-2H-pyrazol-3-ylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(2,2,2-trifluor-etylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-{[(furan-2-ylmetyl)-karbamoyl]-metyl}-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-dimetylkarbamoylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre {3-[(1 -metyl-1 H-[1,2,4]triazol-3-ylkarbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-sykloheksylkarbamoylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-okso-2-pyrrolidin-1-yl-etyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(2-metyl-pyrrolidin-1 -yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-okso-2-piperidin-1-yl-etyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(syklopropylmetyl-metyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormethoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-morfolin-4-yl-2-okso-etyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(3-hydroksy-pyrrolidin-1-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(3-hydroksy-pyrrolidin-1-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(3-hydroksy-pyrrolidin-1-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(etyl-isopropyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(karbamoylmetyl-metyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(3-metyl-piperidin-1-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(4-metyl-piperidin-1-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-okso-2-tiazolidin-3-yl-etyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(3-hydroksymetyl-pyrrolidin-1 -yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(2-hydroksymetyl-pyrrolidin-1 -yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(3-hydroksy-piperidin-1-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-okso-2-tiomorfolin-4-yl-etyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(2,6-dimetyl-morfolin-4-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(metyl-tiofen-2-ylmetyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluorTTietoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(furan-2-ylmetyl-metyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(benzyl-metyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(1,3-dihydro-isoindol-2-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(3,4-difluor-pyrrolidin-1-yl)-2-okso-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-{[metyl-(2,2,2-trifluor-etyl)-karbamoyl]-metyl}-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(metyl-tiofen-3-ylmetyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[(metyl-fenetyl-karbamoyl)-metyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylic syre (3-{[metyl-(1-pyridin-4-yl-etyl)-karbamoyl]-metyl}-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-okso-2-(3-fenyl-pyrrolidin-1-yl)-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-{[(2-metansulfonyl-etyl)-metyl-karbamoyl]-metyl}-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-okso-2-(2-pyridin-4-yl-pyrrolidin-1-yl)-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(2-hydroksy-indan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(6-fenoksy-pyridin-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid; Tiazol-4-karboksylisk syre [3-(3-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-fluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-metoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-sykloheksylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(3-fluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-fenoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-fenyl-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-cyano-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-bifenyl-4-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(3-cyano-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(4-trifluormetyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
Tiazol-4-karboksylisk syre [3-(3,5-dimetyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(3-klor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2,4-dimetyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(3-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
Tiazol-4-karboksylisk syre [3-(4-etyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(4-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
Tiazol-4-karboksylisk syre [3-(1 -metyl-1 H-imidazol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(5-metoksymetyl-furan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(6-okso-1,6-dihydro-pyridin-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 -etyl-3-metyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1-metyl-1 H-pyrrol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(2-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
Tiazol-4-karboksylisk syre (3-furan-3-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1,5-dimetyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 H-pyrrol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(3-fenyl-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1-metyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-fluor-3-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(5-metyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-furan-2-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid; (6-{[(Tiazol-4-karbonyl)-(3-trifluormetoksy-benzyl)-amino]-metyl}-3-aza-bisyklo[3.1.0]heks-3-yl)-asketisk syre butyl ester
Tiazol-4-karboksylisk syre [3-(3-fluor-4-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-etyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-etyl-5-metyl-3H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(tetrahydro-furan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-p-tolyl-etyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 -etyl-5-metyl-1 H-pyrazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-klor-pyridin-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-isoksazol-3-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 H-indol-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid; 2-Metyl-3-(6-{[(tiazol-4-karbonyl)-(3-trifluormetoksy-benzyl)-amino]-metyl}-3-aza-bisyklo[3.1.0]heks-3-yl)-propionisk syre etyl ester
Tiazol-4-karboksylisk syre [3-(5-metyl-2H-pyrazol-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-butoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-benzo[1,3]dioksol-5-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-etoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-isopropyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-naftalen-2-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-benzo[1,3]dioksol-4-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2,3-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2,5-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-quinolin-7-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-metoksy-3-metyl-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2,4-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre {3-[3-(5-metyl-furan-2-yl)-butyl]-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 -pyrimidin-2-yl-1 H-pyrrol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(3,5-difluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-difluorometoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-quinolin-8-ylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-butyl-1 H-imidazol-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 H-indol-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(3-cyano-4-fluor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 H-indol-5-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-fluor-4-metoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(1 H-benzoimidazol-2-ylmetyl)-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(2-klor-tiazol-5-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre [3-(4-klor-1-metyl-1 H-pyrazol-3-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-hydroksy-indan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(1-hydroksy-sykloheksylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(2-hydroksy-indan-2-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-hydroksy-sykloheksylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-hydroksy-syklopentylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopentylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre sykloheksylmetyl-(3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-hydroksy-2-metyl-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopentyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklobutyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-klor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-sykloheksylmetyl-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(2-hydroksy-syklopentyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1,5-Dimetyl-1 H-pyrazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5-Metyl-isoksazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5-Propyl-isoksazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-isopropoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-syklopentyloksy-4-fluor-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2-dimetyl-propoksy)-4-fluor-benzyl]-amid;
Tiazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-sykloheksyloksy-4-fluor-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3,5-diklor-benzyl)-amid;
1- Metyl-1 H-imidazol-4-karboksylisk syre (3-isopropyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Quinolin-2-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Pyridin-2-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5-Metyl-isoksazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5-Etyl-isoksazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Quinolin-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5-Syklopropyl-2H-pyrazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1,5-Dimetyl-1 H-pyrazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
2- Etyl-5-metyl-2H-pyrazol-3-karboksylic syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
4- Metyl-1 H-imidazol-2-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5- Propyl-isoksazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5-lsopropyl-2H-pyrazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-pyrazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5-Etyl-2-metyl-2H-pyrazol-3-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
2-lsopropyl-tiazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
Tiazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
5- Klor-pyridin-2-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre pentyl-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (2-metyl-butyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (2-etyl-butyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre syklopropylmetyl-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre heptyl-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre butyl-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre sykloheksylmetyl-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-klor-benzyl)-3-aza-bisyklo[3.1 .OJheks-6- ylmetyl]-(2-metyl-butyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopentyl-propyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-klor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-pentyl-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre butyl-[3-(4-klor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-klor-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-syklopropylmetyl-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-klor-benzyl)-3-aza-bisyklo[3.1 .OJheks-6-ylmetyl]-(2-etyl-butyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(tetrahydro-pyran-4-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(4-hydroksy-tetrahydro-pyran-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(4-hydroksy-tetrahydro-pyran-4-ylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(tetrahydro-pyran-4-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(tetrahydro-pyran-4-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre sykloheksylmetyl-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1- Metyl-1 H-imidazol-4-karboksylisk syre sykloheksylmetyl (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
2- Klor-N-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-N-(1 -metyl-1 H-imidazol-4-ylmetyl)-3-trifluormetyl-benzamid; 6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-2-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
3- Klor-N-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-N-(1 -metyl-1 H-imidazol-4-ylmetyl)-benzamid;
1-Propyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-(4-Trifluorometoksy-fenyl)-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-lsopropyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(3,3,3-trifluor-propyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-[2-(4-Trifluormetoksy-fenyl)-etyl]-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-propyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Propyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-propyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-(4-Trifluormetyl-fenyl)-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-propyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Butyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-propyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-(4-Trifluormetoksy-benzyl)-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-propyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-(4-Trifluormetoksy-fenyl)-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-propyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-lsopropyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-propyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Butyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-(3-Klor-fenyl)-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Propyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-lsopropyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-(4-Trifluormetoksy-fenyl)-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-pyrazin-2-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1 H-benzoimidazol-2-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-klor-benzyl)-amid; N-(3-klor-4-fluorbenzyl)-N-((3-metyl-3-aza-bisyklo[3.1.0]heksan-6-yl)metyl)-1 H-imidazol-4-karboksamid;
og farmasøytiske salter derav.
12. Forbindelse i samsvar med krav 7,karakterisert vedat nevnte forbindelse er valgt blant: 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-klor-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-klor-4-fluor-benzyl)-amid Hydroklorid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-isopropoksy-benzyl)-amid; 1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-syklopentyloksy-4-fluor-benzyl)-amid;
1 -Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2-dimetyl-propoksy)-4-fluor-benzyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-sykloheksyloksy-4-fluor-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-1-trifluormetyl-etyl)-benzyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-etyl)-benzyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopentylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-trifluormetoksy-benzyl)-[3-(4-trifluorTTietoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-syklopentylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(4-trifluormetoksy-benzyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-syklopropylmetyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid Hydroklorid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3,5-diklor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3,5-diklor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid Hydroklorid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-4-fluor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-4-fluor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (2,4-diklor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (2,4-diklor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3,4-diklor-benzyl)-(3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3,4-diklor-benzyl)-(3-etyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metansulfonyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(4-fluor-3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-klor-4-fluor-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (4-fluor-3-trifluormetyl-benzyl)-[3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-4-fluor-benzyl)-[3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-azetidin-3-yl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetyl-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-klor-benzyl)-[3-(1-metyl-azetidin-3-yl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-etyl)-benzyl]-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre (3-metyl-3-aza-bisyklo[3.1.0]heks-6-ylmetyl)-[3-(2,2,2-trifluor-1-trifluonTietyl-etyl)-benzyl]-arnid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-hydroksy-sykloheksylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre {3-[2-(2-klor-fenyl)-2-hydroksy-etyl]-3-aza-bisyklo[3.1.0]heks-6-ylmetyl}-(3-trifluormetoksy-benzyl)-amid;
1-Metyl-1 H-imidazol-4-karboksylisk syre [3-(1-hydroksy-syklopentylmetyl)-3-aza-bisyklo[3.1.0]heks-6-ylmetyl]-(3-trifluormetoksy-benzyl)-amid;
og farmasøytiske salter derav.
13. En forbindelse i samsvar med krav 1,karakterisert vedat forbindelsen er 1 -metyl-1 H-imidazol-4-karboksylisk syre (3-klor-4-fluor-benzyl)-(3— metyl-3-aza-bisyklo[3.1.0]-heks-6-ylmetyl)-amid.
14. Farmasøytisk sammensetning for behandling av en forstyrrelse eller tilstand valgt blant psykoser, schizofreni, oppførselsforstyrrelse, forstyrrende atferdsforstyrrelse, bipolar forstyrrelse, psykotiske episoder av angst, angst assosiert med psykoser, psykotiske sinnsstemnings forstyrrelser, så som alvorlig hoved depressiv forstyrrelse; sinnsstemningsforstyrrelse assosiert med psykotiske forstyrrelser så som akutt mani eller depresjon assosiert med bipolar forstyrrelse og sinnsstemningsforstyrrelser assosiert med schizofreni, atferds manifestasjoner av mental utviklingshemming, oppførselsforstyrrelser og autistiske forstyrrelser, bevegelsesforstyrrelser så som Tourettes syndrom, akinetisk rigid syndrom, bevegelsesforstyrrelser assosiert med Parkinsons sykdom, tardiv dyskinesi og andre medikamentinduserte og nevrodegenerering baserte dyskinesier; konsentrasjonssvikt hyperaktivitetsforstyrrelse; kognitive forstyrrelser og hukommelsesforstyrrelser i et pattedyr, omfattende en forbindelse av formel I i samsvar med krav 1 eller et farmasøytisk akseptabelt salt derav, i en mengde som er effektiv for å behandle en slik tilstand eller forstyrrelse.
15. Farmasøytisk sammensetning for behandling av sentralnervesystemforstyrrelser, kognitive forstyrrelser, schizofreni, demens og andre forstyrrelser i et pattedyr,karakterisert vedat sammensetningen omfatter en forbindelse av formel I i samsvar med krav 1, og minst et antipsykotisk middel valgt blant gruppen omfattende: Ziprasidon (Geodon), Clozapin, Molindon, Loxapin, Pimozid, Risperidon, Olanzapin, Remoxiprid, Sertindol, Amisulprid, Quetiapin, proklorperazin, Flufenazin, Trifluorperazin, Thioridazin, Haloperidol, Klorpromazin, Flupentixol og Pipotiazin.
16. En forbindelse i samsvar med krav 1 eller farmasøytisk akseptable salter eller solvater derav for anvendelse for å behandle en forstyrrelse eller tilstand valgt blant psykoser, schizofreni, oppførselsforstyrrelse, forstyrrende atferdsforstyrrelse, bipolar forstyrrelse, psykotiske episoder av angst, angst assosiert med psykoser, psykotiske sinnsstemnings forstyrrelser, så som alvorlig hoved depressiv forstyrrelse; sinnsstemningsforstyrrelse assosiert med psykotiske forstyrrelser så som akutt mani eller depresjon assosiert med bipolar forstyrrelse og sinnsstemningsforstyrrelser assosiert med schizofreni, atferds manifestasjoner av mental utviklingshemming, oppførsels-forstyrrelser og autistiske forstyrrelser, bevegelsesforstyrrelser så som Tourettes syndrom, akinetisk rigid syndrom, bevegelsesforstyrrelser assosiert med Parkinsons sykdom, tardiv dyskinesi og andre medikamentinduserte og nevrodegenerering baserte dyskinesier; konsentrasjonssvikt hyperaktivitetsforstyrrelse; kognitive forstyrrelser og hukommelsesforstyrrelser.
17. En forbindelse for anvendelse i samsvar med krav 16, hvor nevnte forbindelse administreres med minst et antipsykotisk middel valgt blant gruppen omfattende: Ziprasidon (Geodon), Clozapin, Molindon, Loxapin, Pimozid, Risperidon, Olanzapin, Remoxiprid, Sertindol, Amisulprid, Quetiapin, proklorperazin, Flufenazin, Trifluorperazin, Thioridazin, Haloperidol, Klorpromazin, Flupentixol og Pipotiazin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66947205P | 2005-04-08 | 2005-04-08 | |
PCT/IB2006/000947 WO2006106425A1 (en) | 2005-04-08 | 2006-03-27 | Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20074993L NO20074993L (no) | 2007-11-02 |
NO339422B1 true NO339422B1 (no) | 2016-12-12 |
Family
ID=36649611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20074993A NO339422B1 (no) | 2005-04-08 | 2007-10-03 | Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer |
Country Status (31)
Country | Link |
---|---|
US (2) | US20060229455A1 (no) |
EP (1) | EP1869019B1 (no) |
JP (1) | JP4193949B2 (no) |
KR (1) | KR100969402B1 (no) |
CN (1) | CN101189228A (no) |
AP (1) | AP2007004198A0 (no) |
AR (1) | AR056307A1 (no) |
AU (1) | AU2006231917B2 (no) |
BR (1) | BRPI0608148A2 (no) |
CA (1) | CA2603939C (no) |
CR (1) | CR9493A (no) |
DK (1) | DK1869019T3 (no) |
DO (1) | DOP2006000078A (no) |
EA (1) | EA014311B1 (no) |
ES (1) | ES2520015T3 (no) |
GE (1) | GEP20105053B (no) |
GT (1) | GT200600136A (no) |
HN (1) | HN2006013804A (no) |
IL (1) | IL186409A (no) |
MA (1) | MA29672B1 (no) |
MX (1) | MX2007012463A (no) |
NL (1) | NL1031539C2 (no) |
NO (1) | NO339422B1 (no) |
NZ (1) | NZ563238A (no) |
PE (1) | PE20061400A1 (no) |
TN (1) | TNSN07380A1 (no) |
TW (1) | TW200719890A (no) |
UA (1) | UA88518C2 (no) |
UY (1) | UY29456A1 (no) |
WO (1) | WO2006106425A1 (no) |
ZA (1) | ZA200708481B (no) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008065500A2 (en) * | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
WO2009131958A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
EP2278879B1 (en) | 2008-04-21 | 2016-06-15 | PATH Drug Solutions | Compounds, compositions and methods comprising oxadiazole derivatives |
WO2009131947A2 (en) * | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
FR2932479A1 (fr) * | 2008-06-13 | 2009-12-18 | Servier Lab | Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
ES2439291T3 (es) * | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
EP2341776A4 (en) * | 2008-09-19 | 2012-05-30 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES |
US8642772B2 (en) * | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
JPWO2010107115A1 (ja) * | 2009-03-19 | 2012-09-20 | 大正製薬株式会社 | グリシントランスポーター阻害物質 |
US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
US20100267706A1 (en) * | 2009-04-20 | 2010-10-21 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Pyridazine Derivatives |
US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
TW201116516A (en) * | 2009-07-15 | 2011-05-16 | Taisho Pharmaceutical Co Ltd | Glycine transporter inhibitors |
BR112012010648A2 (pt) | 2009-11-06 | 2020-12-01 | Sk Biopharmaceuticals Co., Ltd. | uso de compostos na preparação de composições farmacêuticas para tratar síndrome de fibromialgia e composição farmacêutica |
MX2012005258A (es) | 2009-11-06 | 2012-06-19 | Sk Biopharmaceuticals Co Ltd | El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad. |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
JP2013249257A (ja) * | 2010-09-16 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
JP2013249258A (ja) * | 2010-09-17 | 2013-12-12 | Taisho Pharmaceutical Co Ltd | グリシントランスポーター阻害物質 |
TW201225957A (en) | 2010-09-17 | 2012-07-01 | Taisho Pharmaceutical Co Ltd | Glycine transporter inhibitor |
JP2013542929A (ja) | 2010-09-28 | 2013-11-28 | パナセア バイオテック リミテッド | 新規ビシクロ環化合物 |
US9394257B2 (en) | 2012-10-16 | 2016-07-19 | Tolero Pharmaceuticals, Inc. | PKM2 modulators and methods for their use |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP3134406A1 (en) | 2014-04-24 | 2017-03-01 | Dart Neuroscience (Cayman) Ltd | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors |
EP3215500A1 (en) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted azetidinyl compounds as glyt1 inhibitors |
MX2020005517A (es) | 2017-12-05 | 2020-11-09 | Sunovion Pharmaceuticals Inc | Formas cristalinas y metodos de produccion de las mismas. |
CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
US11274082B2 (en) | 2019-05-31 | 2022-03-15 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
SG11202113266YA (en) | 2019-06-04 | 2021-12-30 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
KR20220125326A (ko) * | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089411A1 (fr) * | 2002-04-19 | 2003-10-30 | Sanofi-Aventis | Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique |
WO2005037216A2 (en) * | 2003-10-14 | 2005-04-28 | Pfizer Products Inc. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200002570T2 (tr) | 1998-03-06 | 2000-12-21 | Janssen Pharmaceutica N.V. | Glisin naklini önleyiciler |
JP2002212179A (ja) | 2001-01-15 | 2002-07-31 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
EP1442018A1 (en) | 2001-10-31 | 2004-08-04 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Novel anticancer compounds |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
KR101347830B1 (ko) | 2004-05-23 | 2014-01-07 | 에이치엠아이, 인코포레이티드 | 테라뮤틴 조절물질 |
-
2006
- 2006-03-27 CA CA2603939A patent/CA2603939C/en not_active Expired - Fee Related
- 2006-03-27 DK DK06727516.4T patent/DK1869019T3/da active
- 2006-03-27 BR BRPI0608148-7A patent/BRPI0608148A2/pt not_active IP Right Cessation
- 2006-03-27 UA UAA200711021A patent/UA88518C2/ru unknown
- 2006-03-27 CN CNA2006800198904A patent/CN101189228A/zh active Pending
- 2006-03-27 EA EA200701902A patent/EA014311B1/ru not_active IP Right Cessation
- 2006-03-27 EP EP06727516.4A patent/EP1869019B1/en active Active
- 2006-03-27 AU AU2006231917A patent/AU2006231917B2/en not_active Ceased
- 2006-03-27 JP JP2008504868A patent/JP4193949B2/ja not_active Expired - Fee Related
- 2006-03-27 WO PCT/IB2006/000947 patent/WO2006106425A1/en active Application Filing
- 2006-03-27 NZ NZ563238A patent/NZ563238A/en not_active IP Right Cessation
- 2006-03-27 ES ES06727516.4T patent/ES2520015T3/es active Active
- 2006-03-27 GE GEAP200610309A patent/GEP20105053B/en unknown
- 2006-03-27 KR KR1020077025888A patent/KR100969402B1/ko active IP Right Grant
- 2006-03-27 MX MX2007012463A patent/MX2007012463A/es active IP Right Grant
- 2006-03-27 AP AP2007004198A patent/AP2007004198A0/xx unknown
- 2006-03-31 DO DO2006000078A patent/DOP2006000078A/es unknown
- 2006-04-05 UY UY29456A patent/UY29456A1/es unknown
- 2006-04-06 PE PE2006000374A patent/PE20061400A1/es not_active Application Discontinuation
- 2006-04-06 GT GT200600136A patent/GT200600136A/es unknown
- 2006-04-06 HN HN2006013804A patent/HN2006013804A/es unknown
- 2006-04-06 AR ARP060101362A patent/AR056307A1/es unknown
- 2006-04-06 US US11/399,071 patent/US20060229455A1/en not_active Abandoned
- 2006-04-07 NL NL1031539A patent/NL1031539C2/nl not_active IP Right Cessation
- 2006-04-07 TW TW095112431A patent/TW200719890A/zh unknown
-
2007
- 2007-10-03 NO NO20074993A patent/NO339422B1/no not_active IP Right Cessation
- 2007-10-04 ZA ZA200708481A patent/ZA200708481B/xx unknown
- 2007-10-07 IL IL186409A patent/IL186409A/en active IP Right Grant
- 2007-10-08 MA MA30281A patent/MA29672B1/fr unknown
- 2007-10-08 TN TNP2007000380A patent/TNSN07380A1/fr unknown
- 2007-11-01 CR CR9493A patent/CR9493A/es not_active Application Discontinuation
-
2010
- 2010-08-30 US US12/870,928 patent/US8124639B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089411A1 (fr) * | 2002-04-19 | 2003-10-30 | Sanofi-Aventis | Derives de n-[phenyl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique |
WO2005037216A2 (en) * | 2003-10-14 | 2005-04-28 | Pfizer Products Inc. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
NO20062193L (no) * | 2003-10-14 | 2006-05-15 | Pfizer | Bisykliske [3.1.0] derivater som glysintransportorinhibitorer |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO339422B1 (no) | Bisykliske [3.0.1]heteroarylamider som type 1 glysin transport inhibitorer | |
KR100814599B1 (ko) | 신경퇴행성 장애 치료용 이미다졸 화합물 | |
KR101432112B1 (ko) | 도파민 d3 수용체 리간드로서의 신규 카보닐화된 (아자)사이클로헥산 | |
CA2542279C (en) | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors | |
WO2008065500A2 (en) | Heteroaryl amides as type i glycine transport inhibitors | |
WO2007063925A1 (ja) | 2-アミノベンズアミド誘導体 | |
CA3158079A1 (en) | Heterocyclic trpml1 agonists | |
WO2013154109A1 (ja) | 新規1位置換インダゾール誘導体 | |
CA2561441A1 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
CA3153083A1 (en) | Indazole carboxamides as kinase inhibitors | |
KR102582197B1 (ko) | 2-([1,2,3]트리아졸-2-일)-벤조산 유도체의 제조 | |
US20240083896A1 (en) | Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors | |
US20050222227A1 (en) | Oxazole-amine compounds for the treatment of neurodegenerative disorders | |
US7220865B2 (en) | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
JP2004517079A (ja) | 新規化合物 | |
WO2009081246A2 (en) | Bicyclic diamines as nicotinic receptor agonists | |
MXPA06011118A (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
MXPA06009686A (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
ITMI972352A1 (it) | Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |